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 Lung cancer is the most fatal and second most prevalent type of cancer in the 
United States with a current five-year survival rate of only 16%. Thus, novel therapeutic 
agents to both prevent and treat lung cancer are necessary. One such agent is selenium, a 
micronutrient present in the diet. Epidemiological studies and supplementation trials with 
selenium have shown it to decrease lung cancer incidence and mortality. Selenium has 
also been shown to decrease lung tumor burden in animal studies, with the benefit being 
compound dependent. The mechanisms of action of selenium in cancer remain under 
investigation, but may relate to cellular redox status regulation. The hypothesis of this 
work is that distinct selenocompounds alter the cellular redox state of human lung cells 
through the Nrf2/antioxidant response element (ARE) pathway and the antioxidant 
selenoprotein thioredoxin reductase 1 (TR1). This hypothesis was tested using three 
specific aims: 
 1. Determine the redox effects of selenocompounds in A549 adenocarcinoma      
        cells and BEAS-2B nonmalignant bronchial epithelial cells. 
 2.    Investigate the ability of selenocompounds to activate the Nrf2/ARE  
  pathway in nonmalignant BEAS-2B cells.  
 3.    Determine if TR1 modulates the cytotoxcity of selenocompounds in  
  malignant A549 cells.    
 iv 
 Several selenocompounds were investigated, including the selenoamino acids 
selenomethionine and selenocystine, the selenocysteine prodrugs 2-butyl selenazolidine-
4(R)-carboxylic acid (BSCA) and 2-cyclohexylselenazolidine-4(R)-carboxylic acid 
(ChSCA), and methylseleninic acid (MSA). This work indicates that selenium can 
modulate cellular redox status, but the effects are compound and cell-line specific. 
Selenocystine and ChSCA induced oxidative stress in A549 cells and activated the Nrf2 
pathway in BEAS-2B cells. Selenocystine, ChSCA and BSCA also demonstrated 
enhanced cytotoxicity in A549 cells with TR1 knockdown, which was related to their 
ability to deplete intracellular glutathione. MSA produced a reductive stress in A549 cells 
and activated the Nrf2 pathway in BEAS-2B cells, but its cytotoxicity was not altered by 
TR1 status. Selenomethionine failed to modulate cellular redox status, activate the Nrf2 
pathway, or demonstrate enhanced cytotoxicity with TR1 knockdown. These findings 
further demonstrate that selenium has compound-dependent redox effects and certain 
compounds, namely selenocystine and ChSCA, may have actions as both cancer 
preventive and anti-tumor agents in the lung.  
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RATIONALE FOR EXAMINING THE REDOX EFFECTS  
 





 Lung cancer is the most fatal and second most prevalent type of cancer in the 
United States [1]. Lung cancer is divided into two classes: small cell and non-small cell. 
Of the two, non-small cell lung cancer is the more prevalent, accounting for 85% of lung 
cancers [2]. Non-small cell lung cancer can be further subdivided into three types: 
adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, with 
adenocarcinoma being the most common. Adenocarcinomas develop in alveolar type II 
cells and typically occur in the periphery of the lung. Tobacco smoking is the number one 
risk factor for lung cancer development, accounting for over 85% of cases [2]. Other 
environmental risk factors include exposure to radon, asbestos and second-hand smoke. 
There is some evidence for cytochrome P450 1A1 and glutathione S-transferase M1 
polymorphisms as genetic factors for increased susceptibility [3, 4], but these continue to 
be evaluated. Lung cancer rates in the United States are beginning to decline due to 
decreased tobacco smoking; however, lung cancer is expected to remain a public health 
problem for the next 50 years. Former smokers continue to be at higher risk for lung 
cancer than never smokes even decades after cessation [5]. Worldwide smoking rates and
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lung cancer incidence continue to increase, especially in China [6]. 
 The current long-term prognosis for most patients with lung cancer is poor. The 
five-year survival rate for lung cancer has only increased from 13% for patients 
diagnosed between 1975 and 1977 to 16% for diagnosis between 1996 and 2005 [1]. Poor 
clinical outcome is attributed to the typical late stage diagnosis of lung cancer and failure 
of current chemotherapy treatments. Almost 70% lung cancers are not diagnosed until 
they are locally advanced (Stage III) or metastatic (Stage IV) [6]. Once progressed to 
these late stages, lung cancer is not treatable by surgical resection. Lung cancer is also 
not treatable by resection in approximately 40% of patients with early stage disease due 
to co-morbidities [2].  
 First-line chemotherapy regimens for lung cancer generally include a platinum 
agent (cisplatin or carboplatin) in combination with an anti-mitotic agent (paclitaxel, 
docetaxel, or vinorelbine) or the topoisomerase I inhibitor irinotecan. The epidermal 
growth factor receptor (EGRF) tyrosine kinase inhibitors gefitinib and erlotinib have 
demonstrated efficacy in tumors with high EGFR expression, and monoclonal antibodies 
against vascular endothelial growth factor, such as bevacizumab, have also shown some 
success [6]. However, only a minority of patients responds and tumors often reoccur after 
resection and first-line chemotherapy. Second-line therapies are generally unsuccessful 
and only extend survival a few months [7]. Thus, there is a great need to develop agents 
that will prevent lung cancer development and progression, as well as improve treatment.  
 Few lung cancer chemoprevention trials have been conducted, but they generally 
have not been successful. The finding that lung cancer incidence is negatively correlated 
with a diet rich in fruits, vegetables, and vitamins [8] and serum antioxidant levels [9] 
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spurred the investigation of vitamins and antioxidants in clinical supplementation trials. 
The vitamin trials surprisingly showed an increase in lung cancer incidence and mortality 
with β-carotene and no effect of α-tocopherol or retinoids [10-12]. Cigarette smoke has 
since been shown to oxidize these vitamins in lung cells [13-15], indicating that they 
might exert prooxidant effects in the current smoker populations of these studies rather 
than function as antioxidants. The glutathione precursor N-acetylcysteine decreased DNA 
adduct formation in bronchoalveolar lavage fluid from smokers but demonstrated no 
benefit on overall survival or event-free survival in patients with lung cancer   [16, 17].  
 Phytochemicals have also been of interest as chemoprevention agents. This is a 
structurally diverse group of non-nutritive plant components that are thought to be 
chemopreventive by inducing phase II enzymes. One class is the isothiocyanates, which 
are sulfur-containing compounds found in cruciferous vegetables such as broccoli. 
Sulforaphane is a methylsulfinylalkyl isothiocyanate that has been shown to induce phase 
II enzyme expression and activity in the lung both in vitro and in vivo [18]. Despite this 
efficacy in preclinical models, no evidence for phase II gene induction has been found 
following short term dietary intervention with broccoli [19], but pure sulforaphane has 
not been evaluated. Phenethyl isothiocyanate (PEITC), an aromatic isothiocyanate, is 
effective at inhibiting lung tumorigenesis in animals [20] and hypothetically inhibited the 
oxidative metabolism of tobacco carcinogens in smokers who consume watercress, a rich 
source of a PEITC precursor [20]. However, there is little data for PEITC inducing phase 
II enzymes in the lung. It is thought that this isothiocyanate works primarily through 
cytochrome P450 inhibition to prevent the generation of reactive tobacco carcinogen 
metabolites [20]. Therefore, PEITC might work best in current smokers, who would be 
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concurrently exposed to tobacco carcinogens, rather than in former smokers. Polyphenols 
and flavins from teas are effective in the post-initiation phase, but high doses are needed 
to provide a benefit due to presumed low bioavailability [21]. Green tea was also studied 
in humans for the treatment of lung cancer, but no benefit against existing tumors was 
found [22]. The synthetic dithiolethione oltipraz, a phase II enzyme inducer in preclinical 
models, failed to decrease DNA adduct formation, modulate phase II enzyme expression 
or activity, or increase glutathione in chronic smokers and appears to have toxicity issues 
that prevent its use as a chemopreventive agent [23].  
 Although studies have demonstrated mixed results of dietary compounds in 
preventing lung cancer at best, two studies have shown a benefit in patients with 
diagnosed lung cancer. High dose vitamin A adjuvant treatment of stage I lung cancer 
patients decreased new primary tumor formation and increased the disease-free interval 
[24]. Multivitamin use increased the survival time of small cell and non-small cell lung 
cancer patients [25, 26], but which vitamin produced the benefit or if it was a 
combination remains unknown.  
 Together these clinical and animal studies show that while an association between 
a plant-based diet and decreased cancer risk exists, the observed benefits in human trials 
are moderate at best. Additionally, nutritional supplements might have differential 
mechanisms in preventing lung cancer compared to treating established lung cancers. 
Further investigation of dietary compounds for lung cancer prevention, such as selenium, 
is necessary. The studies described in this work focus on using selenium as an agent 
whose unique redox mechanisms may make it a more efficacious dietary compound in 
lung cancer chemoprevention. 
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Selenium and Human Health 
 Selenium is a trace element discovered in 1817 by Jons Joakob Berzelius. It is a 
nonmetal and found in both organic and inorganic compounds. Selenium has the atomic 
number 34 and is chemically related to the other Group 16 element sulfur. It is found in 
soil and present in the diet as a micronutrient. Selenium was originally thought to be a 
carcinogen from the toxic effects observed in grazing cattle, but found to be essential for 
human health in 1957 in that it prevented liver necrosis [27].  
 The U.S. Recommended Dietary Allowance of selenium for adults is 55 µg, the 
level shown to be adequate for selenoprotein synthesis [28]. Brazil nuts are especially 
rich in selenium; other food sources include grains, cereals, seafood, and meat. The 
selenium content of plants is related to the selenium content of the soil in which they 
were grown, and meat selenium content comes from the plants and forage crops eaten by 
animals. Selenium from the diet can enter the body in the form of two selenoamino acids: 
selenocysteine and selenomethionine. Selenium can also be introduced as                      
Se-methylselenocysteine from selenium concentrating plants such as garlic and broccoli. 
In mammals, selenocysteine present in proteins is the predominant biological form of 
selenium even though selenomethionine is present in the diet at a greater amount than 
selenocysteine. This is because selenocysteine insertion, rather than selenomethionine, is 
specified in selenoproteins. The relationship between selenium plasma levels and all-
cause mortality follows a U-shaped curve, with detrimental effects at both the low (<90 
ng/mL) and high (>150 ng/mL) ends of plasma selenium concentration [29]. The ideal 
selenium plasma level is approximately 130 ng/mL [29]. In the United States, individuals 
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are generally selenium adequate and consume selenium at greater amounts than the 
recommended 55 µg/day [29].  
 Selenium deficiency is implicated in the development of several diseases [30]. 
Keshan disease is a cardiomyopathy named for the county in China where it was first 
observed. Dietary levels of selenium are low (<19 µg per day) in this and other regions of 
China due to low soil selenium levels. Selenium supplementation is able to ameliorate the 
cardiac disease and pulmonary edema associated with Keshan. Another disease 
associated with selenium deficiency is Kashin-Beck, an osteoarticular condition that 
affects joint cartilage and results in bone deformities. Cases of Kashin-Beck syndrome 
have been reported primarily in China and northern Russia, another area with low 
selenium soil content. Debate over what constitutes selenium deficiency continues, as 
New Zealanders also have lower serum selenium levels that other populations, but no 
relation to disease incidences has been observed [31]. There is also a body of evidence 
for the involvement of Se deficiency in cancer susceptibility. As the focus of this work is 
on the role of selenium in cancer, this association between selenium status and cancer 
will be discussed in depth later in this chapter.  
On the other side of the spectrum, excess selenium can also produce negative 
health effects. The maximum amount of selenium that has been deemed safe for lifetime 
daily intake is 350 µg per day [32]. Levels above 900 µg are toxic [30]. These amounts 
represent general guidelines, as they are not selenocompound specific. Chronic selenium 
toxicity results in a condition termed selenosis. Symptoms of selenosis include brittle hair 
and nails, diarrhea, dermatitis, nervous system abnormalities, lowered hemoglobin levels, 
a garlic odor on the breath, nausea, and fatigue [33] Observable changes in fingernails as 
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an indicator of selenosis begin to occur at 1600 µg per day [30]. Selenium toxicity can 
also occur from acute poisoning. A case report of acute selenium toxicity describes the 
ingestion of 10 g sodium selenite by a 75-year-old male for its reputed health benefits, 
resulting in hypotension, acidosis, hypokalemia, and ultimately cardiac arrest [34]. The 
toxicity of selenium is thought to stem from incorporation of selenium in place of sulfur 
in enzymes involved in cellular respiration and the generation of reactive species [34]. 




Selenocompounds and Their Metabolism 
 Distinct selenocompounds enter the selenium cellular metabolism pathway 
through either reduction or methylation, producing compound-specific metabolites (for 
selenocompound structures see Figure 1.1; for metabolism scheme see Figure 1.2). 
Depending on the dose and form, selenocompounds can be chemopreventive, toxic, or 
even carcinogenic [35]. The metabolism of a selenocompound may be a contributing 
factor in the observed differential efficacy of selenocompounds in chemoprevention.   
 The reductive metabolism pathway is responsible for generating hydrogen 
selenide [36]. Hydrogen selenide is thought to be the central selenium pool, where 
selenium can be converted into selenocysteine for insertion into selenoproteins or form 
methylated metabolites termed methylselenols. Sodium selenite, an inorganic 
selenocompound, is reduced to selenodiglutathione and then to hydrogen selenide by 
glutathione. Selenite is one of the more toxic forms of selenium. Its toxicity is thought to 
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Figure 1.2. Entry of selenocompounds into the Se cellular metabolism pathway. Depending on the form, selenocompounds can 
enter cellular selenium pools through reductive metabolism to generate hydrogen selenide or via the methylation pathway to form 
methylselenol in the case of MSA or a selenol derivative in the case of p-XSC. Figure adapted from [36].
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 The selenoamino acids are also a part of the reductive pathway [36]. To form 
hydrogen selenide, selenocysteine first undergoes a glutathione-independent β-lyase 
reaction to cleave elemental selenium, which is then spontaneously reduced to hydrogen 
selenide [37]. Selenomethionine enters the hydrogen selenide pool by forming 
selenocysteine via the trans-sulfuration pathway [37]. Once in the hydrogen selenide 
pool, selenium can form selenophosphate by selenophosphate synthetase. Selenocysteine 
is synthesized from selenophosphate to be utilized in selenoprotein synthesis. While the 
selenoamino acids selenocysteine and selenomethionine both form the same hydrogen 
selenide intermediate, selenoproteins specifically incorporate selenocysteine. This is 
because selenoproteins have selenocysteine encoded for by a UGA codon upstream of a 
selenocysteine insertion sequence element [38]. For this reason, selenocysteine is referred 
to as the 21st amino acid [39]. Selenomethionine can leave the central selenium pool 
through nonspecific incorporation into general body proteins, as cells do not differentiate 
selenomethionine from methionine. 
 Also in the reductive metabolism pathway are the selenazolidines, a novel class of 
selenocompounds. Selenazolidines are designed to function as selenocysteine prodrugs. 
Selenocysteine itself is unstable, difficult to work with, and can oxidize to form the 
diselenide selenocystine; it is thought that these negative properties can be overcome 
through a prodrug approach. The selenazolidines were patterned after the thiazolidine 
class of sulfur compounds to serve as selenocysteine delivery agents with low toxicities 
[40]. Several different selenazolidines that have the same selenazolidine carboxylic acid 
ring structure, but differ in the 2-position functional group, have been synthesized. 
Depending on the functional group, these compounds are hypothesized to release 
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selenocysteine either enzymatically or nonenyzmatically. 2-oxo-selenazolidine-4-
carboxylic acid (OSCA) was designed to release selenocysteine through a 5-oxoprolinase 
enzymatic reaction (Figure 1.3). The remainder of the synthesized selenazolidines, 2-
butyl (BSCA), 2-cyclohexyl (ChSCA), 2-phenyl (PhSCA), 2-methyl (MSCA), and 2-(2’-
hydroxy)phenyl (PhOHSCA) selenazolidine-4-carboxylic acid, are thought to release 
selenocysteine through nonenzymatic ring opening and hydrolysis (Figure 1.3). These 
selenazolidines that release selenocysteine through spontaneous hydrolysis also generate 
an aldehyde species. In addition to liberating selenocysteine, selenazolidines may also 
generate the selenocysteine dimer selenocystine. The selenazolidines also differ in their 
lipid partition coefficients, with OSCA and ChSCA being the most lipophilic and 
PhOSCA and MSCA being the least lipophilic [41].  
 Selenocompounds can form methylselenol independently of hydrogen selenide in 
what is termed the methylation pathway [36]. Methylseleninic acid (MSA) can directly 
form methylselenol through a nonenzymatic reaction. MSA is a synthetic 
selenocompound designed as Se-methylselenocysteine without the amino acid moiety. 
MSA does not require metabolism by β-lyase to produce methylselenol, while              
Se-methylselenocysteine does. MSA was designed to be a more efficacious form of      
Se-methylselenocysteine, since it can produce methylselenol in cells lacking β-lyase. The 
organoselenium compound 1,4-phenylenebis(methylene)selenocyanate (p-XSC) is 
thought to behave similarly to methylselenol in cells. p-XSC is hypothesized to form a 
glutathione conjugate (p-XSeSG), then undergo metabolism to selenol (p-XSeH), and 
finally be excreted as tetraselenocyclophane [42]. The possibility for the reductive 










Figure 1.3. Formation of selenocysteine from the selenazolidines BSCA, OSCA, and 
ChSCA. BSCA and ChSCA are hypothesized to spontaneously release selenocysteine 
through hydrolysis, also generating aldehydes. OSCA is thought to release selenocysteine 
and CO2 through a 5-oxoprolinase enzymatic reaction. Figured adapted from [40]. 
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the ability of p-XSC to restore glutathione peroxidase activity in selenium-deficient rats, 
thereby contributing selenium to the hydrogen selenide pool for incorporation into 
selenoproteins [43]. However, this reductive metabolism of p-XSC is thought to be a 
minor metabolism pathway, as very low levels of the dimethyl selenide metabolite of 
hydrogen selenide were detected [42] and p-XSC was not incorporated into glutathione 
peroxidase as efficiently as selenite [43], which is primarily metabolized to hydrogen 
selenide. Selenomethionine can also directly form methylselenol by a methioninase 
reaction [44]. Hydrogen selenide can also be converted to methylselenol by 
methyltransferase [45], and methylselenol into hydrogen selenide via demethylation by 
demethylase.   
 The excretory metabolites of selenium are primarily methylated forms. In humans 
and rodents, the predominant mechanism for ridding the body of absorbed selenium is 
urinary excretion of methylselenosugars [46, 47]. Methylselenol can also form 
dimethylselenol and trimethylselenol through thiol S-methyltransferase reactions [45; 
48]. Formation of these further methylated metabolites generally occurs only when 
selenium levels are very high and selenosugar synthesis is saturated. The di- and 
trimethyselenols are excreted through breath and urine, respectively. Fecal selenium 
excretion also occurs, but is primarily the route for unabsorbed selenium [49]. 
 
Selenium and Cancer 
 In 1969, Shamberger and Frost brought to attention the possible ability of 
selenium to protect against cancer in humans by citing two published studies [50]. One 
study by Allaway et al. was the first to associate selenium blood levels with cancer death 
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rates, finding a negative Pearson correlation coefficient of r = -0.96 [51]. The second 
study, by Kubota et al., found a lower death rate for regions of the United States with 
high forage crop selenium concentrations compared to those with low selenium 
concentrations [52]. An unpublished study showing a lower cancer death rate for 
Canadian provinces with selenium accumulator plants than provinces with plants that did 
not accumulate selenium was also described [50], further implicating selenium soil levels 
in mortality rates. Several other studies have confirmed these inverse associations 
between selenium plasma and soil levels and cancer mortality [53-56].  
 Since these original observations, inorganic and organic selenium compounds 
have been shown to decrease tumor formation in a number of chemical and viral 
carcinogenesis models [57]. It is important to note that the antitumor effects of selenium 
occur at supranutritional selenium levels, that is, above the levels needed to maximize 
selenoprotein activity [58]. The actions of selenium are both compound and model 
specific. An example is Se-methylselenocysteine, which is one of the most efficacious 
selenocompounds at reducing mammary tumors [59]. Se-methylselenocysteine is not 
effective at reducing lung tumors, whereas other selenocompounds have been [60]. 
Tissue distribution and expression of metabolizing enzymes such as β-lyase might 
explain the differential activity of selenocompounds in animal models.  
 In addition to numerous animal studies, epidemiological and case-control studies 
have also indicated a protective benefit of selenium in several cancers [57]. Some of the 
first clinical trials to test the ability of selenium prevent cancer in humans were conducted 
in Linxian, China. The population of this region is deficient in many nutrients, including 
selenium, and has high mortality rates for esophageal and gastric cancers. A combination 
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of selenium with β-carotene and α-tocopherol decreased total cancer mortality, stomach 
cancer mortality, and stomach cancer incidence [61], but did not decrease the prevalence 
of precancerous legions or early cancers in the esophagus or stomach in a smaller subset 
of participants evaluated by endoscopy [62]. To better evaluate the role of selenium in 
cancer prevention, two clinical trials were conducted in the United States: the Nutritional 
Prevention of Cancer (NPC) trial and Selenium and Vitamin E in Cancer Prevention Trial 
(SELECT). 
 The NPC trial was the first to evaluate selenium in cancer prevention [63]. It 
enrolled patients with a history of nonmelanoma skin cancers residing in the southeast 
United States, a recognized low soil selenium area. Selenium was supplied in the form of 
selenized yeast at 200 µg/day. No benefit of selenium was shown for preventing the 
reoccurrence of basal or squamous cell carcinoma in the initial follow-up time (4.5 mean 
treatment years), but decreases in prostate, colon and lung cancer incidence were found, 
as well as decreased rates of lung cancer and total cancer mortality. The reduction in 
prostate cancer incidence was the most statistically significant and was the only cancer 
for which the reduction remained significant in long-term follow up (7.9 mean treatment 
years) [64]. Further analysis of the NPC trial also showed that selenium was the most 
protective against prostate cancer in men with low baseline selenium levels [64-66]. 
Extended follow-up also indicated a significant increased risk of nonmelanoma skin 
cancers in participants with the highest baseline plasma selenium levels [66]. Overall, the 
findings of the NPC trial indicate that selenized yeast is efficacious in decreasing cancer 
mortality and preventing specific cancers, namely prostate, but baseline selenium status 
may be an important factor in this protective effect. 
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 To further verify the NPC prostate cancer findings, The Selenium and Vitamin E 
in Cancer Prevention Trial (SELECT) began in 2001 and was designed with prostate 
cancer as its primary outcome [67]. This trial enrolled over 35,000 cancer-free men and 
provided oral 200 µg/day selenomethionine, 400 IU/day synthetic α-tocopherol, or both. 
The trial was scheduled to continue follow-up through 2013 but was stopped in October 
2008 when analysis showed no decrease in prostate cancer incidence with either agent 
alone or in combination and no possibility that a benefit could occur in the follow-up 
period. No change in incidence of lung cancer, colon cancer, or all other cancers was 
found and no effect on cancer mortality shown. A statistically nonsignificant increase in 
type II diabetes was shown with selenium alone, a finding that was also reported for the 
NPC trial population within the highest baseline plasma selenium tertile [68].  
 Two hypotheses have been made to explain the conflicting results of these two 
selenium supplementation trials. First, the choice of selenocompound was different. The 
NPC trial used selenized yeast, which is comprised of greater than 65% selenomethionine 
[69, 70]. Selenocysteine, Se-methylselenocysteine, and other unknown organoselenium 
compounds account for the remaining total selenium content [70]. SELECT used pure 
selenomethionine since it is the predominant selenocompound in selenized yeast. It is 
possible that the other selenocompounds in selenized yeast that were not given in 
SELECT could be responsible for some benefit. Also, selenomethionine may not be the 
best form of selenium for producing biologically available selenium, as it can be non-
specifically incorporated into general body proteins in place of methionine. Second, the 
baseline plasma selenium levels of the two study populations differed. The NPC trial 
enrolled subjects from the historically selenium low region of the southeastern United 
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States. This is in contrast with SELECT, where the majority of the population was 
selenium sufficient. Only 22% of men in SELECT were within the NPC trial's lowest two 
tertiles of plasma selenium levels. These results of the NPC trial indicated that low 
plasma selenium populations might benefit the most from selenium supplementation. 
Perhaps this low selenium population was too small in SELECT to demonstrate a benefit 
great enough to be seen when analyzing the entire population. To date, the data for the 
low selenium population in SELECT have not been analyzed to determine if a benefit 
occurred in this subpopulation. Despite the differential findings between the NPC trial 
and SELECT, it is important to note that they do not discredit the use of selenium in 
cancer prevention. Rather, they highlight the need for a better understanding of selenium 
biology and which populations might best benefit from supplementation [71, 72].  
 
Proposed Mechanisms of Selenium in Cancer 
 Selenium is thought to function as a chemoprevention agent, defined as that 
which inhibits, reverses, or retards tumorigenesis [73], at multiple stages of neoplastic 
transformation. These stages include initiation, a rapid process when a cell is first 
exposed to carcinogens and DNA modifications occur; promotion, a lengthier process 
when proliferating preneoplastic cells accumulate; and progression, when a tumor with 
invasive and metastatic potential forms [73]. A range of mechanisms have been 
hypothesized for selenium in chemoprevention, including protection against oxidative 
stress, altered carcinogen metabolism, detoxification of carcinogenic intermediates, 
induction of apoptosis, cell cycle effects, immune system modulation, and inhibition of 
angiogenesis [74]. This work is focused on redox effects of selenium in the lung, with 
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studies in subsequent chapters relating to the ability of selenium to attenuate reactive 
species in nonmalignant cells and enhance apoptosis in malignant cells. 
 Selenocompounds have demonstrated capabilities in vitro that are attractive from 
a cancer therapy standpoint, that is, properties that would promote the death of a cell that 
has entered the transformation pathway and may become tumorigenic. Certain 
selenocompounds, such as selenite, selenocystine, MSA, and p-XSC can redox cycle with 
thiols, such as reduced glutathione, at physiological pH [44, 75, 76]. Selenomethionine 
does not produce superoxide in the presence of glutathione unless it generates 
methylselenol via the methionase reaction, which may explain its lower toxicity than 
other selenocompounds that can produce greater amounts of superoxide [44, 76]. These 
specific selenocompounds can redox cycle because they are able to form the RSe- 
selenide anion (Figure 1.4). Redox cycling results in depletion of glutathione and 
generation of reactive species, such as superoxide, that can produce DNA strand breaks 
[36, 77]. This ability of selenocompounds to generate oxidative stress and DNA strand 
breaks has been directly associated with their ability to also induce apoptosis [78-80]. 
Certain selenocompounds have also been shown disrupt mitochondrial integrity by a 
mechanism involving thiol oxidation and superoxide generation [81, 82]. Through these 
mechanisms, selenium can promote cancer cell death through both caspase dependent and 
independent pathways, as demonstrated in several malignant cell lines [36, 83-87]. 
 In regard to chemoprevention, two specific hypotheses for how selenium exerts its 
associated mechanisms exist. One hypothesis implicates increased formation of the 
selenium metabolite methylselenol as the basis for chemopreventive effects. Another 







Figure 1.4. Redox cycling of selenides. Selenocompounds such as selenocystine, MSA, 
p-XSC, and selenite can form the selenide anion (RSe-) and redox cycle with reduced 







 Alkylselenols are low-molecular weight selenocompounds that can form by 
methylation  of  hydrogen  selenide from the central selenium pool, or  directly from such 
compounds as Se-methylselenocysteine and MSA. The alkylselenol class includes 
monomethylselenol, a key metabolite generated by Se-methylselenocysteine and MSA. 
Both Se-methylselenocysteine and MSA were found to be more effective than 
selenomethionine or selenite in a human prostate cancer xenograft model [88]. Selenized 
garlic, containing selenium primarily as Se-methylselenocysteine and its gamma glutamyl 
conjugate [69], was more efficacious in a mammary cancer model than selenite [89] or 
selenized yeast, which contained selenium primarily as selenomethionine [69, 89]. The 
superior efficacy of Se-methylselenocysteine and MSA in these studies is attributed to 
their ability to more readily form methylselenol than the other evaluated 
selenocompounds. Methylselenol precursors can inhibit cell cycle progression [90-92], 
induce caspase-mediated apoptosis [90] and prevent angiogenesis [93]. The 
methylselenol metabolite has been shown in vitro and in vivo to be responsible for the 
chemopreventive actions associated with Se-methylselenocysteine and MSA [94]. The 
exact mechanism by which methylselenols produce this benefit that other 





 To date, over 25 mammalian selenoproteins have been identified [95]. These 
proteins specifically contain selenium in their active sites in the form of genetically 
encoded selenocysteine. Proteins with nonspecific incorporation of selenium or selenium-
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binding proteins are not grouped within this selenoprotein category. The most studied 
selenoproteins are the thioredoxin reductases and glutathione peroxidases, discussed in 
depth further in this chapter; the selenium transporter selenoprotein P; and the thyroid 
hormone activating iodothyronine deiodinases. Many of the identified selenoproteins 
have unknown functions that are just beginning to be elucidated. Selenocysteine is vital 
for the enzymatic activity of selenoproteins, as selenoproteins with mutated 
selenocysteine residues demonstrate significantly decreased activity [96]. Selenoprotein 
synthesis utilizes specific protein synthesis machinery to insert selenocysteine [95]. 
Insertion of selenium as selenocysteine is coded for by the UGA codon. In 
nonselenoproteins, UGA is a stop codon that terminates translation. For the UGA codon 
to be instead translated as selenocysteine, a selenocysteine insertion sequence (SECIS) 
element must be present downstream. This SECIS element is a stem-loop structure found 
in the 3'-untranslated region of eukaryotic selenoprotein mRNAs. To produce a 
selenocysteine-specific tRNA (tRNASec), serine is first conjugated and then modified to 
phosphoserine. Selenium from the hydrogen selenide pool is phosphorylated to 
selenophosphate by selenophosphate synthetase 2 and then added to phosphoserine by 
selenocysteine synthetase. A tRNASec-specific elongation factor and binding of the 
SECIS-binding protein 2 to the SECIS element are also required for selenocysteine 
incorporation [97]. Other currently unknown machinery may also be required. Under 
conditions of selenium deficiency, decreased selenoprotein synthesis and activity is 
observed [98].  
  One model for investigating the role of selenoproteins in cancer is the i6A-  
transgenic mouse. The tRNASec, is mutated in vitro by replacing an adenosine with a 
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guanosine, preventing the incorporation of selenocysteine into selenoproteins [99]. These 
mice have decreased selenoprotein expression, but do not exhibit an overt phenotype 
[99]. This strategy is employed to decrease selenoprotein expression rather than a   
tRNASec knockout mouse, as this is embryonic lethal [100]. In the azoxymethane model 
of colon cancer, the i6A- mouse was found to have more aberrant crypt foci than wild-
type [101]. Selenium supplementation as selenite at supranutritional levels was able to 
non-significantly decreased the aberrant crypt foci in the i6A- mouse, indicating both 
selenoprotein dependent and independent mechanisms for chemoprevention by selenium. 
Selenoprotein deficiency was also found to increase lesions associated with prostate 
cancer in a transgenic cancer model [102]. One limitation of the i6A- mouse model is that 
it does not identify which selenoproteins are required for the observed benefit. 
 The relationship between selenoprotein expression and cancer risk has also been 
studied in humans. Decreased expression of selenoprotein P has been found in tumor 
tissues relative to matched nonmalignant tissue [103-105] and has also been correlated 
with risk of colon cancer [106]. Single nucleotide polymorphisms in the selenoprotein P 
gene have also been related to cancer risk [107]. As the primary function of selenoprotein 
P is to transport selenium to extrahepatic tissues, its decreased expression or activity 
could limit the amount of selenium available for selenoprotein synthesis or methylselenol 
formation [108]. Selenoprotein P may also have an antioxidant function that could 
contribute to decreased cancer risk [108, 109]. Glutathione peroxidase 1 (GPx1) is 
another selenoprotein that has been associated with cancer risk in humans. As a 
glutathione peroxidase, GPx1 primarily has an antioxidant function by reducing cellular 
hydroperoxides. Polymorphisms in GPx1 [110, 111] and allelic loss of GPx1 [112] are 
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associated with the development of several cancers. Polymorphisms and decreased 
expression of selenoprotein 15, which is located in the endoplasmic reticulum and 
functions in protein folding, have also been implicated [113]. While these studies indicate 
associations between certain selenoproteins and cancer, it is not known if changes in 
expression or activity are early occurrences that contribute to cancer development or 
occur later as a result of transformation. 
 One problem with the selenoprotein hypothesis as the single mechanism of 
selenium is that observed benefits occur at supranutritional levels [58]. This indicates that 
the associated benefits are not the result of increased selenoprotein expression or activity 
alone, as these are maximized at levels below supranutritional status. As the animal 
studies and clinical data indicate, maximal selenoprotein activity in conjunction with 
increased methylselenol production is the likely mechanism of chemoprevention [101]. 
 
 
Maintenance of Cellular Redox Status by Selenium 
 Selenium is thought to indirectly act as an antioxidant through the functions of 
selenoenzymes. This is in contrast to antioxidants that function by non-enzymatically 
reacting with oxidative species, such as α-tocopherol and ascorbic acid [114]. Control of 
redox status is important in chemoprevention, as oxidative stress can lead to DNA, 
protein, or lipid damage [115, 116]. Damage to these cellular components typically 
occurs in the initiation phase of carcinogenesis, ultimately resulting in mutagenesis [115]. 
Also, many of the signal transduction cascades for cell growth and proliferation, 
processes that become deregulated in cancer, are redox controlled [116]. The ability of 
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selenium to modulate redox status seems to be primarily related to the actions of two 
classes of selenoenzymes: the thioredoxin reductases and the glutathione peroxidases.  
 
Thioredoxin Reductase 
 The main function of thioredoxin reductase is to reduce the redox-active disulfide 
in the thioredoxin active site [117, 118]. This reaction is carried out using electrons from 
NADPH cycled through flavin adenine dinucleotide (Figure 1.5). After the glutathione 
system, the thioredoxin system is the most important cellular antioxidant system. In 
humans, there are three thioredoxin reductase isoforms. Thioredoxin reductase 1 (TR1) is 
cytosolic, thioredoxin reductase 2 is mitochondrial, and thioredoxin reductase 3 is 
localized to the testes for involvement in spermatogenesis [117]. This work is focused 
specifically on the cytosolic TR1 isoform.  
 The TR1 isoform is expressed in all cell types and tissues, but in low 
concentrations relative to other antioxidants such as glutathione. Selenium 
supplementation has been shown to increase thioredoxin reductase activity until it 
plateaus [119]. In addition to thioredoxin, thioredoxin reductase can control the redox 
status of other substrates, such as thioredoxin-dependent peroxiredoxins and the tumor 
suppressor p53. An important role of the thioredoxin system is its function in 
deoxyribonucleotide biosynthesis. Thioredoxin provides electrons to ribonucleotide 
reductase for the conversion of ribonucleotides to deoxyribonucleotides, allowing for 
DNA synthesis in the S-phase of the cell cycle [120]. It is thought that this function leads 
to the requirement of TR1 and thioredoxin for embryogenesis [121, 122]. Thioredoxin 
























Figure 1.5. Maintenance of cellular redox status by the thioredoxin system. 
Thioredoxin reductase reduces oxidized thioredoxin by using electrons from NADPH 
cycled through flavin adenine dinucleotide (FAD). Thioredoxin can then maintain 
cellular proteins in a reduced state. The thioredoxin system is implicated in transcription 





their activity [123], and modulates the redox state of selenocompounds [124]. The 
thioredoxin system is also implicated in apoptosis, as the oxidation state of thioredoxin 
regulates apoptosis signaling kinase 1 (ASK1) activity [125]. Through these actions, 
thioredoxin reductase can regulate redox status and prevent oxidative stress that can 
contribute to cancer development.  
 While thioredoxin reductase expression is advantageous in nonmalignant cells for 
redox balance, it can also benefit cancers. TR1 has been implicated in the malignant and 
tumor phenotypes of cancer cells, as well as metastasis [126, 127]. TR1 is overexpressed 
in a number of human tumors, including lung, and is associated with poor prognosis 
[128-130]. This overexpression has been shown to decrease the sensitivity of cancer cells 
to electrophilic and oxidative insults, a common mechanism of anti-cancer drugs [131, 
132]. TR1 knockdown increases the sensitivity of cancer cells to the anti-cancer drug 
cisplatin [133, 134] and certain selenocompounds [135]. These studies indicate a role for 
TR1 in cancer develop, progress, and therapy resistance, making its inhibition a target for 
cancer therapy.  
 
Glutathione Peroxidases 
 The glutathione peroxidases are another group of selenoproteins by which 
selenium can maintain cellular redox state. The glutathione peroxidases are responsible 
for the majority of glutathione-dependent hydrogen peroxide-reducing activity. There are 
five selenium-containing glutathione peroxidase isoforms in humans: cytosolic GPx1, 
gastrointestinal GPx2, plasma GPx3, phospholipid hydroperoxide GPx4, and olfactory 
GPx6 [95]. Like thioredoxin reductase, expression of these glutathione peroxidases is 
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selenium dependent. Although GPx2 was originally thought to be expressed only in the 
gastrointestinal tract, it has since been found to be expressed in other tissues, including 
the lung. It is the major isoform of glutathione peroxidase induced in the lung in response 
to cigarette smoke [136], indicating it as the primary glutathione peroxidase involved in 
lung antioxidant defense. 
 
The Nrf2/ARE Pathway 
 
 To date, TR1 and GPx2 are the only two selenoproteins shown to contain an 
antioxidant response element (ARE). The ARE is a cis-acting element located in gene 
promoters that enhances transcription under conditions of oxidative stress. Activation of 
ARE gene transcription is regulated by the basic leucine zipper transcription factor 
nuclear factor erythroid 2-related factor 2 (Nrf2). Several gene classes are Nrf2-regulated, 
including those with antioxidant, protein folding, cell growth, cell survival, and immune 
functions [137-141]. In addition to TR1 [142, 143] and GPx2 [136], other antioxidant 
genes regulated by Nrf2 include NAD(P)H-quinone oxidoreductase 1 (NQO1), [144] the 
phase II detoxifying glutathione S-transferases [145], UDP glucuronosyltransferases 
[146], and genes involved in glutathione biosynthesis and reduction [147, 148]. Nrf2 
itself has an ARE in its promoter and thus can autoregulate its own expression [149].  
 The mechanism of Nrf2 activation involves its translocation from the cytoplasm 
to the nucleus (Figure 1.6). When no ARE inducers are present, Nrf2 remains in the 
cytoplasm due to an interaction with Kelch-like ECH- associated protein 1 (Keap1) 
[150]. The Nrf2-Keap1 complex is redox-controlled via thiol groups on Keap1. Keap1 









Figure 1.6. Mechanism of Nrf2 activation. Under basal conditions, Nrf2 is tethered to 
the cytoplasm through an interaction with Keap1, allowing for its ubiquitination and 
subsequent degradation by the 26s proteasome. Under conditions of electrophilic or 
oxidative stress, key cysteine residues on Keap1 are modified, releasing Nrf2. Nrf2 can 
then translocate the nucleus, where it heterodimerizes with small Maf proteins to induce 
the transcription of ARE genes. Figure adapted from [151]. 
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subsequent degradation of Nrf2 by the 26S proteasome [152]. Under basal conditions, 
Nrf2 is unstable (t1/2 ~ 15 minutes) and only low levels of Nrf2 activation occur [153]. 
Under conditions of oxidative or electrophilic stress, key cysteine residues on Keap1 are 
modified. When modification of these cysteine residues occurs, the enzymatic activity of 
the Keap1-Cul3-Rbx1 E3 complex is inhibited and the Nrf2-Keap1 interaction is 
disrupted [154]. Dissociation of Nrf2 from Keap1 increases the stability of Nrf2 and 
allows for it to translocate into the nucleus. Once in the nucleus, Nrf2 heterodimerizes 
with small Maf proteins [145, 155]. This allows Nrf2 to bind to the ARE, activate the 
ARE, and increase transcriptional expression of downstream genes [145].  
 When cellular redox homeostasis is reached, Nrf2 activation is terminated. One 
model for termination is through a mechanism by which Keap1 translocates to the 
nucleus. It is thought that Keap1 contains a nuclear export signal that is inactivated under 
conditions of oxidative stress, but activated when the stress is attenuated [156]. Once in 
the nucleus, Keap1 dissociates Nrf2 from the ARE and reforms a complex with Nrf2. 
This Nrf2-Keap1 complex is returned back to the cytosol by a nuclear export sequence in 
Keap1, where Keap1 again complexes with Cul3-Rbx1 [157] and the degradation of Nrf2 
can resume.  
 Since the discovery of Nrf2-Keap1 complex, other regulatory mechanisms have 
been associated with Nrf2 activation. These include negative regulation by Bach1 [158], 
and positive regulation by DJ-1 [159] and KAP1 [160]. The involvement of these other 
regulators may be specific for the induction of certain downstream genes. Nrf2 
phosphorylation has also been implicated, but does not appear to be required for 
increased Nrf2 stability or nuclear accumulation [161]. While evidence for these other 
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mechanisms exists, Keap1 modification appears to be the primary means by which Nrf2 
activation occurs.   
 The Nrf2 pathway has been implicated in chemoprevention through its induction 
of ARE genes. Antioxidant genes can attenuate oxidative stress implicated in 
carcinogenesis, while phase II metabolizing enzymes can detoxify carcinogens or 
reactive intermediates. Nrf2 knockout mice are prone to developing more tumors in 
tissues such as the colon, liver, bladder, skin, and stomach [162]. While the 
tumorigenicity of lung carcinogens has not been explicitly evaluated in Nrf2 knockout 
animals, the lungs of Nrf2 knockout mice develop more spontaneous and 
benzo(a)pyrene-induced genomic DNA mutations [163]. Nrf2 has also been strongly 
implicated in lung antioxidant defense [164-169], a recognized chemoprevention 
mechanism. Activation of Nrf2 is one recognized mechanism of chemoprevention by 
several compounds, including the isothiocyanate sulforaphane [170] and the 
dithiolethione oltipraz [171]. These findings highlight Nrf2 activation as a therapeutic 
strategy to enhance antioxidant defense and detoxification pathways, maintain cellular 
redox homeostasis, and ultimately inhibit carcinogenesis.  
 Similarly to TR1, Nrf2 can benefit malignancies. Mutations in Nrf2 or Keap1 that 
lead to constitutively active Nrf2 in the absence of oxidative stress are common in many 
cancers, including lung [172, 173]. These mutations frequently occur in the regions 
responsible for binding Nrf2 to Keap1 and prevent the negative regulation of Nrf2 by 
Keap1. High basal activity of Nrf2 is associated with resistance to anti-cancer drugs [172-
175] and its knockdown can increase drug toxicity and basal oxidative stress [174]. When 
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modulating the Nrf2 pathway for chemoprevention, it is important to take the malignancy 
status of the tissue into consideration.  
 Induction of antioxidant genes and phase II enzymes is one hypothesized 
mechanism of selenium in chemoprevention. The ability of selenocompounds to do so 
has been demonstrated in both animal tissue and cell culture. Glutathione S-transferase 
and total GPx activity was increased by one week of dietary p-XSC in mouse lung and 
liver, but no change in UDP-glucuronosyltransferase or selenium-dependent GPx activity 
was found [175]. p-XSC has also been shown to increase glutathione and antioxidant 
levels in the lung of A/J mice [176]. mRNA expression and activity of antioxidant and 
phase II enzymes have been assessed in the liver of animals administered selenocystine 
or the selenazolidines, but no pattern of induction relating to the chemoprevention 
activity of the compounds was found 24 hours after a single dose [41] or after a week of 
daily administration [177]. Induction of these enzymes by selenocystine, selenazolidines, 
and selenomethionine was also observed in Hepa1c1c7 mouse hepatoma cells [178]. 
Various other selenocompounds have also induced antioxidant and phase II enzymes in 
tissues [179-183]. It is hypothesized that the generation of reactive species, such as 
superoxide, by certain selenocompounds may lead to activation of the Nrf2 pathway, but 
there is currently little data that implicitly demonstrate selenocompound-mediated 
activation of Nrf2. At present, there is only one published study demonstrating such a 
mechanism of selenocompounds. This study showed Nrf2 activation by two 3-selena-1-
dethiacephem compounds in LNCaP prostate cancer cells [184]. That selenocompounds 
can induce antioxidant genes and phase II enzymes through the Nrf2 pathway in the lung 
is one hypothesis to be tested in this work.    
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Lung Cancer and Selenium 
 The 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) model of lung 
cancer has been utilized to evaluate selenocompounds in preventing lung cancer. NNK is 
a tobacco-specific N-nitrosamine carcinogen that forms from nicotine reacting with 
nitrite. It has a strong affinity for the lung and is the most abundant lung carcinogen in 
cigarette smoke [185]. NNK must undergo activation via metabolism to exert its 
carcinogenic effects. The primary metabolism pathway for NNK activation is cytochrome 
P450-mediated α-hydroxylation of the methylene and methyl carbons adjacent to the    
N-nitroso group [186]. These hydroxylated NNK metabolites are reactive electrophiles 
that form DNA adducts via methylation or pyridyloxobutylation, leading to 
tumorigenesis [185, 186]. In addition to being a suspected human lung carcinogen, NNK 
has been shown to induce lung tumors in rodents independent of the route of 
administration [185]. These rodent lung tumors have similar pathology as that of human 
adenocarcinomas [185]. The A/J mouse is one strain sensitive to NNK. In female A/J 
mice on an AIN-76A diet, a single i.p. dose of 10 µM NNK reproducibly results in 7-12 
lung tumors per mouse after 16 weeks [187]. 
 Selenocompounds have been evaluated in the female A/J mouse NNK model with 
variable success (Table 1.1). p-XSC demonstrates activity in this model when present 
during or after NNK administration [188-190]. When present from pre-initiation to post-
initation, selenocystine, OSCA, BSCA, ChSCA, and PhSCA also reduced lung tumor 
formation [60; 190]. Further studies showed that selenocystine, OSCA, and ChSCA were 
effective in the post-initiation phase, PhSCA was effective in the pre-initiation phase, and 
BSCA was effective both pre- and post-initiation but not during NNK administration 
   
 
 
Table 1.1. Selenocompound Efficacy at Decreasing Lung Tumor Number in the Female A/J Mouse NNK Model.  
 
 
‘’ indicates a statistically significant decrease in lung tumor number versus no supplementation. 
‘’ indicates no significant decrease in lung tumor number versus no supplementation.  








(Relative to NNK 
Administration) 
Dietary Supplementation 
p-XSC SECY ChSCA OSCA BSCA PhSCA SEM Se-MSC 
Pre, During, and Post a b,c c b,c c c b b 
Pre Only --- c c c c c --- --- 
Post Only a c c c c c a --- 
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[191]. Selenized yeast, selenomethionine, Se-methylselenocysteine, selenite, MSCA, 
PhOSCA and the unsubstituted selenazolidine-4-carboyxlic acid were not effective when 
given  from the pre-initiation phase to the post-initiation phase [60, 188-191]. MSA has 
yet to be evaluated in an animal model of lung cancer, but has elicited changes in gene 
expression of lung cancer cells in vitro that could be beneficial in lung cancer prevention 
[92]. These studies support the use of selenium in lung cancer prevention and 
demonstrate that its effects are compound-dependent.           
 Gene profile analyses of lung cells or tissue have been performed to delineate 
what mechanisms may be associated with the selenocompounds. Microarray analysis of 
H460 lung cancer cells treated with p-XSC showed changes in transcription factor, 
growth factor, and apoptotic gene expression [192]. MSA altered the expression of 
regulatory cell cycle proteins involved in the G1 to S phase transition in H520 lung cancer 
cells, resulting in G1 phase arrest [92]. This profile of MSA in lung differed slightly from 
that observed in prostate cancer cells, with fewer cell cycle proteins modulated in the 
NSCLC cells [92]. Lung tissue from mice provided selenocystine or the selenazolidines 
OSCA, BSCA and ChSCA in the diet for 10 days following NNK administration was 
also assessed by microarray analysis. With these treatments, only six genes were found to 
be differentially expressed compared to animals receiving no selenium supplementation 
[191]. However, these genes demonstrated modest changes and were not good indicators 
of selenium supplementation. No changes in the transcription factor, apoptotic or cell 
cycle genes altered by p-XSC or MSA were observed with selenocystine and certain 
selenazolidines, indicating a differential mechanism of these compounds. Additionally, 
selenocompounds may affect different gene profiles in the malignant cells used for the   
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p-XSC and MSA studies compared to nonmalignant tissue utilized for the selenocystine 
and selenazolidine study.       
 Clinical selenium supplementation trials in humans have had mixed results in 
regard to lung cancer. The initial follow-up of the NPC trial showed a significant benefit 
of selenium in decreasing lung cancer incidence and mortality (Relative Risk = 0.54,        
p = 0.04) [63]. A trend towards decreasing risk was found with extended follow-up for 
the whole population, but was not statistically significant (Relative Risk = 0.70, p = 0.18) 
[70]. A significant decrease in incidence remained for the low tertile baseline plasma 
selenium group (Hazard Ratio = 0.42, p = 0.04). No difference in risk was found between 
former and current smokers supplemented with selenium. SELECT found no effect of 
selenomethionine in the total population, but has not had the data for low baseline 
selenium population analyzed for lung cancer incidence. However, selenomethionine has 
not demonstrated efficacy in animal models and perhaps other selenocompounds that are 
more efficacious in these models may demonstrate a benefit in human trials. Other 
studies evaluating serum or toenail selenium status and lung cancer risk have not 
conclusively shown a protective effect of high selenium levels [193], but a meta-analysis 
of thirteen of these epidemiological studies has  indicated populations with low selenium 
levels as the population which benefits most from selenium [193]. Again, these findings 
emphasize the selenocompound form and baseline selenium levels as important factors in 
determining the benefits of selenium in lung cancer prevention. 
 A Phase III clinical trial is currently underway to investigate the ability of 
selenium as selenized yeast to prevent new tumor growth in patients with previously 
resected Stage I non-small cell lung cancer (ClinicalTrials.gov Identifier NCT00008385). 
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This trial began enrolling patients in October 2000 and is estimated to be completed in 
November 2014. It will be interesting to see if participants have a similar benefit with 
selenium to that which was seen for vitamin A and whether any observed benefits 
correlate with baseline selenium status.      
 Taken together, these studies indicate a role for selenium in lung cancer, but the 
mechanisms are not well understood. The ability of selenium to serve in the antioxidant 
defense system may be particularly advantageous in lung cancer prevention. Oxidative 
stress, especially from tobacco smoke, has been strongly linked to the pathogenesis of 
lung cancer and attenuation of this stress by selenium could be a beneficial mechanism. 
Additionally, targeting selenium-dependent redox regulation in lung cancer, such as 
through TR1 inhibition, may be useful in anti-cancer therapy to promote an oxidized 
redox state and cell death. Further studies into mechanisms of selenium, such as the ones 
detailed in this work, are necessary to provide greater understanding as to how cancers 
can be most effectively prevented and treated. 
 
Research Objectives 
The overall objective of this research is to determine the redox mechanisms of 
selenium in malignant and nonmalignant human lung cancer cells. The hypothesis for this 
work is that distinct selenocompounds alter the redox status in the lung, with Nrf2/ARE 
pathway activation and TR1 playing a role in this modulation. The effects of various 
selenocompounds on cellular redox status in the lung are currently unknown and may 
relate to the cellular metabolism of a given compound and malignancy status. It is 
thought that selenium may contribute to chemoprevention in nonmalignant lung cells by 
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priming the antioxidant defense system with low levels of redox stress, and in effect 
prepare the antioxidant defense system to attenuate oxidative stress and detoxify potential 
carcinogens. In malignant cells, it is anticipated that TR1 is able to mitigate the redox 
effects of selenocompounds and decreasing its expression will shift cellular redox status 
to the oxidative side and enhance selenocompound-induced cell death. As several 
selenocompounds are assessed in each objective, this work also seeks to provide evidence 
for which form of selenium might be most efficacious in the lung. The findings of this 




 Parameters of cellular redox status were assessed in malignant A549 human 
adenocarcinoma cells and nonmalignant BEAS-2B human bronchial epithelial cells. The 
results indicate that selenium has disparate effects that are both selenocompound and cell 
line-specific. Selenocystine and ChSCA elicited a moderate oxidative stress at 24 hours 
in A549 cells, but not BEAS-2B cells. MSA produced a reductive stress. 
Selenomethionine had no effect on the parameters evaluated in either cell line. The 
selenocompounds investigated also demonstrated greater toxicity in the BEAS-2B line at 
this time point. Additional findings from this work indicate that the basal redox status of 
malignant A549 human adenocarcinoma cells tends to be more reduced in comparison to 
nonmalignant BEAS-2B human lung cells. The difference in basal redox state of these 
two cell lines may explain the differential effects of the selenocompounds in each line.  
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Chapter 3          
 The ability of selenocompounds to induce antioxidant and glutathione-related 
genes in the lung was assessed. Selenocystine showed increased expression of genes 
related to glutathione metabolism (glutathione S-transferases, GPx2) and oxidoreductase 
activity (TR1, NQO1) in the lung tissue of mice provided selenocystine in the diet for 
seven days after NNK administration. Expression of TR1, NQO1, and the glutathione 
biosynthesis gene glutamate cystine ligase catalytic subunit (GCLc) was increased with 
selenocystine, ChSCA, MSA, and selenomethionine in BEAS-2B cells. These 
compounds initially produced reactive oxygen species and depleted glutathione, but 
restored intracellular glutathione to levels at or above baseline by 24 hours. Induction of 
TR1, NQO1, and GCLc by selenocystine, ChSCA, and MSA was shown to be Nrf2 
regulated, as these compounds increased nuclear Nrf2 protein expression and the 
induction of gene expression was attenuated in Nrf2 knockdown cells. No increase in 
nuclear Nrf2 protein expression was found at the same time point for selenomethionine. 
This work concludes that selenocompounds may initially function as prooxidants to 




 In A549 human adenocarcinoma cells, TR1 knockdown enhanced the toxicity of 
selenocystine, BSCA, and ChSCA at 48 hours, but not MSA, selenomethionine or the 
anticancer drug cisplatin. TR1 knockdown also increased the ability of selenocystine and 
the selenazolidines to generate reactive oxygen species. Enhanced cytotoxicity with these 
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compounds was associated with their ability to deplete intracellular total glutathione to 
levels less than 20% of baseline. The cell death mechanism was caspase-independent and 
shown to involve mitochondrial dysfunction, DNA strand breaks, and release of 
apoptosis inducing factor from the mitochondria. The findings from this work emphasize 
inhibition of both the TR and glutathione antioxidant systems as a novel treatment 
strategy for lung cancer.  
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MODULATION OF REDOX STATUS IN HUMAN LUNG  
 





 Cancer prevention strategies utilizing selenium-containing compounds have 
demonstrated reduced cancer mortality and efficacy for some cancer types but the types 
of selenocompounds evaluated have been limited. The literature suggests that there are 
considerable differences in cellular effects among selenocompounds observed in 
preclinical studies. We used human lung cell lines, A549 and BEAS-2B, to evaluate the 
effect on cell viability, redox modulation, and disruption of subcellular compartments by 
the conventional selenium-containing amino acid, selenomethionine, and compare its 
effects with other organoselenocompounds, including selenocysteine prodrugs, which 
have demonstrated provocative anticancer activity in preclinical lung tumor models. In 
these studies, we observed little effect on the cells with selenomethionine treatment, 
evidence of reductive stress with methylseleninic acid, and mild oxidative stress with 
certain selenocysteine prodrugs in the adenocarcinoma cell line but the effects were 
attenuated in the normal, but virally transformed cell line. These data support the notion 




cellular response to the selenocompound and that perhaps other novel selenocompounds 






Selenium is a micronutrient that is required for the synthesis of selenoenzymes, 
including some that are essential for embryogenesis [1-3]. Selenium plays a role in 
human health, with deficiencies in the diet predisposing individuals to certain rare 
diseases such as Keshan disease [4] as well as increase susceptibility to cancer [5].  
However, selenium has also been considered toxic and can even be carcinogenic in 
certain forms [6]. The mechanisms for selenium effects in cancer are not well understood 
and most likely vary with the selenocompound. Nevertheless, several studies have 
demonstrated that selenium supplementation attenuates cancer mortality and disease [7, 
8] and historically, in the United States, dietary selenium levels in forage crops have 
inversely correlated with cancer mortality [9, 10].   
 While the relationship between selenium and cancer is complex, the Nutritional 
Prevention of Cancer (NPC) trial is the seminal study to date that identified a selenium 
cancer prevention benefit by demonstrating an overall decrease in cancer mortality with 
particular benefits to colon, lung, and prostate cancer incidence [11]. Follow up 
evaluation of NPC trial participants maintained a selenium benefit in prostate and a 
marginal benefit for colon cancer but the lung cancer benefit has not remained 
statistically significant [12, 13]. The NPC trial utilized selenium in the form of selenized 




selenomethionine [14]. The results of the NPC trial were instrumental for the largest 
ongoing cancer prevention trial, the Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) [15, 16].  
The biochemistry of selenium and selenocompounds is of interest due to their 
redox properties. However, the cancer prevention activities and toxicities of these 
compounds vary considerably in lung tumor model systems. The inorganic selenium 
compound, sodium selenite, has shown minimal activity while organic selenocompounds 
like 1,4-phenylenebis(methylene)selenocyanate (p-XSC), and certain selenium containing 
amino acids, including selenocystine and many selenazolidines (selenocysteine prodrugs) 
have demonstrated anticancer activity [17-21]. It is of interest that the form of selenium 
most frequently utilized in cancer prevention trials, selenomethionine, as well as a 
methylated form of selenocysteine, Se-methylselenocysteine, also show minimal activity 
in lung cancer model systems [17, 18]. In human lung cell lines various 
selenocompounds have demonstrated anticancer activities; for example, p-XSC and 
methylseleninic acid (MSA) induced cell cycle arrest and apoptosis [22, 23]. Therefore, it 
does not appear that it is merely selenium itself, but perhaps instead, the metabolism and 
biological utility of the selenocompound that will dictate which selenocompounds will be 
most useful for cancer prevention [24]. 
Since the mechanisms for selenium-mediated cancer prevention appear to vary 
among selenocompounds and as there is an unexplained variability in chemopreventive 
efficacy that does not correlate with selenium levels alone, more studies are needed to 
evaluate the activity of distinct selenocompounds to determine which compounds may 




of several classes of selenocompounds, including p-XSC, methylseleninic acid, 
selenoamino acids and selenazolidines on cellular viability, thiol status, generation of 




Materials and Methods 
Materials 
 Materials used included L-selenomethionine and L-selenocystine from Acros 
Organics (Morris Plains, NJ). 2-oxoselenazolidine-4(R)-carboxylic acid (OSCA) and 2-
cyclohexylselenazolidine-4-(R)-carboxylic acid (ChSCA) were synthesized as described 
[25, 26] (supported by USPHS Grant No. GM058913). p-XSC was from LKT 
Laboratories, Inc (St. Paul, MN) and MSA was from PharmaSe, Inc. (Lubbock, TX).  
Cell Counting Kit-8 was from Dojindo Molecular Technologies (Gaithersburg, 
Maryland). Monoclonal antibodies directed against BiP/GRP78 and α-tubulin were 
purchased from Becton Dickinson and Company (Franklin Lakes, NJ) and Zymed 
Laboratories, Inc. (South San Francisco, CA), respectively, and donkey polyclonal anti-
mouse antibodies conjugated with horseradish peroxidase were purchased from Santa 
Cruz Biotechnology  (Santa Cruz, CA). Bovine serum albumin standard and Coomassie 
Plus Protein Reagent were from Pierce Biotechnology (Rockford, IL). Human fibronectin 
and bovine collagen were purchased from Fisher Scientific (Houston, TX).  LHC-8 
medium, Advanced  (DMEM), monobromobimane (mBBr), 2,7-dichlorofluroescein 
diacetate (DCFH-DA), propidium iodide (PI), 5,5’,6,6’-tetrachloro-1,1’,3,3’-




bovine serum albumin were purchased from Invitrogen (Carlsbad, CA). Protease inhibitor 
cocktail tablets (complete) were purchased from Roche (Indianapolis, IN). PVDF 
membrane was purchased from Millipore (Burlington, MA). Western Lighting 
chemiluminescence reagents were from PerkinElmer Life Sciences (Boston, MA). 
Dimethylsulfoxide (DMSO), retinoic acid, and epinephrine were purchased from Sigma-
Aldrich (St. Louis, MO). Common buffers and salts were purchased from Sigma-Aldrich, 
Fisher Scientific or VWR scientific. 
 
 
Cell Lines and Culture Conditions 
 The A549 cell line was purchased from the American Type Culture Collection 
and was cultured in Advanced Dulbecco’s modified essential medium supplemented with 
2% fetal bovine serum and glutamine. BEAS-2B cells (gift from Dr. Christopher Reilly, 
University of Utah) were cultured in LHC-8 medium supplemented with 0.33 nM retinoic 
acid and 2.75 µM epinephrine. To facilitate adhesion, a plate coat of LHC medium 
supplemented with 1 mg/100 ml human fibronectin, 1 mg/100ml bovine collagen, and 
0.75 g/100ml bovine serum albumin was applied to BEAS-2B cell culture flasks and 
plates prior to seeding cells. Both cell lines were maintained at 37oC in an atmosphere of 
5% CO2 and 95% air, with passages made once cells reached ~ 80-90% confluence.  
Selenocystine and selenomethionine were dissolved in the appropriate cell culture 
medium for the cell type. All other selenocompounds were dissolved in DMSO. Final 
concentrations of DMSO for selenocompounds treatments where DMSO served as 







 Cellular viability was determined using a Cell Counting Kit-8 (CCK-8). Briefly, 
cells were seeded into 48-well plates at 2-4 × 104 cells/well and allowed to recover 
overnight. Cells were then treated with selenocompounds in log increment concentrations 
for 24 hours. Following the treatment period, medium was aspirated and replaced with 
4% CCK-8 in the appropriate cell culture medium. Absorbance at 460 nm and 650 nm 
was measured after incubation at 37oC until the reagent developed sufficiently for 
maximal reading using a Perkin-Elmer VictorV3 Multimode Microplate Reader. Sample 
absorbance, measured at 650 nm was subtracted from the 460 nm absorbance to ensure 
that the measurements were not affected by sample turbidity. 
 
 
Cytometric Assays for Redox Metrics 
 Cells were seeded into 6-well plates at a density of ~ 2 × 105 cells/well and 
allowed to grow overnight. Culture medium was refreshed at the time of treatment.  
Cellular fluorescence concentrations were determined 24 hours after treatment using a 
Beckman Cell Lab Quanta SC flow cytometer by dividing the fluorescence for each cell 
by its measured electronic volume. For each assay, a minimum of 10,000 events per 
sample was recorded.   
Free Thiols: Cells were trypsinized, centrifuged at 250×g for 5 minutes, and 
resuspended in 1 ml phosphate buffered saline (PBS). Cells were then centrifuged at 
250×g for 5 minutes and resuspended in a fresh 1 ml of 1× PBS. 40 µM 
monobromobimane (mBBr) was added and samples were incubated at room temperature 




Reactive Oxygen Species: 10 µM 2,7-dichlorofluroescein diacetate (DCFH-DA) 
was added to media of cells in 6-well plates following selenocompound treatment and 
incubated at 37oC with 5% CO2 and 95% air for 30 minutes. Cells were trypsinized, 
centrifuged at 250×g for 5 minutes, and resuspended in 1 ml PBS. 2 µg/ml propidium 
iodide (PI) was then added to the cell suspension to distinguish between viable and 
compromised cell populations. Both DCF and PI fluorescence were measured for each 
sample. DCF fluorescence concentration from PI negative (viable) cells was used for 
reported results.   
 
 
Subcellular Organelle Targets 
 Cells were seeded into 6-well plates at a density of ~ 2 × 105 cells/well and 
allowed to grow overnight. Culture medium was refreshed at the time of treatment. 
Selenocompound effects were measured by evaluation of the mitochondrial potential and 
immunochemical hybridization to determine expression levels of the ER chaperonin 
BiP/GRP78 as a marker of the unfolded protein response. 
Mitochondrial potential: 1 µM JC-1 was added to medium of cells attached to 6-
well plates after selenocompound treatment. Cells were incubated at 37oC with 5% CO2 
and 95% air for 20 minutes and then trypsinized, washed and resuspended as described 
above for cytometric analysis. JC-1 fluorescence at 525 nm (JC-1 “green”) and 575 nm 
(JC-1 “red” or “J-aggregates”) was determined for each sample. JC-1 fluoresces green 
when the mitochondrial potential has been depolarized and forms aggregates that 




3-chlorophenylhydrazone (CCCP) was used at 25 µM to disrupt the mitochondrial 
membrane potential as a positive control. 
BiP/GRP78 Western blot: Cells in 6-well plates were placed on ice. Media was 
aspirated and cells were then washed with 1ml of cold 1× PBS and the PBS aspirated. 
100 µl of a lyses buffer containing 50 µl of 25× complete protease inhibitor cocktail, 12.5 
µl of 10% sodium dodecyl sulfate, 1187.5 µl of a buffer containing 50 mM Tris pH 7.4, 
100 mM NaCl, and 2 mM EDTA was added to each well and cells scraped. Lysate was 
transferred to 1.5 ml microfuge tubes and sonicated 10× using a 40% duty cycle on an 
ultrasonic processor. Lysates were centrifuged 10,000×g for 10 minutes at 4oC and the 
supernatants transferred. Protein concentrations were determined using Bradford 
reagents. Absorbance at 595 nm was measured using a Perkin-Elmer VictorV3 
Multimode Microplate Reader and sample concentrations were determined using a 
bovine serum albumin standard curve. The membrane was probed with primary anti-
BiP/GRP78 antibody at a 1:1000 dilution overnight at 4°C. Membranes were then 
washed with washing buffer (5 mM Tris pH 8.0, 150 mM NaCl, 2.7 mM KCl, 0.1% 
Tween-20), probed with secondary donkey anti-mouse IgG horseradish peroxidase 
antibody at a 1:5000 dilution for 45 minutes at room temperature, and washed again. For 
detection of α-tubulin, membranes were incubated with stripping buffer (62.5 mM Tris 
pH 6.7, 2% sodium dodecyl sulfate, 0.7% β-mercaptoethanol) at 50oC for 1 hour and 
washed. Membranes were probed with anti-α-tubulin at a 1:500 dilution overnight at 4oC, 
washed, and probed with secondary donkey anti-mouse IgG horseradish peroxidase 
antibody as described above. Protein was detected using Western Lightning Western Blot 





 1-way ANOVA was used to determine statistical significance between control and 
treatment values (GraphPad InStat Version 3.06). Dunnett’s multiple comparisons post 
hoc testing was used to establish significance among the distinct selenocompound 





Toxicity of Selenocompounds in Lung Cells 
 Differential toxicity of the selenocompounds was observed between the BEAS-2B 
and A549 cell lines (Figure 2.1). The A549 cells demonstrated greater resistance to 
toxicity for the majority of the selenocompounds, exceptions being p-XSC and higher 
doses of selenocystine. In the more sensitive BEAS-2B cells, p-XSC was highly toxic 
(100% lethal at > 10 µM), followed by selenocystine. The selenazolidines, ChSCA and 
OSCA demonstrated only minor toxicity at doses >100 µM. In the BEAS-2B cells, the 
selenazolidines showed an enhancement of cell viability compared with control at doses 
<20 µM. Within the 24 hour time period of evaluation, MSA-treated cells displayed 
decreased viability at low doses (<2 µM) in both cell lines, but the viability decrease did 
not follow the expected sigmoidal dose response curve. Selenomethionine showed very 
little (BEAS-2B) or no (A549) toxicity. 
 
Alterations in Cellular Redox Parameters 
 Since selenium is redox active, the cellular redox state was determined following 






































































































Figure 2.1. Human lung cell line viability following treatment with 
selenocompounds.  Dose response curves for A549 cells (open squares) and BEAS-
2B cells (filled circles) treated with: (A)  SEM, (B)  MSA, (C) p-XSC, (D) OSCA, 
(E) ChSCA, and (F) SECY for 24 hours. p-XSC and MSA were evaluated at 
concentrations between 0 to 60 µM while all other selenocompounds were evaluated 
at concentrations between 0 to 600 µM. Symbols represent the mean viability of 




cell death, selenocompound concentrations that resulted in less than 25% loss of viability 
were selected for use in further experiments. Since p-XSC was considerably more toxic 
than the other compounds assessed, it was not included in these or any further analyses.   
Cellular free thiol levels were determined as a measure of reducing capacity in a 
time-dependent assay using the fluorophore monobromobimane (mBBr, Figure 2.2). As 
thiol levels can change with cell size, the fluorescence concentration was normalized to 
the electronic volume of the cells. After a 24 hour incubation with 2.5 µM MSA, both 
cell lines showed significant increases in mBBr fluorescence. Selenomethionine 
treatment resulted in an increase in mBBr fluorescence in the A549 cells, but not in the 
BEAS-2B cells. In contrast to MSA, ChSCA and selenocystine exposure produced a 
significant decrease in mBBr fluorescence. The other selenazolidine investigated, OSCA, 
had no statistically significant effect in either cell line.   
Cellular reactive oxygen species (ROS) levels were measured by the oxidation of 
DCFH to the fluorophore DCF (Figure 2.3). Again, the fluorescence concentration of 
cells treated with the selenocompounds was normalized to electronic cell volume. Only       
100 µM selenocystine resulted in a significant alteration in cellular ROS within this 24 
hour period and only in A549 cells. However, we observed a considerable difference in 
the basal DCF fluorescence between these cell lines suggesting that BEAS-2B cells have 
higher basal ROS levels. 
 It should be noted that these alterations in cellular redox status do not appear to 
result from a direct effect of the compounds since cellular redox status changes were not 
seen when cells were evaluated after 4 hours of exposure (data not shown). The changes 
































































































































Figure 2.2. Thiol status following treatment with selenocompounds in human lung 
cells. Analysis of (A) A549 cells and (B) BEAS-2B cells using the fluorophore mBBr as 
a measure of cellular thiol status. Cells were incubated with 40 µM mBBr for 5 minutes 
prior to cytometric analysis. Selenocompounds were used at concentrations that resulted 
in less than 25% decreases in viability. Concentrations used were: SEM, 100 µM; OSCA, 
100 µM; MSA, 5 µM (A549) or 2.5 µM (BEAS-2B); ChSCA, 100 µM (A549) or 50 µM 
(BEAS-2B); SECY, 100 µM (A549) or 25 µM (BEAS-2B). Bars represent the mean 
mBBr fluorescence concentrations normalized to the control with standard deviations.  
The control mean mBBr fluorescence concentrations were 0.267 and 0.203 with 
coefficient of variation of 13% and 12% for A549 and BEAS-2B, respectively.  Samples 



























































































































Figure 2.3. Generation of ROS in human lung cell lines following treatment with 
selenocompounds. Analysis of (A) A549 cells and (B) BEAS-2B cells using the 
oxidation sensitive fluorophore DCFH as a measure of cellular ROS. Cells were 
incubated with DCFH-DA for 30 minutes and then incubated with PI prior to cytometric 
analysis so that only PI-negative cells were assessed for DCF fluorescence. Cells were 
exposed to the selenocompounds for 24 hours. Concentrations used were: SEM, 100 µM; 
OSCA, 100 µM; MSA, 5 µM (A549) or 2.5 µM (BEAS-2B); ChSCA, 100 µM (A549) or 
50 µM (BEAS-2B); SECY, 100 µM (A549) or 25 µM (BEAS-2B). Bars represent the 
mean DCF fluorescence concentrations normalized to the control with standard 
deviations. The control mean DCF fluorescence concentrations were 0.009 and 1.398 for 
A549 and BEAS-2B, respectively. Only SECY in the A549 cells demonstrated a 




shown in Figures 2.2 and 2.3). 
  
Effects of Selenocompounds on Subcellular Organelles 
 To better understand the mechanisms of toxicity seen in Figure 2.1, 
selenocompound effects on the mitochondria and endoplasmic reticulum (ER) were 
evaluated. Of the selenazolidines, only ChSCA was used in these experiments since 
OSCA-treated cells displayed minimal toxicity (Figure 2.1) and did not show significant 
differences in thiol status (Figure 2.2) or ROS (Figure 2.3).   
The mitochondrial potential was measured cytometrically using JC-1 (Figure 2.4).  
In these experiments, a high degree of consistency between cell lines was observed. 
Selenomethionine and MSA treatments did not alter the mitochondrial potential in either 
cell line. Selenocystine and ChSCA treatments both depolarized the mitochondrial 
membrane to an extent similar to the mitochondrial potential disrupter CCCP.  
ER stress has been identified as a consequence of exposure to certain 
selenocompounds [27, 28]. For these studies, BiP/GRP78 protein expression was used as 
a marker of ER stress. BEAS-2B cells appear to have higher basal expression of 
BiP/GRP78 than A549 cells and there was less modulation of the protein level in    
BEAS-2B cells. This higher level of Bip/GRP78 protein expression in BEAS-2B cells is 
consistent with the higher basal ROS levels observed above (Figure 2.3). In A549 cells, 
MSA, selenocystine, and ChSCA induced BiP/GRP78 protein expression (Figure 2.5). In 
BEAS-2B cells, minor changes in BiP/GRP78 expression were observed but not 
consistently among multiple experiments. Selenomethionine did not appear to induce ER 
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Figure 2.4. Depolarization of mitochondrial membrane potential by 
selenocompounds.  Analysis of (A) A549 cells and (B) BEAS-2B cells using the 
mitochondrial fluorophore JC-1 to cytometrically measure the mitochondrial membrane 
potential. CCCP (25 µM), a recognized mitochondrial membrane potential disrupter, was 
utilized as a positive control. Cells were incubated with selenocompounds for 24 hours. 
The concentrations of the compounds used were: SEM, 100 µM; MSA, 5 µM; ChSCA, 
200 µM (A549) or 100 µM (BEAS-2B); SECY, 100 µM (A549) or 50 µM (BEAS-2B). 
Bars represent the percentage of the cellular population with polarized mitochondria as 
indicated by red fluorescence (525 nm) or depolarized mitochondria as indicated by green 
fluorescence (575 nm) with standard deviations. Treatment with CCCP, ChSCA, and 














Figure 2.5. Induction of BiP/GRP78 expression by selenocompounds in human lung 
cells. As an indicator of ER stress and the unfolded protein response, BiP/GRP78 was 
evaluated by immunoblot (a representative blot of replicate experiments is shown). Cell 
lysates were homogenized and 10 µg of protein was loaded onto a NuPAGE 10% Bis-
Tris gel and transferred to a PVDF membrane for immunochemical analysis as described 
in the Methods. Cells were incubated with the selenocompounds for 24 hours. The 
concentrations of the compounds used were: SEM, 100 µM; MSA, 5 µM; ChSCA,      
200 µM (A549) or 100 µM (BEAS-2B); SECY, 100 µM (A549) or 50 µM (BEAS-2B). 




























































Selenium compounds can display differential effects in cancer and noncancer 
cells; however the mechanisms that delineate these differences are not clear. Previous 
studies have demonstrated selenium-mediated effects in premalignant and neoplastic rat 
and canine mammary cells but minimal effects in normal cells [29, 30]. In addition, 
another study has demonstrated differences between normal and transformed human cell 
lines treated with selenite [31]. In the experiments described herein, A549 cells, a 
commonly used lung adenocarcinoma-derived cell line, and BEAS-2B cells, normal lung 
epithelial cells virally transformed for immortal growth in culture that generally display a 
non-tumorigenic phenotype [32, 33], were utilized to examine selenocompound selective 
sensitivity. We observed differences in the viability and redox modulation by distinct 
selenocompounds between these cells, and these differences may reflect the basal redox 
states that reflect the mutational status of KEAP1, a negative regulator of NRF2, an 
activator of antioxidant genes, in these cells [34].  
Distinct selenocompounds have also demonstrated unexplained variability in 
cancer prevention model systems. In human lung cell lines, various selenocompounds 
have demonstrated anticancer activities; for example, p-XSC and MSA induced cell cycle 
arrest and apoptosis [22, 23], while selenomethionine enhanced the radiation-mediated 
cell killing [35]. These studies are consistent with potential antitumor activities.  
Nevertheless, in the widely used murine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) lung tumor model, inorganic sodium selenite was ineffective [17, 18] while the 
organic selenocompound, p-XSC, reduced the tumor burden in NNK-induced lung cancer 




selenocystine and many selenazolidines (selenocysteine prodrugs), were effective against 
NNK-induced lung tumors [18, 21]. However, a methylated form of selenocysteine,     
Se-methylselenocysteine, lacked activity in this model [17, 18]. Selenomethionine, the 
currently preferred agent in human selenium cancer prevention studies, does not show 
efficacy at chemoprevention in studies in animal models of lung cancer [18, 36] and has 
not proven effective as a cancer prevention agent in the follow-up studies of human lung 
cancer [12, 13]. In contrast to MSA and the selenazolidines, selenomethionine did not 
modulate redox parameters measured in the experiments herein, except a modest increase 
in cellular thiol levels in A549 cells (Figures 2.2 and 2.3), and did not affect the 
mitochondrion or ER subcellular compartments. A possible explanation for the lack of 
efficacy of selenomethionine may be due to misincorporation in protein synthesis [12], 
i.e., replacing methionine, rather than metabolic conversion of the selenium component 
into either newly synthesized selenoproteins or methylselenol. Other selenocompounds 
that have demonstrated preclinical efficacy in lung cancer models await clinical scrutiny.   
The mechanisms of MSA-mediated cancer prevention have been rigorously 
pursued and indicate that the methylselenol metabolite is crucial for activity [37].  
Mechanistic studies point to induction of the unfolded protein response (UPR) in the ER 
as a likely cellular locus of action [27, 28]. Our data with MSA are consistent with these 
previous studies and support the hypothesis that it generates a reductive stress, which was 
observed by increased monobromobimane fluorescence in both A549 and BEAS-2B cells 
(Figure 2.2). This stress on the ER was validated by the increase in BiP/GRP78 protein 




Of the selenium-containing amino acids, the diselenide selenocystine was clearly 
the most toxic and demonstrated an oxidative activity in cells by decreasing free thiols in 
both A549 and BEAS-2B cells (Figure 2.2), as well as overtly increasing ROS levels in 
A549 cells (Figure 2.3). The selenocysteine prodrugs, OSCA and ChSCA, were 
considerably less toxic than selenocystine (Figure 2.1), and their redox modulation of the 
lung cell lines may reflect the differences in the expected metabolism of these 
compounds. ChSCA is expected to spontaneously hydrolyze to selenocysteine while 
OSCA is expected to require enzymatic degradation by 5-oxo-L-prolinase to release 
selenocysteine [26]; OSCA displayed less redox modulation than ChSCA, especially in 
A549 cells. Indeed, there are reports of oxoprolinase levels differing in the tissue of 
normal lung and lung cancer, with oxoprolinase expression decreasing in lung cancer 
compared to normal lung tissue [38]. The cellular redox alterations observed with 
ChSCA may suggest that a more rapid release of selenocysteine from ChSCA may 
generate some selenocystine.   
  Based on the differences in redox modulation by distinct selenocompounds, we 
suggest that these differences may provide a basis for distinct mechanisms of action in 
tumor models. Of the redox modulating selenocompounds, we speculate that the 
selenocystine and the selenazolidines may activate an antioxidant response while MSA 
activates a reductive stress pathway. The selenazolidines show particular promise due to 
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SELENOCOMPOUND INDUCTION OF ANTIOXIDANT GENES                                
 






 Organoselenium compounds have been shown to decrease lung tumor incidence 
in tobacco carcinogen animal models, such as the NNK model. Selenium 
supplementation trials and epidemiological studies have also indicated a potential benefit 
of selenium in lung cancer, although the chemoprevention mechanism of selenium in the 
lung is not well understood.  Here we show that independent of NNK administration, 
selenocystine induces mRNA expression of genes associated with glutathione 
metabolism and oxidoreductase activity in the lungs of female A/J mice. To further 
investigate the mechanism of gene induction, we utilized the BEAS-2B human lung cell 
line and found that selenocystine, the selenocysteine prodrug ChSCA, MSA, and the 
common nutritional supplement, selenomethionine all increased reactive oxygen species 
levels and depleted intracellular glutathione at 2 hours. Selenocystine, ChSCA, and MSA, 
but not selenomethionine, increased nuclear Nrf2 protein expression at 4 hours.  
Nevertheless, all the selenocompounds increased both TR1 mRNA and protein 
expression, and NQO1 mRNA at 24 hours. With the exception of selenomethionine, the 
compounds increased intracellular glutathione levels at 24 hours. ChSCA and MSA also 
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increased expression of these genes in normal human bronchial epithelial cells, while 
none of the compounds modulated expression in A549 adenocarcinoma cells. Nrf2 
knockdown inhibited the ability of the selenocompounds to induce antioxidant gene 
mRNA in BEAS-2Bs. Taken together, these findings indicate that although the time 
course and cell line sensitivity may differ among compounds, organoselenium 
compounds can increase cellular antioxidant capacity through the Nrf2/ARE pathway and 






 Selenium in the form of several organic compounds has been investigated as an 
agent for lung cancer prevention. Selenocystine and certain selenazolidines 
(selenocysteine prodrugs) have demonstrated efficacy in reducing the number of lung 
tumors formed in the NNK mouse model of lung tumorigenesis [1, 2]. p-XSC has also 
demonstrated efficacy in the NNK model, while sodium selenite and, notably, 
selenomethionine were ineffective [1, 3]. Se-methyl-L-selenocysteine, the methylated 
cysteine congener of selenomethionine, was also ineffective [1]. Methylseleninic acid 
(MSA), a methylselenol precursor, has yet to be evaluated in an animal model of lung 
cancer, but has exhibited antiproliferative activity in lung cell culture [4]. These studies 
show that selenium can function as a chemopreventive agent in the lung, but efficacy is 
compound dependent. The NPC trial has also indicated a potential benefit for selenium in 
decreasing lung incidence and mortality [5]. The mechanism of chemoprevention and 
which form of selenium might be most efficacious both remain under investigation. 
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 It is well established that cigarette smoke contains reactive oxygen and nitrogen 
species that can place a large oxidative burden on the lung. Oxidative stress contributes to 
the initiation and progression of lung carcinomas [6] and a chemoprevention strategy to 
combat oxidative insult is to increase the antioxidant defense system of the lung. 
Activation of the Nrf2 pathway is one mechanism by which antioxidant capacity can be 
enhanced. Nrf2 is basic leucine zipper transcription factor that under basal conditions is 
tethered to the cytoplasm by its negative regulator Keap1, where it remains inactive and 
is targeted for proteasomal degradation by ubiquitation [7, 8]. Under conditions of 
oxidative or electrophilic stress, Nrf2 dissociates from Keap1 and can then translocate to 
the nucleus. Once in the nucleus, Nrf2 associates with small Maf proteins and binds to 
ARE sequences located in gene promoters to initiate transcription. A battery of 
antioxidant and phase II detoxifying genes are recognized as being regulated by Nrf2 [9], 
including the antioxidant enzymes NQO1 [10], TR1 [11, 12], and GPx2 [13]; the 
glutathione-S-transferase (GST) and UDP glucuronosyltransferase (UGT) detoxification 
enzymes [9, 14, 15]; and the glutamate cysteine ligase catalytic (GCLc) and modulatory 
subunits required for glutathione biosynthesis [16]. Thus, Nrf2 activation serves as a 
method by which the inherent cellular antioxidant defense can be enhanced to attenuate 
oxidative stress, such as that implicated in lung cancer development.  
 Previous work focused on the lung has been shown that certain selenocompounds 
have the ability to modulate redox parameters in vitro [17] and decrease tumor burden in 
vivo [1, 2]. These alterations in cellular redox status coupled with the observed 
chemopreventitive activity led us to investigate whether Nrf2 is involved in the response 
of the lung to organoselenium compounds. We demonstrate herein that selenocystine,                                  
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ChSCA and MSA increase endogenous antioxidant and glutathione biosynthesis gene 
expression in the lung in an Nrf2-dependent manner. 
 
Materials and Methods 
 
Reagents 
 L-selenocystine and DMSO were purchased from Sigma–Aldrich (St. Louis, 
MO), L-selenomethionine was from Acros Organics (Morris Plains, NJ), MSA was 
purchased from PharmaSe, Inc. (Lubbock, TX), R-sulforaphane [1-isothiocyanate-(4R)-
(methylsulfinyl)butane] was from LKT Laboratories (St. Paul, MN), and ChSCA was 
synthesized as previously described [18]. AIN-76A diet was from Dyets, Inc. 
(Bethlehem, PA) and NNK was obtained from Toronto Research (Toronto, Canada). 
BEAS-2B cells were a gift from Dr. Christopher Reilly (University of Utah). Advanced 
DMEM, LHC-8 media, LHC basal media, First Strand cDNA synthesis kit with 
SuperScriptIII, H2DCFDA, PI, NuPAGE Bis-Tris gels, Lipofectamine 2000, and Opti-
MEM I reduced-serum media were from Invitrogen (Carlsbad, CA). SYBR Green I 
Master Mix and Complete protease inhibitor tablets were from Roche (Indianapolis, IN). 
Bovine serum albumin standard, Coomassie Plus Protein Reagent, SuperSignal 
chemiluminescence reagent, and tris(2-carboxyethyl)phosphine hydrochloride (TCEP 
HCl) were from Thermo Scientific (Rockford, IL). Primary monoclonal antibody against 
TR1 and primary polyclonal antibodies against Nrf2 (C-20), lamin B1 and GAPDH were 
from Santa Cruz Biotechnology (Santa Cruz, CA). NQO1 polyclonal primary antibody 
was purchased from Abcam (Cambridge, MA). Secondary horseradish peroxidase 
(HRP)-conjugated antibodies were from Santa Cruz Biotechnology or CalBioChem (San 
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Diego, CA). GSH-Glo and CellTiter-Fluor kits were purchased from Promega (Woods 
Hollow, WI). Primers for QPCR and siRNA oligos were synthesized at the University of 





 BEAS-2B cells were cultured in LHC-8 media supplemented with 2.75 µM 
epinephrine and 0.33 nM retinoic acid. The normal human bronchial epithelial (NHBE) 
primary cell line with retinoic acid was purchased from Lonza and cultured in bronchial 
epithelial growth media (BEGM). A549 cells were from ATCC and were cultured in 
advanced DMEM supplemented with 1% Glutamax and 2% fetal bovine serum. Prior to 
seeding, BEAS-2B and NHBE cell culture surfaces were pretreated with a plate coat 
consisting of LHC basal media, 10 µg/ml bovine serum albumin, 10 µg/ml fibronectin, 
and 30 µg/ml collagen. NHBE cells at or below passage number 6 were utilized for 
experiments. For cell treatments the following concentrations were used: 100 µM 
selenomethionine, 2.5 µM MSA, 1 µM (BEAS-2B), 5 µM (NHBE), or 100 µM (A549) 
selenocystine, 5 µM (NHBE), 25 µM (BEAS-2B) or 50 µM (A549) ChSCA, and 1 µM 
(NHBE), 5 µM (BEAS-2B) or 10 µM (A549) SF. Treatments were performed at 
concentrations where cells demonstrated ≥75% viability after 24 hours [17; 19-21]. 






Animals and Lung Tissue RNA Collection 
 Female A/J mice at 5 weeks of age were obtained from the Jackson Laboratory 
(Bar Harbor, ME). Animals were housed on hardwood bedding in a temperature and 
humidity controlled environment on a 12 hour light/dark cycle and given free access to 
food and water. Animals were stabilized on an unsupplemented AIN-76 diet for 1 week 
prior to being given the selenium supplemented diet. The basal level of selenium in the 
diet is 0.35 ppm selenium. NNK was administered i.p. as a single 10 µM injection in 0.2 
mL saline. With this protocol, 100% of animals reproducibly develop lung tumors after 3 
months [22]. Three days after NNK administration, animals were provided AIN-76A 
diets supplemented with selenocystine at 15 ppm selenium ad libitum for 10 days. This 
15 ppm concentration in the diet has demonstrated little toxicity while decreasing lung 
tumor incidence when given during the pre- and post-initiation periods and the post-
initiation period alone in the NNK model [1, 2]. Fresh preparations of the selenocystine 
diet mix were provided to animals daily. Animal procedures were approved by the 
University of Utah Animal Care and Use Committee and conducted in agreement with 
NIH laboratory animal care guidelines. 
 Animals were sacrificed thirteen days after NNK administration. Lung tissue was 
harvested, immediately homogenized in Trizol and frozen. RNA was purified by the 
Trizol protocol followed by Qiagen RNeasy clean-up and then quantified on a Nanodrop 
ND-1000 spectrophotometer. The quality of the RNA samples collected was determined 
using the Experion Automated Electrophoresis Station (Biorad) with the RNA StdSens 




Microarray Expression Analysis 
 Microarray gene expression analysis was performed using Agilent 44K Whole 
Mouse Genome Oligonucleotide Microarrays in a manner similar to how we have 
previously analyzed microarray data [23]. Agilent labeling kits were used to generate Cy-
dye labeled cRNA. The four no-treatment samples were combined and used as a standard 
reference to phenotypically anchor the dataset. Slides were hybridized and then scanned 
with the Agilent Microarray Scanner equipped with Feature Extraction software 
(FEv8.1). This software preprocesses the data as follows: local background is subtracted, 
irregular spots flagged, and global linear regression (lowess) normalization is performed, 
and this ratio is log transformed.  We imported the data into TIGR MEV 3.1 software for 
further analysis. A supervised strategy was used to identify the genes with the greatest 
significant differences among untreated, NNK, selenocystine and NNK plus 
selenocystine treatment groups using multiclass Significance Analysis of Microarrays 
(SAM).  Five-hundred iterations were used in the SAM analysis to evaluate the false 
discovery rate and a conservative cutoff was used (median false discovery rate of 0%) to 
identify differentially expressed genes. Gene Ontology analysis of the differentially 
expressed genes was assessed with Expression Analysis Systematic Explorer (EASE). 
The gene expression profiles for the genes highlighted by the EASE assessment were 
hierarchically clustered for visualization. 
 
Quantitative Real Time PCR 
 Total RNA was isolated from cells using the Qiagen RNAeasy kit. First stand 
cDNA synthesis was performed using 1 µg total RNA and 150 ng/µL random primers 
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with SuperScriptIII according to the manufacturer’s protocol. QPCR was performed 
using a Roche LightCycler 480 for 40 cycles at 95oC for 10 s, 65oC for 5 s, and 72oC for 
10 s. Each amplification reaction contained a 1:80 dilution of cDNA, 500 nM primer, and 
SYBR Green I Master Mix. Target gene mRNA expression was normalized to beta-2 
microglobulin (β2M) mRNA expression. Melt curve analysis was performed after 
amplification to ensure the generation of a single product. The following primer sets were 
utilized:  
 TR1 forward: 5’- TTGGAATCCACCCTGTCTGT-3’ 
 TR1 reverse: 5’-CATCCACACTGGCTTAAC-3’ 
 NQO1 forward: 5’-ATGTATGACAAAGGACCCTTCC-3’ 
 NQO1 reverse: 5’-TCCCTTGCAGAGAGTACATGG-3’ 
 GCLC forward: 5’-ATGCCATGGGATTTGGAAT-3’,  
 GCLC reverse: 5’-AGATATACTGCAGGCTTGGAATG-3’ 
 β2M forward: 5’-TTCTGGCCTGGAGGCTATC-3’ 
 β2M reverse: 5’-TCAGGAAATTTGACTTTCCATTC-3’.  
 
Reactive Oxygen Species 
 Reactive oxygen species were assessed following 2 hour treatments by incubating 
cells with 20 µM H2DCFDA for 20 minutes at 37oC. 2',7'-dichlorofluorescin (DCF) and 
PI fluorescence concentrations were determined cytometrically as previously described, 





Total Intracellular Glutathione 
 Glutathione concentrations were determined after 2 hour treatments using the     
GSH-Glo kit as previously described [24]. Reduced glutathione (GSH) was directly 
measured. Total glutathione (GSSG + GSH) was measured by adding 1 mM TCEP. GSH 
concentrations were normalized to the live cell fluorescence values obtained using the 
CellTiter-Fluor reagent.  
 
Immunoblot Analysis 
 Whole cell lysates were collected in passive lyses buffer as previously described 
[17]. Nuclear lysates were obtained with the Active Motif Nuclear Extract Kit following 
the manufacturer’s protocol. Protein concentrations were determined using the Bradford 
method. Equal amounts of protein were run out on 10% or 4-12% NuPAGE Bis-Tris gels 
and transferred to PVDF membranes. Membranes were blocked with 5% milk in T-BST 
and probed with the following primary antibody dilutions: 1:200 anti-Nrf2, 1:200 anti-
lamin B1, 1:300 anti-TR1, 1:800 anti-NQO1, 1:500 anti-GAPDH. When probing for 
Nrf2, membranes were incubated with primary antibody overnight, fixed in 0.25% 
glutaraldehyde in cold PBS for 15 minutes at 4oC, and blocked again in 5% milk. 
Membranes were washed with T-BST, probed with HRP conjugated secondary 
antibodies, and washed again with T-BST. Protein was detected using 






Nrf2 Knockdown by siRNA 
 BEAS-2B cells were seeded at 5.5 x 104 cells/well and allowed to recover 
overnight. Cells were transfected with 200 nM Nrf2 siRNA [25] or control siRNA that 
does not code for any known human gene (5’-AGGCAAAUCACGGUGUCCUtt-3’, 
sense sequence) using Lipofectamine 2000 in OptiMEM serum free medium. After 24 
hours, the transfection mixture was removed and LHC-9 media containing the treatment 
compounds was added. Treatments were performed for 24 hours, after which whole cell 
lysates for immunoblotting and total RNA for QPCR were collected as described above.      
 
Statistical Analysis 
 Data are presented as mean ± standard deviation. Two-way ANOVA with Holm-
Sidak post-hoc testing was used to analyze the mRNA expression data for BEAS-2B 
Nrf2 knockdown and control cells. All other data were evaluated using one-way ANOVA 
Holm-Sidak post-hoc testing. p < 0.05 was considered significant. SigmaStat Version 3.5 






Induction of Antioxidant and Phase II Genes in Mouse Lung 
 Gene expression in mouse lung RNA was assessed 13 days after NNK 
administration in untreated, NNK-only, selenocystine-only, and selenocystine + NNK 
treated animals. We chose this early time point after carcinogen administration but before 
tumorigenic changes occur to gain insight into effects selenocystine may have on the lung 
92 
 
in this premalignant stage. No tumors or pathology were observed when the lungs were 
harvested. 
 Of the >41,000 data elements on the murine whole genome microarrays, only 60 
elements representing 54 unique genes were identified by multiclass SAM as 
differentially expressed among the four treatment groups designated as untreated, NNK, 
selenocystine, and NNK plus selenocystine. No changes in genes related to NNK 
metabolism, such as cytochrome P450s, were observed at this time point following 
selenocystine consumption. Of the genes induced, enrichment of those related to GSH 
metabolism and oxidoreductase activity was indicated by EASE analysis in the 
selenocystine and selenocystine + NNK animals (Figure 3.1). Little induction of these 
genes occurred in the untreated and NNK-only animals. This indicates that increased 
expression of this set of genes is in response to the selenocystine and is unrelated to 
NNK. Several Gst classes were induced, including the alpha, mu, and pi isoforms. These 
enzymes catalyze the formation of GSH conjugates with a variety of xenobiotics. Gpx2, 
an enzyme that utilizes GSH to reduce hydroperoxides, was also induced.  Thioredoxin 
reductase 1 (Txnrd1) is one of the primary regulators of cellular redox status, contributing 
to overall oxidative tone and redox-dependent signaling. Selenocystine exposure also 
increased expression of the detoxifying enzymes Nqo1, Ugt1a6b, carboxylesterase 1 
(Ces1), sulfiredoxin 1 (Srxn1) and aldehyde dehydrogenase family 1 member A1 
(Aldh1a1), indicating an increased capacity of the lung to metabolize oxidative and 
reactive species. All these genes induced by selenocystine are known to be regulated by 


























Figure 3.1. Heatmap of mRNA expression in mouse lung by selenocystine. Mice were injected with NNK and 3 days later 
provided diets supplemented with selenocystine (SECY) at 15 ppm selenium for 10 days. Lung tissue was then harvested and RNA 
purified for whole genome microarray gene expression analysis. Using multiclass SAM, only 60 elements distinguished the gene 
expression among four groups: untreated, NNK-treated, SECY, and SECY plus NNK.  EASE analysis of those genes identified 
glutathione metabolism and oxidoreductase activity as significantly enriched.  The heatmap displays the relative gene expression 




Induction of Nrf2 Target Genes in Human Lung Cells 
 To investigate the involvement of Nrf2 in the mechanism of antioxidant gene 
induction that was observed in the mouse lung, we utilized the human lung BEAS-2B cell 
line. BEAS-2Bs are a human nonmalignant bronchial epithelial cell line transformed with 
adenovirus. We were interested in whether induction of this class of genes is specific to 
selenocystine, or also occurs with the selenocysteine prodrug ChSCA, the selenoamino 
acid selenomethionine, or the hypothesized methylselenol precursor MSA. The 
isothiocyanate sulforaphane (SF), a known Nrf2 activator and phase II enzyme inducer, 
served as the positive control for cell culture experiments [26].  
 All selenocompounds increased the mRNA expression of two antioxidant genes, 
the selenoenzyme TR1 and the nonselenium containing antioxidant gene NQO1, at 24 
hours, with ChSCA increasing mRNA levels to the greatest extent (Figure 3.2A, B).  
Increases in TR1 protein expression were also observed with all treatments.  However, 
protein levels did not quantitatively correlate with the level of mRNA induction (Figure 
3.2C, D). ChSCA increased TR1 mRNA expression to the greatest extent, but 
selenocystine produced the greatest increase in TR1 protein expression. Modest increases 
in NQO1 expression were observed with all treatments. These data suggest that the 
induction of TR1 and NQO1 is quite dynamic for mRNA but more modest for protein. 
Overall, the organoselenium compound induction of protein for both TR1 and NQO1 was 
similar in magnitude to the positive control, sulforaphane.   
 The ability of the selenocompounds to induce glutathione biosynthesis was also 
assessed. Messenger RNA expression of GCLC, the catalytic subunit for the rate limiting 
step of glutathione synthesis [27] was significantly increased by selenocystine, ChSCA, 


































Figure 3.2. Induction of Nrf2 regulated antioxidant genes in BEAS-2B cells following 24 hour treatment. (A) TR1 and (B) 
NQO1 mRNA expression. Data are presented as mean fold change relative to DMSO control. n=3 for all treatments. Treatments were        
100 µM selenomethionine (SEM), 2.5 µM methylseleninic acid (MSA), 1 µM selenocystine (SECY), 25 µM 2-
cyclohexylselenazolidine-4-carboxylic acid (ChSCA) and, the positive control, 5 µM sulforaphane (SF). Significant differences are 
denoted by: ‘*’, ‘**’, and ‘***” indicate p<0.05, p<0.01, and p<0.001 versus DMSO control, respectively. (C) TR1 and (D) NQO1 
protein expression as determined by Western blotting. GAPDH was probed as protein loading control. Immunoblots shown are 
representative of at least two experimental replicates. 
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selenomethionine, and the positive control, sulforaphane (Figure 3.3A). The 2-fold 
increase in GCLC mRNA elicited by MSA treatment was not statistically significant at 
the p=0.05 level. The intracellular glutathione content was also assessed to determine the 
possible functional consequence of GCLC mRNA induction. We measured both 
intracellular GSH (reduced glutathione) and GSH + GSSG (total glutathione) levels to 
gain insight into the relative redox status of glutathione as a measure of overall oxidative 
tone. Selenocystine, ChSCA and MSA significantly increased glutathione levels to a 
greater extent than sulforaphane (Figure 3.3B). Similar increases occurred for both total 
and reduced GSH, that is, the GSH/GSSG ratio did not markedly change. 
Selenomethionine was unique in that the increased GCLC mRNA expression did not 
result in increased GSH or GSSG content above baseline levels.  MSA was able to elicit 
an increase in GSH and GSSG content despite only the minor two fold increase in GCLC 
mRNA expression.   
 Antioxidant gene mRNA expression was also assessed in NHBE cells, another 
model of the nonmalignant lung, to determine broad applicability of selenocompound 
effects. The changes in gene expression occurred earlier in the NHBE cells for all 
selenocompounds compared to the BEAS-2B cells so effects were primarily monitored 
after 12 hours. While selenocystine did not change mRNA expression of TR1, NQO1, 
and GCLC in this cell line, the selenocysteine prodrug, ChSCA produced a robust 
response in all three genes (Figure 3.4A). Selenomethionine did not induce any of these 
genes in NHBE cells, while MSA increased expression of all three although the 4-fold 



















































Figure 3.3. Glutathione is increased in BEAS-2B cells after 24 hour selenocompound 
treatment. Treatment concentrations were 100 µM SEM, 2.5 µM MSA, 1 µM SECY, 25 
µM ChSCA, and 5 µM SF. (A) GCLC mRNA expression. Data are presented as mean 
fold change relative to DMSO control. n=3 for all treatments. Selenocompound 
treatments are as denoted in Figure 3.2. Significant differences are denoted by: ‘*’, ‘**’, 
and ‘***” indicate p<0.05, p<0.01, and p<0.001 versus DMSO control, respectively. (B) 
Reduced and total intracellular glutathione levels. Data are normalized to cell viability 
fluorescence measurements and are presented as mean % total glutathione DMSO 
control. n=4 for all treatments. ‘**’ indicates p<0.01 and ‘***’ indicates p<0.001 versus 






Figure 3.4. Induction of Nrf2 target genes by selenocompounds is lung cell line-specific. Data are presented as mean fold change 
relative to DMSO control. (A) mRNA expression in NHBE cells following 12 hour treatment. Treatment concentrations were 100 µM 
SEM, 2.5 µM MSA, 5 µM SECY, 5 µM ChSCA, and 1 µM SF. ‘***’ indicates p<0.001 versus DMSO control (B) mRNA expression 
in A549 cells following 24 hour treatment. Treatment concentrations were 100 µM SEM, 2.5 µM MSA, 100 µM SECY, 50 µM 
ChSCA, and 10 µM SF. ‘*’ indicates p<0.05 versus DMSO control.   
A5 4 9  2 4  h r  m RN A e x p re s s io n

























































1 4 TR 1
N Q O 1







































sulforaphane, only significantly increased TR1 mRNA expression at the 12 hour time 
point.  
In a human lung adenocarcinoma cell line in which the Nrf2/ARE induction 
pathway is constitutively active, no change in the mRNA expression of TR1, NQO1, or 
GCLC was observed for any selenocompound (Figure 3.4B). Sulforaphane was the only 
compound to produce a significant induction in this A549 cell line, a 2-fold increase in 
GCLC. 
 
Effects of Selenocompounds on Redox Balance 
 Increased cellular oxidative tone is known to be one mechanism by which the 
Nrf2 induction pathway can be activated. We sought to determine whether 
selenocompound exposure elicits a change in oxidation that could lead to Nrf2 pathway 
activation in the BEAS-2B cells. All the selenocompounds and sulforaphane produced a 
rapid (within 2 hours) increase in reactive oxygen species (Figure 3.5A) and a decrease in 
intracellular glutathione content (Figure 3.5B). As with the 24 hour time point above 
(Figure 3.3B), changes in reduced GSH mirrored those for total GSH, indicating that the 
compounds are depleting GSH and not oxidizing GSH to GSSG. MSA was the least 
effective agent in depleting glutathione.  
 
Effect of Selenocompounds on Nrf2 Nuclear Localization 
 In order for Nrf2 to drive transcription of ARE genes, it must translocate from the 
cytosol to the nucleus. We performed Western blotting of BEAS-2B cell nuclear lysates 
to determine if, after 4 hours, selenocompounds increased the amount of nuclear, and  
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Figure 3.5. Effects of selenocompounds on ROS levels and intracellular GSH in 
BEAS-2B cells at 2 hours. Treatment concentrations were 100 µM SEM, 2.5 µM MSA, 
1 µM SECY,    25 µM ChSCA, and 5 µM SF. (A) DCF fluorescence concentration. Data 
are presented as mean % DMSO control and are for the PI negative population. 
Significant differences are denoted by: ‘*’ indicates p<0.05 and ‘***’ indicates p<0.001 
versus DMSO control, n=3 for all treatments.. (B) Reduced and total intracellular GSH 
content. Data are normalized to cell viability fluorescence measurements and are 
presented as mean % DMSO total glutathione. n=4 for all treatments. ‘*’ indicates 




therefore active, Nrf2 protein. Nuclear Nrf2 was detectable in cells treated with DMSO, 
indicating that basal Nrf2 activity exists in BEAS-2B cells.  Selenocystine, ChSCA, and 
MSA, but not selenomethionine, increased Nrf2 localization in the nucleus to an equal or 
greater extent than sulforaphane (Figure 3.6). 
 
Nrf2 Knockdown Attenuates ARE Gene Induction by Selenocompounds 
 To determine if Nrf2 is responsible for the increased mRNA expression of ARE- 
responsive  genes  by  selenocompounds,  we  used  small  interfering  RNA  (siRNA)  to 
transiently depress Nrf2 expression.  Low basal protein expression of Nrf2 in BEAS-2B 
cells necessitated stimulation with sulforaphane to assess protein attenuation with the use 
of siRNA. In cells transfected with control siRNA, a small amount of Nrf2 protein is 
expressed in DMSO vehicle treated cells but sulforaphane significantly increased Nrf2 
protein expression. However, the induction of Nrf2 protein by sulforaphane was 
attenuated by greater than 95% in the cells transfected with Nrf2-specific siRNA (Figure 
3.7A). To confirm that a functional knockdown was achieved, TR1 and NQO1 protein 
expression levels were also determined from the sulforaphane-treated cells. Both proteins 
show increased expression with sulforaphane stimulation in cells transfected with control 
siRNA, but the induction of TR1 and NQO1 following sulforaphane stimulation was not 
observed in the cells transfected with Nrf2-specific siRNA. GAPDH was used as a 
loading control and did not change with sulforaphane stimulation. 
The mRNA levels of TR1, NQO1 and GCLC were assessed following treatment 
with the siRNAs as well as the selenocompounds or sulforaphane. Nrf2 knockdown 













Figure 3.6. Selenocompounds increase Nrf2 nuclear protein expression. 
Immunoblotting of Nrf2 in BEAS-2B nuclear lysate fractions after 4 hour treatments. 
Treatment concentrations were 100 µM SEM, 2.5 µM MSA, 1 µM SECY, 25 µM 
ChSCA, and 5 µM SF. 20 µg nuclear lysate was loaded per sample. Lamin B1 served as 




0.35, 0.20, and 0.45 that of “control” siRNA cells, respectively. The expression of TR1, 
NQO1, and GCLC in cells transfected with control siRNA (Figure 3.7B, C, and D) the 
same pattern as in nontransfected BEAS-2B cells (Figures 2A, 2B, and 3A). 
Selenocystine, ChSCA, MSA, and sulforaphane increased TR1 and NQO1 expression in 
“control” siRNA treated cells at 24 hours (Figure 3.7B and C).  Selenocystine, ChSCA, 
and sulforaphane, but not MSA, increased GCLC mRNA levels (Figure 3.7D). The 
increases in mRNA expression of TR1, NQO1, and GCLC by selenocompounds or 




Lung cancer is the leading cancer type for cancer deaths. There were an estimated 
222,520 new cases of lung and bronchus cancer in the United States in 2010, making it 
the second most common cancer type [28]. Although other cancer types have seen 
improvements in survival rates, the five-year survival rate for lung cancer has only 
improved marginally from 13% in 1975 to 16% in 2005. The poor prognosis associated 
with lung cancer can be attributed to the typical late stage diagnosis of the disease and 
failure of chemotherapy. Because of this poor clinical prognosis and the large population 
susceptible to lung cancer from tobacco smoke, novel strategies for lung cancer 
prevention are necessary. 
 A role for Nrf2 as a protective pathway in the lung has been well established over 
the past decade. Several studies using Nrf2 knockout mice have demonstrated the ability 
of Nrf2 to protect the lung from oxidative damage. Nrf2 knockout mice are more 
susceptible to developing airway diseases such as asthma [29], emphysema [30-32], and 





















Figure 3.7: Attenuation of selenocompound-induced antioxidant gene expression 
with Nrf2 knockdown. BEAS-2B cells were transfected with Nrf2 or control siRNA for 
24 hours and then treated with compounds for 24 hours. (A) Knockdown of Nrf2 and 
Nrf2 target genes as assessed by Western blot. Cells were treated with 1 µL/mL DMSO 
or       5 µM SF. 25 µg whole cell lysate proteins were loaded per sample. GAPDH was 
probed as loading control. The blot shown is representative of two independent 
experiments. (B, C, D) TR1, NQO1, and GCLC mRNA expression in control and Nrf2 
siRNA cells. Treatment concentrations were 2.5 µM MSA, 1 µM SECY, 25 µM ChSCA, 
and 5 µM SF. Data are presented as fold change relative to DMSO control siRNA. n=3 
for all treatments. ‘**’ indicates p<0.01 and ‘***’ indicates p<0.001 versus DMSO 


































































































































smoke [30], butylated hydroxytoluene [34], diesel exhaust [35], and hypoxia [36], and 
developed more spontaneous and benzo(a)pyrene-induced genomic DNA mutations [37]. 
Lung epithelial cells isolated from Nrf2-/- mice also demonstrate enhanced sensitivity to 
oxidants in comparison to cells from Nrf2+/+ mice [38]. These Nrf2 deficient lung cells 
have an altered redox balance, demonstrated by increased basal ROS and decreased basal 
GSH levels. Strategies that genetically enhance Nrf2 activity have further indicated a 
protective role of Nrf2 in the airway. Lung cells with decreased expression of the 
negative regulator Keap1 exhibit greater antioxidant capacity as demonstrated by 
increased expression of antioxidant and phase II genes and decreased ROS generated 
from H2O2 treatment [39]. Pharmacological treatments to increase Nrf2 activity in the 
lung have also demonstrated benefits [40, 41]. Studies in both mice and humans have 
shown Nrf2 activation and phase II gene induction in the airway in response to cigarette 
smoke [30; 42, 43], presumably to negate its oxidative effects. A protective role for Nrf2 
in the susceptibility of several cancers has been shown [see 45 for a review], but has yet 
to be explicitly tested in a lung cancer model. Still, Nrf2 and phase II enzyme induction 
are recognized mechanisms of lung cancer prevention [6, 44]. 
 Clinical selenium supplementation trials have demonstrated variable benefits for 
lung cancer. The NPC trial, which provided selenium as selenized yeast, did not find a 
significant benefit with selenium for its primary endpoint of nonmelanoma skin cancer, 
but did indicate a decrease in lung cancer incidence and mortality [5]. This benefit was 
diminished in the total population with extended follow-up, but remained significant in 
participants with low baseline plasma selenium levels [45]. SELECT was the largest 
supplementation trial to date, enrolling over 35,000 men [46].The primary endpoint of 
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SELECT was prostate cancer, but also analyzed lung cancer incidence as a secondary 
endpoint. Selenomethionine, the most prevalent selenocompound found in the selenized 
yeast used for the NPC trial, served as the selenium form. SELECT found no benefit of 
selenomethionine in regards to lung cancer incidence or all cancer mortality. However, 
the majority of the SELECT population had higher baseline selenium levels than that of 
the NPC trial population, indicating that selenium status may be an important factor in 
the chemopreventive effects of selenium. The different forms of selenium may also have 
contributed to these differential findings. A better understanding of selenium biology in 
cancer prevention, such as that taken from experiments in this study, is warranted, as well 
as investigation into which populations would most benefit from selenium [47, 48]. 
 In our previous work, we have sought to identify novel selenocompounds that 
exhibit efficacy in lung cancer chemoprevention. Selenocysteine demonstrates intriguing 
properties for chemoprevention, but can be chemically unstable. Selenazolidines were 
designed to be selenocysteine delivery agents and patterned after thiazolidine sulfur 
compounds [49]. This group of compounds is comprised of selenazolidine-4(R)-
carboxylic acids with varying 2-substituents. Many of these compounds, including 
ChSCA, are thought to release selenocysteine through nonenzymatic spontaneous 
hydrolysis. These compounds, along with the selenocysteine dimer selenocystine, have 
been assessed for chemoprevention efficacy in the NNK model of lung cancer [1, 2] with 
varying success. 
 With the animal study design used in this work, selenocystine treatment occurs in 
the post-initiation phase and more closely models the intervention strategy for a former 
smoker. Our previous study indicated that selenocystine is only effective at decreasing 
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lung tumors following NNK administration [2]. Using this approach, we show that 
selenocystine induces Nrf2-regulated ARE genes related to glutathione metabolism and 
oxidoreductase activity (Figure 3.1). We then utilized in vitro experiments in 
nonmalignant lung cell lines to further ascertain the mechanism of action of 
selenocompounds. These lines serve to model lung cells at the pre-initiation step of 
carcinogenesis where chemopreventive agents can be beneficial. Selenocystine and the 
other compounds investigated, ChSCA, MSA, and selenomethionine increased 
antioxidant genes in BEAS-2B cells (Figures 3.2 and 3.3A). ChSCA and MSA 
demonstrated similar ability in the NHBE cell line (Figure 3.4A). These findings 
indicated that selenocompound induction of antioxidant genes is not limited to the mouse. 
The observed increases in antioxidant gene expression at 24 hours were preceded by 
generation of ROS (Figure 3.5A), depletion of GSH (Figure 3.5B), and translocation of 
Nrf2 to the nucleus (Figure 3.6). This is indicative that the selenocompounds generate an 
oxidative insult to promote Nrf2 activation. Interestingly, de novo synthesis of GSH 
appears to be a component of the recovery from the insult rather than recycling of 
oxidized GSSG to reduced GSH. By 24 hours, GSH levels had returned to or were 
greater than baseline (Figure 3.3B). Lack of increased gene expression in Nrf2 siRNA 
knockdown cells further argues for an Nrf2 dependent mechanism of the 
selenocompounds (Figure 3.7). Our previous work has shown that the selenocompounds 
at the same or higher concentrations do not increase ROS levels in BEAS-2B cells at 24 
hours [17], indicating that the increased levels at 2 hours are attenuated by 24 hours, 
potentially via Nrf2. Taken together, our data support a mechanism by which 
selenocompounds initially behave as pro-oxidants to activate the Nrf2 pathway, and it is 
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through this Nrf2 activation and subsequent ARE gene induction that they indirectly exert 
endogenous antioxidant effects. 
 Of the selenocompounds investigated, ChSCA produced the most robust response 
in regard to mRNA expression in both the BEAS-2B and NHBE cells (Figures 3.2, 3.3A, 
3.4A). Selenocystine also increased ARE gene expression in mouse lung tissue (Figure 
3.1) and BEAS-2B cells (Figures 3.2, 3.3A), but did not modulate ARE gene 
transcription in NHBE cells (Figure 3.4A). MSA increased TR1 and NQO1 expression in 
both the BEAS-2B and NHBE cells (Figures 3.2, 3.4A) with the magnitude of induction 
greater in the NHBEs. Unlike the other compounds investigated, MSA did not increase 
GCLC mRNA expression (Figure 3.3A), but was able to increase BEAS-2B GSH levels to 
a similar extent as ChSCA and selenocystine (Figure 3.3B). These three compounds all 
increased intracellular GSH levels and nuclear Nrf2 protein expression to extents similar 
or greater than sulforaphane (Figures 3.3B, 3.6). Selenomethionine was able to increase 
ARE gene expression (Figures 3.2A, 2C, and 3.3A), but did not increase nuclear Nrf2 
protein (Figure 3.6) or GSH levels (Figure 3.3B) in the BEAS-2B cells like the other 
compounds. That selenomethionine failed to increase either nuclear Nrf2 or GSH levels 
does not appear to be a concentration issue, as selenomethionine was used at a 
concentration four times greater than the next highest selenocompound concentration   
(25 µM ChSCA). The results from this study indicate that ChSCA, SECY, and MSA are 
the most effective at activating the Nrf2 pathway in the lung and inducing its downstream 
effects.   
 Previous reports on the mechanisms of selenocompounds in lung cells have not 
indicated changes in expression of antioxidant response genes, but rather cell cycle and 
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apoptotic genes. A microarray study with p-XSC showed changes in transcription factor, 
growth factor, and apoptotic gene expression [50], while MSA induced alterations in cell 
cycle genes involved in the G1 to S phase transition, resulting in G1 phase arrest [4]. 
Changes in apoptosis or cell cycle genes were not indicated in our microarray analysis of 
lung tissue from animals fed selenocystine (Figure 3.1). However, it must be pointed out 
that the model systems differ. Our results are for nontumorigenic mouse lung tissue and 
nonmalignant human lung cells. Human non-small cell lung cancer lines were utilized for 
the p-XSC and MSA gene expression studies (H460 and H520 cells, respectively). The 
effects of selenium seen in these malignant cells are likely to differ from what would be 
observed in nonmalignant cells. Many lung cancer cell lines that have progressed to the 
transformation step of carcinogenesis have Keap1 or Nrf2 mutations that result in 
constitutively active Nrf2 and high basal antioxidant gene expression [51, 52]. Thus, 
these cell lines may not serve as an appropriate system in which to observe an induction 
of antioxidant defense systems. This was evidenced by the lack of increased antioxidant 
and glutathione gene expression with selenocompounds we observed in A549 cells 
(Figure 3.4B). A549 cells harbor a KEAP1 mutation that results in the constitutive 
activation of Nrf2 [51]. Since Nrf2 pathway activation is already maximized in this cell 
line, it is not possible for the selenocompounds to further increase mRNA expression via 
Nrf2. This lack of selenocompound-induced increases in gene expression supports an 
Nrf2-mediated mechanism.  
 In comparison, primary NHBE cells responded most dramatically to MSA and 
ChSCA. The differential effects of the selenocompounds in NHBEs as compared to 
BEAS-2Bs may be due to cell population characteristics of the two lines. BEAS-2B cells 
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are derived from NHBE cells pooled from several noncancerous donors and transformed 
with a 12-SV40 adenovirus hybrid. It is unknown if the NHBE cells exhibit a pathology 
that would cause them to be less responsive to the antioxidant inducer sulforaphane. 
Differences in cell culture medium for the two lines may also contribute to the 
differential patterns of induction. Since a similar induction of antioxidant genes was 
observed with selenocystine in BEAS-2B cells as the mouse lung, we utilized this cell 
line for further experiments related to the mechanism of enzyme induction. 
 Other selenocompounds have been shown to be inducers of phase II enzyme 
expression and activity. Glutathione S-transferase and total GPx activity was increased by 
one week of dietary p-XSC in mouse lung and liver, but no change in selenium-
dependent GPx or UGT activity was found [53]. p-XSC has also been shown to increase 
GSH and antioxidant levels in the lung of A/J mice [54]. It is unknown whether p-XSC 
acts through an Nrf2 mechanism. Various other selenocompounds have also induced 
antioxidant and phase II enzymes in tissues other than the lung [55-58]. A recent study 
evaluating 3-selena-1-dethiacephem compounds in LNCaP prostate cancer cells 
suggested that the mechanism of action of two of these compounds included Nrf2 
activation [59].  
  The mechanism by which the selenocompounds in this study activate Nrf2 
remains to be elucidated. One potential mechanism is modification of critical Keap1 
cysteine residues to activate Nrf2. Sulforaphane has been shown to disrupt the Nrf2-
Keap1 complex by forming thionoacyl adducts with Keap1 [60]. In contrast, other 
electrophiles, such as tert-butylhydroquinone, allow for the alkylation of Keap1 and its 
subsequent polyubiquitination [61]. Whether selenocompounds or their metabolites 
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directly disrupt the Nrf2-Keap1 complex remains to be determined. ROS generation and 
GSH depletion (Figure 3.5) may also be involved in Nrf2 activation. Moderate GSH 
depletion (~40%) is insufficient to activate Nrf2 and it is not until levels reach 10-15% of 
baseline that Nrf2 is activated by this depletion alone [62, 63]. At 2 hours, the 
selenocompounds depleted GSH but not to an extent that would be expected to activate 
Nrf2 alone (Figure 3.5B). Further, Nrf2 activation does not require GSH depletion, as 
compounds such dexamethasone 21-mesylate and 15-deoxy-∆-(12,14)-prostaglandin J2 do 
not decrease GSH levels, but are able to activate Nrf2 by directly interacting with Keap1 
[63]. Therefore, it is unlikely that GSH depletion is the primary mechanism. Other 
indirect mechanisms of Nrf2 activation may also be involved. MSA was shown to inhibit 
glycogen synthase kinase 3 beta [64], which can in turn lead to nuclear Nrf2 
accumulation [65].  
 In conclusion, we demonstrate that selenocompounds increase antioxidant and 
glutathione genes in the lung, and do so through in an Nrf2-dependent mechanism. This 
finding will be of use in further evaluating the chemopreventive mechanisms of 
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THIOREDOXIN REDUCTASE 1 KNOCKDOWN ENHANCES  
 
SELENAZOLIDINE CYTOTOXICITY IN HUMAN LUNG  
 







 TR1 is a selenoprotein that is involved in cellular redox status control and 
deoxyribonucleotide biosynthesis. Many cancers, including lung, overexpress TR1, making it a 
potential cancer therapy target. Previous work has shown that TR1 knockdown enhances the 
sensitivity of cancer cells to anticancer treatments, as well as certain selenocompounds. 
However, it is unknown if TR1 knockdown produces similar effect on the sensitivity of human 
lung cancer cells. To further elucidate the role of TR1 in the mechanism of selenocompounds in 
lung cancer, a lentiviral microRNA delivery system to knockdown TR1 expression in A549 
human lung adenocarcinoma cells was utilized. Cell viability was assessed after 48 hr treatment 
with the selenocysteine prodrug selenazolidines BSCA and ChSCA, selenocystine, MSA, p-
XSC, and selenomethionine. TR1 knockdown increased the cytotoxicity of BSCA, ChSCA, and 
selenocystine but did not sensitize cells to MSA, selenomethionine, or p-XSC. GSH and TR1 
depletion together decreased cell viability, while no change was observed with GSH depletion 
alone. ROS generation was induced only in TR1 knockdown cells treated with the
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selenazolidines or selenocystine. These three compounds also decreased total intracellular 
glutathione levels and oxidized thioredoxin, but in a TR1 independent manner. TR1 
knockdown increased selenazolidine and selenocystine-induced mitochondrial membrane 
depolarization, as well as DNA strand breaks and apoptosis inducing factor translocation 
from the mitochondria. These results indicate the ability of TR1 to modulate the cytotoxic 
effects of BSCA, ChSCA and selenocystine in human lung cancer cells through 




 TR is a selenoprotein that functions to reduce the oxidoreductase Trx in a 
NADPH-dependent manner. Together, this thioredoxin system is an important regulator 
of cellular redox status. TR is also involved in cell proliferation, DNA replication, cell 
cycle, transcription factor regulation, and other redox-sensitive cell signaling pathways 
[1-3]. TR contains selenium in the form of selenocysteine as the penultimate residue at 
the C-terminus. In humans, TR is found in all tissues and is expressed as two major 
isoforms: cytosolic (TR1) and mitochondrial. 
 Many cancers, NSCLC, have high expression levels of both TR1 and Trx. In the 
lung, TR and Trx expression correlate with cell proliferation, survival, and prognostic 
factors such as lymph node status and tumor grade [4-6]. TR1 knockdown reversed the 
malignant phenotype and decreased tumor growth and metastasis of murine lung 
carcinoma cells further implicating TR1 in cancer development [7]. TR1 was also shown 
to be involved in the tumor phenotype of malignant cells [1]. Overexpression of the Trx 
system has been implicated in cell resistance to oxidative and electrophilic insults, 
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including some selenocompounds [8-13]. Thus, TR can protect tumor cells from the 
oxidative stress generated by many anticancer drugs. These findings indicate a role for 
the TR system in lung cancer development, progression, and chemoresistance, and 
identify it as a potential therapeutic target.   
 Selenium supplementation trials have had mixed results in regard to cancer 
incidence and mortality [14-17], but the use of selenium in potential cancer treatment 
remains of interest. Several selenocompounds have demonstrated anticancer activity in 
cell culture and in vivo studies. MSA induces cell cycle arrest and apoptosis in lung 
cancer cells [18] and is effective at inhibiting xenograft growth [18, 19]. The 
organoselenocompound p-XSC has also demonstrated anticancer activity in lung cancer 
models where selenomethionine was not effective [20-22]. Selenocystine and two 
selenazolidine compounds that were designed to nonenzymatically release selenocysteine 
also decreased murine lung tumors when administered post-initiation [23], but did not 
affect transcriptional levels of cell cycle or apoptotic genes. Together, these studies 
indicate that certain selenocompounds exhibit anticancer properties in the lung, though 
potentially via differential mechanisms that require elucidation.  
 Since overexpression of the Trx system contributes to the high antioxidant 
capacity of NSCLCs, we sought to determine if decreasing TR1 would increase the 
sensitivity of malignant cells to redox-modulatory selenocompounds. Specifically, the 
aim of this work was to determine if knockdown of TR1 in A549 human NSCLC cells 
would affect the cytotoxicity and redox effects of several chemically distinct 
organoselenocompounds: two selenocysteine prodrug selenazolidines, BSCA and 
ChSCA, selenocystine, MSA, and selenomethionine. A549 cells express some of the 
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highest levels of TR1 as well as other antioxidant genes due to a KEAP1 mutation [24], 
and therefore, present a unique system to determine role of TR1 in the context of cells 
with many antioxidant genes overexpressed. For comparison, we also utilized the H1666 
human NSCLC cell line, which has lower basal TR1 expression than the A549 cell line 
and does not have a known KEAP1 mutation [24].    
 
 
Materials and Methods 
Reagents 
 The A549 adenocarcinoma cell line (A549 ATCC) was purchased from American 
Tissue Type Culture Collection (Manassas, VA). The H1666 adenocarcinoma cell line 
was a kind gift from Dr. Andrea Bild (University of Utah). BSCA and ChSCA were 
synthesized as described [25]. L-selenomethionine was from Acros Organics (Morris 
Plains, NJ), MSA was from PharmaSe, Inc. (Lubbock, TX), and p-XSC was from LKT 
Laboratories, Inc (St. Paul, MN). L-selenocystine, DMSO, DMF, CDDP, NAC, tiron, 
recombinant thioredoxin from E. coli, insulin solution from bovine pancreas, iodoacetic 
acid, iodoacetamide, 40% acrylamide/bis-acrylamide 37.5:1 solution, and ammonium 
persulfate were purchased from Sigma-Aldrich (St. Louis, MO). Advanced Dulbecco's 
modified Eagle's medium (DMEM), Glutamax, pcDNA™6.2-GW/EmGFP-miR, 
pLenti4/TO/DEST and pLenti6/TR vectors, blasticidin S HCl, Zeocin™, tetracycline, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA), propidium iodide (PI), MitoProbe JC-
1 assay kit, NuPAGE Bis-Tris gels, APO-BrdU TUNEL assay kit, and bovine serum 
albumin were from Invitrogen (Carlsbad, CA). CellTiter-Glo Luminescent Cell Viability, 
  
125
MultiTox-Fluor Multiplex Cytotoxicity, GSH-Glo Glutathione, and Caspase-Glo 3/7 
assays were purchased from Promega Scientific (Madison, WI). Fetal bovine serum was 
from HyClone (Logan, UT). Mitochondrial isolation kit for cultured cells, bovine serum 
albumin standard, Coomassie Plus Protein Reagent, SuperSignal West Dura extended 
duration substrate, and tris(2-carboxyethyl)phosphine hydrochloride (TCEP HCl) were 
from Thermo Scientific (Rockford, IL). Primary antibodies directed against TR1, Trx1, 
AIF, and GAPDH, and polyclonal horseradish peroxidase (HRP)-conjugated secondary 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); the α-
tubulin primary antibody was from Zymed Laboratories (San Francisco, CA). Protease 
inhibitor cocktail tablets (complete) were from Roche (Indianapolis, IN) and PVDF 
membrane was from Millipore (Burlington, MA). Western Lighting chemiluminescence 
reagents were from PerkinElmer Life Sciences (Boston, MA). Nuclear Isolation and 
Staining Solution (NIM-DAPI) was from Beckman Coulter (Miami, FL). L-buthionine-
(S,R)-sulfoximine (BSO) was purchased from Chemical Dynamics Corporation (South 
Plainfield, New Jersey). JNK inhibitor VIII and p38 MAP kinase inhibitor SB203580 
were purchased from Calbiochem (La Jolla, CA) and Upstate Biotechnology (Lake 
Placid, NY), respectively. The HA-ASK1-wt and HA-ASK1-KM constructs were a kind 
gift from Dr. Hidenori Ichijo (Tokyo, Japan). The caspase inhibitor, Z-Asp-CH2-DCB, 
was from Peptides International (Louisville, KY). Other common reagents were from 
Sigma-Aldrich (St. Louis, MO), Fisher Scientific (Pittsburgh, PA) or VWR Scientific 






 A549 and H1666 cells were cultured in advanced DMEM supplemented with 2% 
fetal bovine serum and 1% Glutamax. When supplemented with serum, advanced DMEM 
contains ~37 nM selenium, primarily in the form of sodium selenite. Cells were 
maintained at 37oC in a humidified atmosphere of 5% CO2. Selenocystine and 
selenomethionine were dissolved in advanced DMEM. MSA and BSO were dissolved in 
PBS and CDDP in DMF. All other compounds were dissolved in DMSO. Media was 
refreshed at the time of treatment and 0.01% DMSO added to MSA, selenomethionine 
and selenocystine-treated cells to maintain a constant DMSO concentration amongst 
treatments. For all experiments other than cell viability, compounds were used at the 
following concentrations: selenomethionine, 20 µM; MSA, 1 µM; selenocystine, BSCA, 
and ChSCA, 5 µM; CDDP, 20 µM.  
 
Generation of Lentiviral miRNA Cell Lines 
 MicroRNA (miRNA) targeted against the TR1 mRNA sequence (NM_003330) 
beginning at nucleotide 752 was utilized to knockdown TR1 expression (‘miR-TR1’). 
miRNA targeted at a noneukaryotic gene (‘miNeg’) was used as a nonknockdown 
control. Both miRNAs were cloned into pcDNA™6.2-GW/EmGFP-miR and then cloned 
into the pLenti4/TO/DEST Gateway vector. A549 cells were transduced with either 
pLenti4/TO/EmGFP/miR-TR1 or pLenti4/TO/EmGFP/miNeg as well as pLenti6/TR to 
express tetracycline (tet) repression, creating a tet-inducible miRNA expression system. 
Stably transduced cells were selected for using Zeocin™ (pLenti4) and blasticidin 
(pLenti6). Fluorescence-activated cell sorting was used to obtain an enriched EmGFP 
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positive cell population, producing a population with a high percentage of virally 
transduced cells. Cells were maintained in advanced DMEM.1 µg/mL tet was added to 
culture medium at least 72 hours prior to seeding to induce miRNA expression.  
 
Measurement of TR Activity by NADPH Oxidation 
 Whole cell lysates were collected in lysis buffer. Activity values were measured 
in duplicate and calculated using the slope of NADPH absorbance at 340 nm at 25oC over 
a minimum of 30 minutes with a Perkin Victor V3 microplate reader as previously 
described [26].  
 
Cell Viability by ATP Measurement 
 Cells were seeded into 384-well plates at a density of ~1.25 x 103 cells/well in 
advanced DMEM and allowed to recover. Drug concentrations ranging from 0–60 µM 
(MSA, p-XSC), 0–100 µM (CDDP), 0–120 µM (SECY), or 0–600 µM (SEM, BSCA, 
ChSCA) were added in advanced DMEM and incubated with cells for 24, 48, or 72 
hours. For BSO treatments, 20 µM BSO was added to cells at the time of seeding and 
refreshed every 24 hours. For antioxidant treatments, 5 mM NAC or 1 mM tiron was 
added to cells 2 hour prior to seeding. Viability was measured using CellTiter-Glo 
luminescent reagents as per the manufacturer’s instructions. Luminescence was measured 






Cell Clonogenic Assay 
 Cells were seeded into 6-well plates at a density of 300 cells/well in advanced 
DMEM. Cells were treated with drug concentrations ranging from 0-10 µM (SECY) or  
0-20 µM (BSCA, ChSCA, MSA) for 7 days. Colonies were stained with MTT for 4 hours 
at 37°C. MTT concentrations were determined by solubilizing the MTT in 24:1 
propanol:HCl and measuring the absorbance at 405 nm using the microplate reader.   
 
Cell Cycle Analysis 
 After 48 hr treatments, cells were trypsinized, washed with PBS, resuspended in 
NIM-DAPI, and incubated for 1 hr in the dark. Samples were analyzed using flow 
cytometry (Cell Lab Quanta SC, Beckman Coulter) with a minimum of 20,000 events 
recorded for each sample. Cell cycle distributions were estimated using ModFit LT 
software Version 2.0.  
 
Immunoblot Analysis 
 For the evaluation of TR1, whole cell lysates were collected as described [27] and 
protein concentrations determined by the Bradford method. Whole cell lysate was 
separated by a NuPAGE 10% Bis-Tris gel and transferred to a PVDF membrane. The 
membrane was blocked in 5% milk in TBS-T, probed with 1:200 anti-TR1 (B-2) 
monoclonal primary antibody, washed three times with TBST, and probed with 1:5000 
donkey anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibodies. For 
Trx redox status, urea-PAGE and immunoblotting were performed as described [28, 29]. 
For the evaluation of apoptosis inducing factor (AIF), mitochondrial lysates were isolated 
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from cells using the Mitochondria Isolation Kit for cultured cells with Dounce 
homogenization protocol. Lysates were sonicated, clarified, and protein concentrations 
were determined using the Bradford method. Protein was separated by NuPAGE 4-12% 
Bis-Tris gels, transferred to PVDF membranes and membranes incubated with 1:1000 
anti-AIF (H-300) polyclonal primary antibody, washed, and incubated with 1:5000 
donkey anti-rabbit HRP-conjugated primary antibody. Protein was detected using 
chemiluminescence and visualized on a Kodak ImageStation 440.  
 
Reactive Oxygen Species 
 Cells were incubated with 20 µM H2DCFDA for 20 minutes at 37oC following 48 
hr treatment. Dichlorofluorescein (DCF) and PI fluorescence concentrations were 
cytometrically determined using a Beckman Coulter Cell Lab Quanta SC flow cytometer 
as described [27].  
 
Determination of Intracellular Glutathione 
 MultiTox-Fluor reagent was added to wells following 48 hour drug treatments 
and incubated at 37oC for 30 minutes. Live-cell fluorescence was measured at 505 nm 
using the microplate reader. Media was then removed from wells and GSH-Glo reagent 
containing 1 mM TCEP HCl was added. After incubation at 37oC for 30 minutes, 
Luciferin Detection reagent was added to each well and incubated for 15 minutes at 37oC. 
Luminescence was measured with the microplate reader. GSH concentrations were 
calculated from a GSH standard curve and normalized by the MultiTox-Fluor cell 
viability fluorescence values. 
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Cell Death Assays 
 Mitochondrial  membrane depolarization  was assessed using the  JC-1 cytometric 
assay as described [27]. Caspase activity was measured as previously described [28] and 
luminescence was measured using the microplate reader. DNA fragmentation was 
measured using the APO-BrdU TUNEL assay kit. Cells were trypsinized, incubated in 
1% (w/v) formaldehyde in PBS on ice for 15 minutes, washed with PBS, resuspended in 
cold 70% (v/v) ethanol and placed at -20oC overnight. Cells were resuspended in 1 mL 
wash buffer and centrifuged for 5 minutes at 250 x g. Pellets were resuspended in a 
DNA-labeling solution containing terminal deoxynucleotidyl transferase and BrdUTP 
and incubated for 90 minutes at 37oC. Cells were then washed and incubated with 100 µL 
Alexa Fluor 488 dye-labeled anti-BrdU antibody staining solution for 30 minutes at room 
temperature in the dark, followed by incubation with 0.5 mL PI/RNase A staining buffer. 
BrdU and PI fluorescence concentrations were measured at 525 nm and 670 nm, 
respectively, by flow cytometry.  
 
Statistical Analysis 
 Data are presented as mean ± standard deviation. One-way ANOVA with 
Bonferroni post-hoc testing was used to determine statistical significance (GraphPad 
InStat Version 3.06). p<0.05 was considered significant. Two-way ANOVA with Holm-








TR1 Knockdown in A549 Cells 
 TR1 protein expression was decreased by 95% in A549 miR-TR1 cells compared 
to A549 miNeg cells (Figure 4.1A). TR1 knockdown was further confirmed by 
measuring TR activity via an insulin-dependent NADPH oxidation assay. For A549 miR-
TR1 cells, only ~20% TR activity remained (Figure 4.1B). The mitochondrial isoform 
likely contributes to the majority of the remaining TR activity in the miR-TR1 cells, as 
the NAPDH oxidation assay is not specific for the TR1 isoform. TR activity of A549 
miNeg cells did not differ from nontransduced A549 cells (‘A549 wt’). No observable 
differences in cell viability, morphology, or phenotype existed between the miNeg and 
miR-TR1 cell lines (Figure 4.1C). 
 
Effects of TR1 Knockdown on Drug Cytotoxicity 
 Minimal differences in cell viability between A549 miNeg and miR-TR1 cells 
were observed with 24 hr drug treatments (data not shown). When treatments were 
carried out for 48 hours, decreases in A549 miR-TR1 cell viability were observed with 
the selenocysteine prodrug selenazolidines BSCA and ChSCA at concentrations of              
5–100 µM (Figure 4.2) and selenocystine at concentrations of 1–10 µM. These 
compounds demonstrated >4-fold increases in sensitivity in miR-TR1 cells compared to 
miNeg cells. We also assessed the toxicity of the methylselenol precursor methylseleninc 
acid (MSA) and the selenoamino acid selenomethionine, but did not find differential 
toxicity with TR1 knockdown using treatment times up to 72 hours (72 hour data not 




































Figure 4.1. Knockdown of TR1 in A549 miR-TR1 cells by miRNA. A549 cells were 
transduced with lentiviral miRNA constructs to produce miNeg and miR-TR1 cell lines 
(see Materials and Methods). Cells were treated with 1 µg/mL tetracycline for 72 hours to 
induce miRNA expression. (A) Determination of TR1 protein expression by Western 
blotting. TR1 is the top band of the doublet. GAPDH was probed as a loading control 
using 1:500 anti-GAPDH polyclonal primary antibody. A similar decrease in TR1 protein 
expression was observed in A549 miR-TR1 cells up to 72 hours after removal of             
1 µg/mL tetracycline. The blot shown is representative of two individual experiments. 
(B) Measurement of TR activity via NADPH oxidation. Data are presented as % A549 wt 
activity. n=2 for all groups. ‘*’ indicates p<0.05 versus miNeg. NADPH oxidative 
activity in A549 cell lysates without added Trx (-Trx) in the reaction mixture, basal 
activity, activity in miNeg cells, and in the miR-TR1 cells.  C) Anchorage independent 
growth assay. Cells were allowed to grow in 2% growth factor reduced Matrigel (BD 
Biosciences; Bedford, MA) and advanced DMEM supplemented with 1 µg/mL tet for 7 
days, with media and tet refreshed every 3 days. Colonies were stained with MTT 
overnight and visualized on the Kodak ImageStation. No difference in colony growth was 





















Figure 4.2. Effects of TR1 knockdown on drug cytotoxicity in A549 cells. Viability of 
A549 miNeg (■) and miR-TR1 (●) cells was assessed by measuring cellular ATP content 
after 48 hr drug treatment at the indicated concentrations. Viability values are expressed 
as % relative to vehicle controls, which were set to 100%. n=4 for all data points. No 
sensitization was observed in cells treated with (A) SEM or (B) MSA.  Sensitization was 
observed in cells treated with (C) CDDP (miNeg IC50: 22 ± 4 µM; miR-TR1 IC50: 13 ± 
0.5), (D) SECY (miNeg IC50: 5 ± 1.4 µM; miR-TR1 IC50: 1.2 ± 0.3), (E) ChSCA (miNeg 
IC50: 48 ± 8 µM; miR-TR1 IC50: 3 ± 1.1), and (F) BSCA (miNeg IC50: 28 ± 8 µM;     







is consistent with effects observed with these compounds in colon cancer cells [12]. We 
also determined if TR1 knockdown enhanced the toxicity of cis-platinum(II) diammine 
dichloride (CDDP, cisplatin), as it is a first-line treatment for NSCLC and interacts with 
TR1. A549 miR-TR1 cells were less than 2-fold more sensitive to CDDP after 48 hr 
treatment compared to A549 miNeg cells. These viability data suggest that TR1 can 
protect against selenium toxicity in a compound and cell line dependent manner. 
 To determine if the observed decreases in ATP content were a consequence of 
decreased cell proliferation, we conducted a clonogenic survival assay. Colony formation 
was observed in the miNeg and miR-TR1 cell lines after 7 days of treatment with MSA, 
selenocystine, BSCA, or ChSCA.  All of these selenocompounds decreased clonogenic 
survival in a dose dependent fashion; however, replicate experiments did not demonstrate 
a statistically significant difference between miNeg and miR-TR1 cells. Representative 
examples of clonogenic survival are displayed in Figure 4.3. Taking these data into 
account with the ATP content viability data supports a mechanism whereby TR1 
knockdown enhances selenocystine and selenazolidine cytotoxicity, but may not increase 
the sensitivity of A549 cells to these compounds in longer term experiments. 
 To further evaluate the role of these compounds in cell proliferation, the effects of 
TR1 knockdown and the selenocompounds that demonstrated a TR1-dependence in the 
ATP assay were evaluated for alterations in cell cycle population distributions. The 
effects of TR1 attenuation and selenocompound treatment were statistically significant 
but represent small shifts in the overall population (Table 4.1). Still, attenuation of TR1 









Figure 4.3. TR1 knockdown did not increase sensitization in clonogenic survival in 
A549 cells.  Representative images of 7-day selenocompound treatment of A549 cells 
stained by the addition of MTT to the media and then visualized. Measurements of 
formazan-converted MTT indicate that statistically significant differences were not 













Table 4.1: Cell Cycle Distribution 
miNeg  G1 S G2/M 
 DMSO 68.0 ± 0.2 24.1 ± 0.6 7.9 ± 0.7 
 SECY 75.5 ± 1.4a 18.8 ± 0.6a 5.8 ± 1.0 
 BSCA 73.1 ± 2.0a 20.2 ± 1.3a 6.7 ± 1.6 
 ChSCA 78.3 ± 0.7a 18.3 ± 0.9a 3.4 ± 1.3a 
     
miR-TR1  G1 S G2/M 
 DMSO 64.2 ± 1.5b 27 ± 1.0b 8.8 ± 1.0 
 SECY 69.9 ± 0.5a,b 23 ± 1.1a,b 7.1 ± 0.7 
 BSCA 67.7 ± 0.9a,b 25.6 ± 1.2b 6.7 ± 0.2 
 ChSCA 72.3 ± 2.2a,b  22.8 ± 2.0a,b 4.8 ± 2.0a 
 
Cell cycle distributions are statistically different (Two-way ANOVA) both due to 
selenocompound treatment and the TR1 attenuation (n=3 for all groups). ‘a’ indicates 
p<0.01 versus matched DMSO vehicle control; ‘b’ indicates p<0.01 versus matched 




and the selenazolidines increased cells in G1 phase, but to a lesser extent in miR-TR1 
cells than miNeg cells.   
 To determine if the selenazolidine-mediated cytotoxicity observed in the A549 
cells translated to other non-small cell lung cancer lines, we treated H1666 cells (which 
do not have a KEAP1 mutation) with the cytotoxic agents selenocystine and ChSCA. 
H1666 cells expressed considerably less TR1 than A549 cells (Figure 4.4A), and 
displayed similar sensitivity to the cytotoxicity of these agents (Figure 4.4B). 
Selenocystine, which displayed a more modest sensitization in the A549 cells with 
attenuated TR1, displayed comparable cytotoxicity in these cells, but ChSCA-dependent 
cytotoxicity was more similar to the miR-TR1 A549 cells.  
 
Effects of TR1 Knockdown and Glutathione Depletion on Cell Viability 
 As oxidative stress is a major inducer of cell death, we investigated whether TR1 
and GSH depletion together decrease cell viability independent of any external insult. To 
determine the effect of simultaneously depleting these two antioxidant systems, miR-TR1 
cells were treated with BSO. BSO decreases GSH synthesis via inhibition of gamma-
glutamylcysteine synthetase, thereby decreasing the cellular GSH concentration. 
Treatment of A549 miR-TR1 cells with BSO resulted in decreased cell viability in a 
time-dependent manner, as a difference in cell viability was observed after 72 hours of 
BSO treatment (Figure 4.5). At this time point, BSO decreased miR-TR1 cell viability by 










































Figure 4.4. TR1 expression and selenocompound cytotoxicity in H1666 human 
NSCLC cells. (A) Determination of TR1 protein expression by Western blotting. 10 µg 
protein was loaded for each sample. H1666 cells have ~85% less TR1 protein expression 
than A549 cells as determined by densitometry. (B) H1666 cell viability following 48 hr 
selenocompound treatments. Concentrations ranged from 0-200 µM (ChSCA) or             
0-120 µM (SECY). Viability was assessed by ATP content. Values are expressed as % 
relative to vehicle controls, which were set to 100%, and n=6 for all data points. Both 













Figure 4.5. Effects of TR1 and GSH attenuation on A549 cell viability. miNeg and 
miR-TR1 cells were treated with 20 µM BSO or PBS vehicle for 48 or 72 hours. Cell 
viability was determined by measuring cellular ATP content. BSO-treated viability 
values are expressed as % matched vehicle controls. n=8 for all groups. ‘***’ indicates 
p<0.001 versus -BSO (control); ‘###’ indicates p<0.001 versus 48 hr miR-TR1 +BSO. 
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Selenocompounds Alter Redox Balance in TR1 Knockdown Cells 
 
 As the greatest differences in cell viability between miNeg and miR-TR1 cells at 
48 hours were observed at low micromolar concentrations of BSCA, ChSCA, and 
selenocystine, we chose 5 µM treatments of these compounds to further investigate their 
mechanism of cell death specific to miR-TR1 cells. ROS were increased 2-fold and        
4-fold by the selenazolidines and selenocystine, respectively, in the miR-TR1 cells 
(Figure 4.6A). No increase in ROS was detected with these compounds in miNeg cells, 
indicating that TR1 may function in A549 cells to protect against ROS generation 
observed with these compounds. No change in ROS levels was observed at 48 hours with 
20 µM selenomethionine or 1 µM MSA. To further evaluate the role of ROS, cells were 
pretreated with NAC, a thiol antioxidant, or tiron, a nonthiol antioxidant, prior to 
selenocompound treatment. No attenuation of selenocystine or selenazolidine 
cytotoxicity was observed with either NAC or tiron (data not shown).   
 Since GSH depletion decreased A549 cell viability in combination with TR1 
knockdown, we measured total intracellular GSH following 48 hr drug treatments to 
determine if decreased GSH was involved in the increased sensitivity of the miR-TR1 
cells. No alteration in GSH concentration was observed with TR1 knockdown alone 
(Figure 4.6B). The greatest depletion of total GSH was observed with BSCA, ChSCA, 
and selenocystine, as these compounds decreased total intracellular GSH by 90% 
independent of TR1 status. CDDP also depleted GSH in a TR1 independent manner, but 
to a lesser extent than that elicited by selenocystine or the selenazolidines (~40%). Taken 
together, these data indicate that selenazolidines and selenocystine can alter the cellular 




Figure 4.6. Assessment of cellular redox status parameters. Treatments were for 48 
hours at the following concentrations: SEM, 20 µM; MSA, 1 µM; SECY, BSCA, and 
ChSCA, 5 µM; CDDP, 20 µM. (A) DCF fluorescence concentration. (B) Measurement of 
total intracellular GSH. GSH concentration values were normalized to cell viability 
fluorescence values and are expressed as % miNeg DMSO control. n=3 for all DCF assay 
treatment groups; n=4 for GSH assay treatment groups. ‘**’ indicates p<0.01 versus 
matched DMSO vehicle control; ‘***’ indicates p<0.001 versus matched DMSO vehicle 
control; ‘###’ indicates p<0.001 versus matched miNeg treatment. 
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Selenocompound-induced Trx Oxidation 
 The alterations in ROS and GSH indicative of altered redox balance led us to look 
at Trx redox status since it can be modulated by oxidative stress and is known to be 
involved in apoptotic signaling. Trx contains five cysteine (Cys) residues and therefore 
can exist in six possible oxidation states. In DMSO-treated miNeg and miR-TR1 cells, 
TR1 was primarily in the reduced state (Figure 4.7; Table 4.2). This finding that TR1 
knockdown alone does not alter the Trx oxidation status of A549 cells is in agreement 
with reports for other transformed cell lines [28, 30]. BSCA, ChSCA, and selenocystine 
increased the expression of oxidized forms of Trx, primarily the two residue oxidation 
state, in a TR1-independent manner. No appreciable expression of Trx in the three 
highest oxidation states was detected with any of the treatments. 
 To assess the involvement of Trx oxidation in the cell death mechanism of these 
selenocompounds, we investigated the ASK1 pathway. ASK1 is an apoptotic signaling 
protein that is regulated by the oxidation status of Trx [31, 32]. ASK1 associates with 
Trxred, which prevents its phosphorylation and subsequent activation. When Trx is 
oxidized, ASK1 dissociates and can be phosphorylated, activating apoptotic pathways 
involving JNK and p38 MAP kinase. As BSCA, ChSCA, and selenocystine increased 
Trxox levels, we sought to determine if these compounds were inducing cell death through 
the ASK1 pathway. Prior to selenocompound treatment, cells were transfected with HA-
tagged ASK1 wt or kinase mutant (KM) constructs [31] or treated with 55 nM JNK 
inhibitor VIII or 600 nM p38 MAP kinase inhibitor SB203580. Despite the increased Trx 
oxidation observed in both cell lines with the selenazolidines and selenocystine, there 











Figure 4.7. Selenocompounds induce expression of Trx in an oxidized state. 
Iodoacetic acid/iodoacetamine-labeled samples were collected following 48 hr treatments 
at the following concentrations: SEM, 20 µM; MSA, 1 µM; SECY, BSCA, and ChSCA, 
5 µM. Equal amounts ofprotein were analyzed by urea-PAGE and transferred to PVDF 
membranes that were probed with 1:200 anti-Trx primary antibody. Bands correspond to 
reduced Trx (bottom band) or Trx in various oxidation states (upper two bands). SECY, 
BSCA, and ChSCA increased the expression of Trx in an oxidized state in both A549 
miNeg (left six lanes) and miR-TR1 (right six lanes) cells. The blot shown is 








Table 4.2: Summary of Trx oxidation states. 




DMSO SEM MSA SECY BSCA ChSCA 
miNeg        
 4 (ox) 4.4 ± 1.6 6.3 ± 4.5 4.5 ± 0.5 25 ± 2.7 26 ± 1 34 ± 0.1 
 5 5.6 ± 1.8 8.1 ± 3.3 5.5 ± 2.2 11 ± 5 9.6 ± 1.8 9.5 ± 2.9 
 6 (red) 90 ± 3.4 85 ± 7.8 90 ± 2.6 64 ± 8.4 64 ± 2.9 56 ± 3.4 
miR-TR1        
 4 (ox) 7.4 ± 0.2 6.3 ± 1.7 4.9 ± 0.5 22 ± 4.9 28 ± 4 33 ± 8.7 
 5 5.9 ± 2.5 4.2 ± 1.1 4.4 ± 1 9.9 ± 1.2 7.3 ± 2.9 9.2 ± 0.8 
 6 (red) 87 ± 2.3 89 ± 2.8 91 ± 0.5 68 ± 3.4 64 ± 0.8 57 ± 7.8 
 
Relative band intensities from the Trx oxidation state immunoblot analysis (example in 
Figure 5) were quantified using densitometry. Three of the six possible oxidation states 
(the reduced state = 6 (red), one cysteine oxidized = 5, or two cysteines oxidized = 4 
(ox)) were detected at relative band intensities greater than 1%. The data are presented as 
the mean percent relative net band intensities ± standard deviations. n=3 for all samples. 
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induced cell death (data not shown). These findings suggest that although the 
selenazolidines and selenocystine alter Trx redox status, they do not induce cell death 
through the ASK1 pathway. 
 
Mitochondrial Dysfunction in the Mechanism of  
Selenocompound-Induced Cell Death 
 To verify that the selenocompounds were inducing cell death and not simply 
depleting cellular ATP, mitochondrial membrane potential was assessed using the JC-1 
assay. TR1 knockdown alone did not affect the mitochondrial membrane potential as 
there was no difference in the polarized and depolarized populations of miNeg and miR-
TR1 DMSO-treated cells (Figure 4.8). TR1 knockdown sensitized the A549 cells to 
mitochondrial depolarization induced by the selenazolidines, as an increase in the 
depolarized mitochondrial population was only observed with these compounds in the 
miR-TR1 cells. Knockdown also further sensitized cells to depolarization by 
selenocystine. Although 1 µM MSA did not induce cell death as assessed by ATP 
content, MSA-treated miR-TR1 cells had a greater depolarized mitochondria population 
than MSA-treated miNeg cells, but this population was not statistically different from 
DMSO-treated miR-TR1 cells. Consistent with the lack of effects on cytotoxicity and 
redox parameters in either cell line, selenomethionine did not alter the mitochondrial 
membrane potential. These finding suggest that the selenocompounds are indeed 
inducing cell death, as mitochondrial membrane depolarization is a hallmark of the cell 












Figure 4.8. TR1 knockdown increases selenocompound-mediated mitochondrial 
membrane depolarization. Determination of mitochondrial membrane potential by JC-1 
after 48 hr treatment. Compounds were used at the following concentrations: SEM, 20 
µM; MSA, 1 µM; SECY, BSCA, and ChSCA, 5 µM. Data are expressed as % total 
population, with the 525 nm fluorescence population (JC-1 green) represented as 
depolarized mitochondria and the 575 nm fluorescence population (JC-1 red) represented 
as polarized mitochondria. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP; 25 µM), 
a known mitochondrial membrane disrupter, served as positive control. ‘*’ indicates 
p<0.05 versus matched DMSO vehicle control; ‘***’ indicates p<0.001 versus matched 
DMSO vehicle control; ‘##’ indicates p<0.01 versus matched miNeg treatment; ‘###’ 
indicates p<0.001 versus matched miNeg treatment. 
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Caspase-Independent Mechanism of Cell Death                                                      
Involving DNA Fragmentation 
 We investigated the ability of selenocompounds to induce DNA fragmentation 
using the TUNEL assay to further elucidate the mechanism of cell death. ChSCA and 
selenocystine induced DNA strand breaks, but only with TR1 knockdown (Figure 4.9A). 
Surprisingly, BSCA did not produce significant DNA fragmentation with 48 hr treatment 
despite its ability to decrease cellular ATP content and depolarize the mitochondrial 
membrane. We sought to further characterize selenocystine and the selenazolidines by 
determining if they induce cell death in the miR-TR1 cells through a caspase-dependent 
pathway. Although these compounds elicit mitochondrial membrane depolarization and 
DNA strand breaks, no increase in caspase 3/7 activity was observed (Figure 4.9B) and 
selenocompound cytotoxicity was not attenuated when a broad spectrum caspase 
inhibitor (Z-Asp-CH2-DBM) was used (data not shown). 
 Since there was no indication of caspase activation, we looked for evidence of a 
caspase-independent mechanism of cell death involving apoptosis inducing factor (AIF). 
AIF is a mitochondrial protein that translocates to the nucleus upon mitochondrial outer 
membrane permeabilization, where it induces DNA fragmentation and ultimately 
apoptosis independent of caspases [33]. Decreased AIF expression in the mitochondrial 
fraction was observed in miR-TR1 cells with 48 hr selenazolidine and selenocystine 
treatments as determined by Western blotting (Figure 4.9C). This decreased AIF 
expression is indicative of AIF translocating from the mitochondria to the nucleus. Taken 



















Figure 4.9. SECY and the selenazolidines induce cell death through a caspase-
independent mechanism. For all data shown, cells were treated at the following 
concentrations for 48 hours: SEM, 20 µM; MSA, 1 µM; SECY, BSCA, and ChSCA, 5 
µM. (A) Measure of DNA strand breaks by the TUNEL assay. 10,000 events were 
measured for each sample. Data shown are for BrdU positive, PI negative cell 
populations and are presented as % total population. ‘***’ indicates p<0.001 versus 
matched DMSO vehicle control. All samples were analyzed at least in duplicate. (B) 
Caspase 3/7 activity. Data are presented as expressed as % matched DMSO vehicle 
control. No significance difference between treatment groups was found. (C) AIF protein 
expression in mitochondrial fractions. 1 µg mitochondrial protein was loaded for each 
sample. GAPDH was probed as a protein loading control. α-tubulin protein was not 
detected (data not shown), indicating that the mitochondrial fractions were free of 























































































































































































cell death mechanism of the selenazolidines and selenocystine at low micromolar 





 Lung cancer has the highest mortality rate of all cancer types, with a 5-year 
survival rate of only 16% [34]. One reason for this poor survival rate is the low success 
rate of current treatments. We utilized the A549 human NSCLC cell line as a model of 
lung carcinoma to further determine the effects of TR1 expression on drug sensitivity. 
This cell line was chosen because A549 cells have one of the highest overexpression 
levels of TR1 compared to human bronchial epithelial cells [4]. Additionally, the 
negative regulator of Nrf2, Keap1, is mutated in this cell line, resulting in constitutive 
Nrf2 activation [24]. Nrf2 is a transcription factor that regulates the expression of a 
battery of antioxidant defense genes, including TR1. Thus, A549 cells represent a lung 
carcinoma with high expression of the Trx system and aberrant Nrf2. Dysfunction of 
these antioxidant systems has been shown to be a factor in resistance to several anticancer 
drugs [8, 10, 35, 36]. Altered expression levels of Nrf2 and Keap1 are common 
occurrences in NSCLC tumors and are associated with worse overall patient survival [24, 
37]. Of the lung tumors studied, 26% had nuclear Nrf2 expression, 56% had undetectable 
or low KEAP1 expression, and 41% had a KEAP1 mutation. An additional study of 
NSCLC tumors found that almost half of the tumors studied had strong TR expression 
[4]. These Nrf2, Keap1, and TR1 expression patterns observed in patient tumor samples 
are similar to those of A549 cells, making this cell line an applicable model for many 




gene, TR1. There was no observable difference in A549 viability with TR1 knockdown 
alone in our study or a previous report [38]. We also observed a lack of effects on redox 
parameters and mitochondrial membrane integrity with TR1 knockdown alone. One 
explanation for this is the unregulated antioxidant response and increased reductive 
capacity of the A549 cell line. We extended the observation from the KEAP1 mutant 
phenotype under study with a comparison of the cytotoxic activity of selenocystine and 
ChSCA in H1666 cells. The selenazolidine, ChSCA, demonstrated cytotoxicity 
comparable to the miR-TR1 A549 cells.    
 Studies have demonstrated decreased anticancer drug resistance with Nrf2 
knockdown and the consequential global effects on Nrf2-regulated gene transcription. 
We observed that knockdown of only one Nrf2-regulated gene, TR1, was able to enhance 
selenocompound cytotoxicity. The data presented here demonstrate that 
selenocompounds exhibit differential cytotoxic effects in A549 cells with decreased TR1. 
TR1 knockdown only increased selenazolidine and selenocystine cytotoxicity as 
determined by cellular ATP content. Our clonogenic survival assays suggest that the 
long-term treatment with these compounds may preclude the advantage of TR1 
attenuation; however, additional experiments, perhaps including xenograft studies, may 
be more applicable to determining if targeting TR1 while treating with redox active 
agents provides therapeutic advantage in vivo.  TR1 attenuation did not alter the 
cytotoxicity of MSA, selenomethionine, or p-XSC (data not shown for p-XSC). Increased 
sensitivity to MSA has been observed in the RKO colon cancer cell line with TR1 
knockdown via an autophagic mechanism [12], indicating that while MSA can have 




also investigated CDDP since the Trx system has been linked to its resistance. CDDP 
interacts with TR1 at the selenocystine residue, resulting in irreversible inhibition of the 
enzyme [39]. TR1 knockdown did not affect CDDP cytotoxicity in this study, indicating 
that other factors may be responsible for CDDP resistance in vitro, such as the 
glutaredoxin system that can be inhibited by the GSH adduct of CDDP. However, it was 
recently shown that CDDP with the organoselenium TR inhibitor ethaselen reduced 
tumor size in A549-grafted nude mice to a greater extent than CDDP alone [8], 
demonstrating that targeting TR1 in combination with redox active anticancer drugs is an 
effective strategy to reduce tumor growth in vivo.  
 Interestingly, the selenazolidines and selenocystine were the only compounds 
whose cytotoxicity was affected by TR1 expression. These compounds also increased 
ROS in a TR1 dependent manner, indicating a protective role for TR1 in A549 cells. TR1 
has been shown to protect other cancer cell lines from oxidative species generated by 
hydrogen peroxide, radiation, and CCDP. It is also possible that knockdown of TR1 
lowers the concentration at which selenocompounds function as pro-oxidants rather than 
antioxidants. The selenazolidines and selenocystine decreased intracellular GSH levels to 
the greatest extent (~90%). Given that these compounds decreased total GSH 
independent of TR1 status, it is not surprising that they also affected the Trx oxidation 
state regardless of TR1 expression. However, GSH depletion and Trx oxidation are 
unlikely to be solely responsible for the cell death mechanism, as these compounds 
altered these parameters to an equal extent in the miNeg cells but did not alter miNeg cell 
viability. Pretreatment with the antioxidants NAC and tiron did not decrease the 




pretreatment regimen was ineffective or the ROS generation was a consequence rather 
than initiator of cell death. Cell death was also observed with depletion of both the TR1 
and GSH systems in the absence of an external oxidative or electrophilic insult, 
indicating the need for depletion of both these antioxidant systems to induce cell killing 
in the basally reduced A549 cell line. In one study, the depletion of TR1 and GSH 
together for 48 hours did not result in A549 cell death [38]; we show here that it is 
necessary to maintain simultaneous depletion of these antioxidant systems out to 72 hours 
to elicit cell death. This need for sustained antioxidant depletion further demonstrates the 
high reserve antioxidant capacity of the A549 cell line and presents a potential treatment 
strategy for these types of tumors.  
 As one selenocystine molecule contains two selenium atoms, the selenium content 
of one mole of selenocystine is twice that of compounds containing one selenium atom, 
such as the selenazolidines. To ensure that the observed cytotoxic and redox effects of 
selenocystine were not merely a result of a higher selenium concentration from this 
compound, ROS generation was evaluated for 2.5 µM selenocystine. This concentration 
provided an equivalent molar amount of selenium as 5 µM BSCA or ChSCA. No 
increase in ROS was detected with 2.5 µM selenocystine in miR-TR1 cells (data not 
shown), indicating that the selenium concentration itself is not solely responsible for the 
observed redox effects. Of course, this assessment of selenium content and selenium-
mediated cytotoxicity cannot account for potential differences in absorption, metabolism 
and elimination that may exist among the selenocompounds in vivo. These parameters 




 Mitochondrial dysfunction and AIF-induced cell death, such as that induced by 
the selenocompounds in this study, has been shown to be an effective method of killing 
chemoresistant NSCLC cell lines [40, 41]. Consistent with our results, evidence for 
selenocompounds inducing a caspase-independent mechanism of cell death in 
transformed cells through mitochondrial pathways has been demonstrated, including AIF-
mediated mechanisms for selenocystine and selenite [42-45]. In this work, we observed 
that selenocompounds in combination with TR1 knockdown can induce mitochondrial 
dysfunction at lower concentrations than those used in our previous study, even as the 
mitochondrial isoform remains intact. Since caspase-dependent mechanisms of cell death 
are not effective at killing resistant NSCLC cells, the caspase-independent mechanism 
indicated by our results presents an intriguing ability of the selenazolidines to induce cell 
death with decreased TR1 expression. 
 Selenazolidines are organoselenocompounds designed to release selenocysteine 
either enzymatically or through spontaneous hydrolysis [46]. Once selenocysteine is 
liberated, it can dimerize with itself to generate selenocystine. These prodrugs lack the 
chemical instability associated with selenocysteine, as selenocysteine can easily oxidize 
to diselenide. Selenazolidines exhibit decreased cytoxicity and greater biological 
availability of Se in comparison to sodium selenite and selenomethionine in cell culture 
[47, 48] and comparable chemoprevention efficacy to selenocystine [49]. In this study, 
we utilized two selenazolidines, BSCA and ChSCA, which are thought to release 
selenocysteine through spontaneous hydrolysis and have demonstrated anticancer activity 
in vivo. Herein, we have demonstrated that the cytotoxic and redox modulatory properties 




 In summary, our data demonstrate that TR1 knockdown increases the cytotoxicity 
of the selenocompounds BSCA, ChSCA, and selenocystine in A549 cells through a 
mitochondrial pathway, as summarized in Figure 4.10. Further work to investigate the 
use of these compounds in combination with thioredoxin reductase inhibitors or current 
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Figure 4.10. Proposed mechanism of cell death by selenocompounds in combination with thioredoxin reductase inhibition in A549 
cells. Inhibition of the glutathione system by selenocystine, BSCA, and ChSCA coupled with thioredoxin system inhibition by siRNA 
leads to mitochondrial dysfunction as indicated by mitochondrial membrane polarization. Apoptosis inducing factor is released from 
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 The overall aim of this work was to evaluate the ability of selenocompounds to 
modulate the redox status of lung cells and consequently activate pathways associated 
with cancer prevention or cell death. This dissertation has presented data to support the 
hypothesis that selenocompounds can induce an oxidative or reductive stress in a 
compound and cell-line specific manner. Findings from Chapters 3 and 4 demonstrate 
that selenocystine and ChSCA may have applications both as chemotherapy agents to 
prevent tumorigenesis by activating the Nrf2/ARE pathway and as anti-cancer agents in 
combination with TR1 attenuation to induce cell death through oxidative stress. BSCA 
remains to be evaluated for its ability to activate Nrf2, but was also shown to increase 
oxidative stress and cell death with TR1 attenuation. MSA produced a reductive stress in 
A549 cells and a moderate oxidative stress in BEAS-2B cells that could activate the Nrf2 
pathway, but its toxicity was not affected by TR1 status. Selenomethionine was unable to 
modulate redox status and did not activate the Nrf2 pathway in nonmalignant cells or a 
caspase-independent cell death pathway in malignant cells. These findings will be 
beneficial in determining which form of selenium and what type of cell line (malignant or 
nonmalignant) to use in future studies and will also contribute to predicting how a 
given selenocompound  may  affect  cellular  redox  status. This work also indicates 
novel mechanisms of selenium in cancer prevention and treatment for future study. 
 
Discussion 
 A potential dual action of selenocystine and ChSCA related to malignancy state is 
indicated by this work (Figure 5.1). These compounds produced a shift in cellular redox 
tone to the oxidative side, but with different consequences in the BEAS-2B cells 
compared to the A549 cells. In nonmalignant BEAS-2B cells, the two compounds 
initially generated ROS species and depleted intracellular glutathione levels in a rapid 
manner (2 hours) but had increased levels to above baseline by 24 hours. These 
compounds decreased intracellular glutathione levels in the malignant A549 miNeg and 
miR-TR1 cells, but not as rapidly as in the BEAS-2B cells, as the decreases were 
observed following 48 hour treatment of the A549s. These decreases in glutathione 
content do not appear to be related to the toxicity of the selenocompounds, as the 5 µM 
concentrations used in both of the A549 cell lines only decreased viability of the A549 
miR-TR1 cells, but depleted glutathione in both the A549 miNeg and miR-TR1 cells. 
Additionally, selenocystine and ChSCA depleted glutathione to a similar extent at 2 
hours in the BEAS-2B cells even though the 1 µM selenocystine concentration was less 
toxic than the 25 µM ChSCA concentration. Selenocystine and ChSCA also increased 
ROS levels at 48 hours, but only in the context of TR1 knockdown. It is likely that the 
generation of ROS at the 48 hour time point is a consequence of cell death, as it is 
occurring at the same point as the decrease in cellular ATP content and pretreatment with 
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Figure 5.1. Cell fate following treatment with SECY and ChSCA can be malignancy 
status and basal redox state dependent. In a nonmalignant lung cell with low basal 
Nrf2 and TR1 expression (BEAS-2B), SECY and ChSCA activate the Nrf2 pathway, thus 
increasing antioxidant defense to contribute to cell survival. MSA also activates this 
pathway. In a malignant lung cell with high basal Nrf2 activity and TR1 expression 
(A549), SECY and ChSCA alone do induce cell death. However, delayed cell death can 
occur with these compounds, and also BSCA, in the context of TR1 knockdown. 




point, selenocystine increased ROS levels in A549 cells, while ChSCA did not. This 
difference between selenocystine and ChSCA is most likely attributed to the higher 
toxicity of the 100 µM selenocystine concentration used at the 24 hour time point (~60% 
viable cells) compared to the 100 µM ChSCA concentration (~100% viable cells). This 
difference in cell viability with these selenocystine and ChSCA concentrations did not 
result in differential effects on free thiol levels or mitochondrial membrane potential in 
the A549 cells at 24 hours, as both measurements were similarly affected by 
selenocystine and ChSCA.  
 Although the generation of selenocystine from the selenazolidines has yet to be 
formally evaluated, the similar actions of ChSCA to selenocystine described in Chapters  
2, 3, and 4 indicate that ChSCA may indeed release selenocysteine as it was designed to 
do. BSCA also demonstrated similar effects as selenocystine in the A549 miNeg and 
miR-TR1 cell lines. Taken together, these data indicate that the observed effects of these 
two selenazolidines is likely due to their functioning as selenocysteine prodrugs to release 
selenocystine that may then form the more stable selenocystine dimer in vitro.  
 The effects of MSA on cellular redox status also varied between the A549 and 
BEAS-2B cell line even though the 2.5 µM concentration resulted in ~70% viability of 
both cell lines at 24 hours. In the A549 cells, MSA was shown to produce a reductive 
stress and increase expression of the ER stress marker BiP/GRP78. This finding is in 
agreement with studies showing MSA generates ER stress in prostate [1, 2] and colon [3] 
cancer cells. TR1 knockdown in the A549s did not modulate the toxicity of MSA, in 
contrast to the oxidative compounds selenocystine, ChSCA, and BSCA. It is possible that 




would not further increase cell death from MSA-mediated ER stress. As TR1 is localized 
to the cytosol, it is unlikely that it has direct actions in the ER. This is supported by the 
finding that TR1 knockdown in RKO colon cancer cells did not increase ER stress 
generated by MSA [3]. Another possibility is that reductive stress imparted by MSA does 
not consume as much glutathione as an oxidative or electrophilic stressor. This less 
dramatic depletion of glutathione by MSA in the absence of oxidative stress may explain 
why the toxicity of MSA was not enhanced in A549 cells with TR1 knockdown. In the 
BEAS-2B cells, MSA did not produce a reductive stress as indicated by altered 
BiP/GRP78 expression at 24 hours, but rather elicited oxidative stress at the 2 hour time 
point in these cells. MSA generated ROS and depleted glutathione in BEAS-2B cells at 2 
hours, although to a lesser extent than selenocystine or ChSCA at the concentrations 
utilized. The magnitude of changes in ROS and glutathione with MSA do not appear to 
be related to cell viability, as the less toxic 1 µM selenocystine (~100% viable cells at 24 
hours) depleted glutathione to a greater extent and generated ROS at a similar level 
compared to 2.5 µM MSA (~70% viable cells at 24 hours). Thus it appears that the redox 
effects of MSA are dependent on the malignancy status of a cell line.  
 Of particular note are the findings related to selenomethionine. Selenomethionine 
is of high interest due to its use as the form of selenium supplementation in SELECT and 
its high presence in the selenized yeast used for the NPC trial. These trials have shown a 
modest benefit for selenium in decreasing cancer incidence and mortality [4, 5]. While 
the results of these two trials may be related in part to subject selenium status, the choice 
of selenomethionine may also have been a contributing factor [6, 7]. To this end, the 




the other selenocompounds investigated. Selenomethionine did not alter cellular ROS or 
free thiol levels and did not affect mitochondrial integrity, despite being used at a 
concentration (100 µM) up to 20 times greater than the other compounds investigated. 
This 100 µM selenomethionine concentration was not associated with decreased viability 
of the BEAS-2B cells at 24 hours or the A549 cells at either 24 or 48 hours. The most 
likely explanation for these findings is that selenomethionine does not form the selenide 
anion for redox cycling unless it first forms methylselenol through a methionase reaction 
[8], while selenocystine and MSA have been shown to [9], and the selenazolidines are 
hypothesized to, form the selenide anion. Further, selenomethionine can be incorporated 
into general cellular proteins and diverted from the hydrogen selenide pool, decreasing 
the amount of selenium available for selenoprotein biosynthesis, methylselenol 
formation, and redox cycling. The lack of altered cellular redox status elicited by 
selenomethionine in this study may explain its lack of efficacy in animal models [10, 11]. 
These findings for selenomethionine provide further evidence that the form of 
selenocompound, and not merely the presence of selenium, is a major determinant of 
observed effects. 
 The data presented in Chapter 2 indicate a greater sensitivity of the nonmalignant 
BEAS-2B cells than the malignant A549 cells to the selenocompounds assessed. Previous 
studies have also investigated the sensitivity of malignant cells to selenium in comparison 
to that of normal, nonmalignant cells. The results have primarily indicated a greater 
sensitivity of malignant cells to selenocompounds [12-19], with one study showing 
nonmalignant cells to be more sensitive [20]. One explanation for the greater toxicity of 




levels of a given cell line [12]. It is thought that the higher glutathione levels found in 
malignant cells provide greater amounts of thiols for selenocompounds to redox cycle 
with, producing more reactive species that would lead to cell death. Another explanation 
involves higher selenium uptake and accumulation related to a reduced extracellular 
environment and expression of the xc- cystine transporter [21], but this has only been 
investigated for selenite toxicity. The lower toxicity of the selenocompounds in the 
malignant A549 cells is in contrast to the idea that cell lines with higher glutathione 
levels and thus a more reduced cellular redox tone are more sensitive to 
selenocompounds. In the case of the A549 cells, the higher basal level of glutathione, 
higher expression of antioxidant defense genes, and a basal reduced state [22] may result 
in the lower sensitivity of these cells to the selenocompounds as the cells would be better 
equipped to attenuate oxidative stress generated by the selenocompounds. This is in 
comparison to the BEAS-2B cells that have lower glutathione levels, lower expression of 
antioxidant defense genes, and a more oxidative basal redox tone [22], making them 
more susceptible to selenocompound-induced cell death. In fact, the higher expression of 
the manganese superoxide dismutase enzyme in normal prostate cells compared to the 
paired malignant prostate cells was related to the lower toxicity of selenite in the normal 
cells [13]. Additionally, the data in Chapter 4 indicates that TR1 expression can be a 
determinant of selenocompound toxicity; the low expression of TR1 in BEAS-2B cells 
[23] may also contribute to the greater sensitivity of these cells. Expression of genes 
related to selenium sensitivity, such as selenoprotein 15 [14], may also differ between the 




for the differential toxicity profiles of the selenocompounds in the A549 and BEAS-2B 
cells and have not yet been investigated.       
 In addition to toxicity, the basal redox tone of a cell may also be an important 
determining factor in the actions of certain selenocompounds, such as their ability to 
modulate glutathione and ROS levels, and the time course that such actions follow. It was 
shown in Chapter 2 that the basal redox status of these two cell lines differs, with the 
A549 cells being in a more reduced state than the BEAS-2B cells. This can be further 
extended to the differential basal Nrf2 activity of the A549s and BEAS-2Bs [22], which 
may be a determining factor in the differential basal redox state of these two cell lines. It 
is likely that selenocystine and ChSCA undergo redox cycling in both cell lines. In the 
BEAS-2B cells, Nrf2 activity is low, but is stimulated by the consequences of 
selenocompound redox cycling, such as ROS generation and glutathione depletion. Nrf2 
may also be activated by redox cycling through oxidation of Keap1 reactive cysteines. 
This would lead to the increased glutathione levels observed in the BEAS-2B cells at 24 
hours. In the A549 cells, the basal Nrf2 activity is already high, even prior to 
selenocompound treatment. When the selenocompounds are introduced and begin to 
redox cycle, the A549 cells are well prepared to attenuate oxidative stress from their 
already high Nrf2 activity, antioxidant gene expression, and glutathione levels. By 48 
hours, these compounds have depleted glutathione through an unknown mechanism, even 
though Nrf2 activity should still be high. When TR1 is present, as it is at high levels in 
A549 cells, this glutathione depletion does not lead to cell death. It is thought that is 
because TR1 can continue to maintain the cellular redox state for such redox sensitive 




depleted, mitochondrial dysfunction occurs, leading to cell death. This outline serves as 
one explanation that attempts to integrate the observed findings for selenocystine and 
ChSCA with the known Nrf2 status of these cell lines. 
 One limitation of the studies in this dissertation is that it is not known exactly 
which reactive species are being generated in cell culture by the selenocompounds. 
H2DCF-DA was utilized to measure generated ROS, as it is a commonly published 
protocol used to measure ROS in vitro. H2DCF-DA is a lipophilic compound that is not 
itself fluorescent. When taken up by cells in culture, the acetate groups on H2DCF-DA 
are cleaved, producing the cell membrane-impermeable DCFH. Reactive species then 
react with DCFH, generating fluorescent DCF. For data in this dissertation, PI 
fluorescence was also measured in the cytometric assay to assess DCF fluorescence from 
viable (PI negative) cells. There are conflicting reports as to what oxidants (superoxide 
radical, H2O2) primarily react with DCFH to produce DCF [24]. In addition to ROS, 
other reactive species may be generated by the selenocompounds that could increase DCF 
fluorescence. BSCA and ChSCA also generate aldehydes when releasing selenocysteine 
that could be responsible for their observed downstream effects. However, BSCA and 
ChSCA behaved similarly to selenocystine, indicating that the actions of these 
selenazolidines are related more to their release of selenocystine than generation of 
aldehydes. BSCA and ChSCA were also shown to be less toxic than selenocystine at 24 
hours in the BEAS-2B cells and at both 24 and 48 hours in the A549 cells. If these 
selenazolidines were releasing high concentrations of aldehydes, which are regarded as 
toxic compounds, they would elicit a more dramatic decrease in cell viability than what 




selenocompounds were not of interest, but rather whether an overall increase in ROS was 
observed that would be consistent with a shift in cellular redox tone. Intracellular 
glutathione content was also measured following selenocompound treatments in the A549 
and BEAS-2B cells to serve as a further measurement to assess alterations in cellular 
redox tone. 
 
Mechanism of Chemoprevention 
 Selenocystine, ChSCA, and MSA were shown to increase antioxidant gene 
expression through Nrf2 activation, but the mechanism of Nrf2 activation by these 
compounds is unknown. These selenocompounds were shown to increase ROS levels at 2 
hours when used at concentrations that demonstrate less than a 30% loss in BEAS-2B cell 
viability at 24 hours as shown in Chapter 2. Whether the generation of these ROS is 
responsible for the disruption of the Keap1/Nrf2 complex and subsequent Nrf2 
translocation to the nucleus is currently unknown. While 25 µM ChSCA elicited the 
greatest fold increase in Nrf2 target gene mRNA expression and produced the greatest 
loss in cell viability at 24 hours at the selenocompound concentrations utilized, it 
generated ROS at levels equivalent to those generated by 1 µM selenocystine and 2.5 µM 
MSA. These findings indicate that perhaps another mechanism in addition to ROS 
generation is involved in Nrf2 activation by these selenocompounds. Additionally, 5 µM 
ChSCA also produced a greater increase in TR1, NQO1, and GCLC mRNA expression in 
the NHBE cells than 2.5 µM MSA, although both of these selenocompound treatments 




An important step in elucidating the mechanism of Nrf2 activation would be to 
determine how these selenocompounds modify reactive thiols on Keap1. The sulfhydryl 
groups of Keap1 cysteines can be modified by oxidation, reduction, or alkylation [25]. 
Selenocompounds have been shown to interact with protein thiols through direct protein 
adduct formation [26] or protein thiol oxidation from hydrogen selenide and 
methylselenol products [26-29]. The Keap 1 cysteines Cys-151, Cys-273 and Cys-288 
have been shown to be key targets of  Nrf2 activators [30-32], but the Keap1 cysteines 
modified appear to be compound dependent [25, 33]. One study performed by Kobayashi 
et al. used zebrafish to categorize 11 Nrf2 activators into six classes based on how they 
activate Nrf2 [25]. This study also indicated that compounds that target specific cysteines 
may have distinct biological effects [25]. Determining how the selenocompounds activate 
Nrf2 would allow them to be classed with these other activators that are better 
characterized in regard to the Nrf2 activation mechanism and may provide further insight 
into the biological effects these selenocompounds may produce as a result of Nrf2 
activation. 
The Nrf2 pathway can also be activated by ER stress, leading to the increased 
expression of such Nrf2 target genes as GCLC and NQO1 [34, 35].  PERK, a protein 
kinase involved in the unfolded protein response, is activated following ER stress and 
phosphorylates eukaryotic initiation factor 2α, resulting in the inhibition of translation 
initiation [36]. PERK has also been shown to phosphorylate Nrf2 independent of 
eukaryotic initiation factor 2α phosphorylation, resulting in its dissociation from Keap1 
and translocation to the nucleus [34]. Additionally, Nrf2 is implicated in enhancing 




While it was shown in Chapter 2 that selenocystine, ChSCA, and MSA did not alter 
BiP/GRP78 protein expression at 24 hours in BEAS-2B cells, it is unknown whether 
these Nrf2-activating selenocompounds cause ER stress at an earlier time point (e.g., 2 
hours) that would result in the translocation of Nrf2 to the nucleus at 4 hours as shown in 
Chapter 3.  
 Chapter 3 shows that the selenocompounds can activate the Nrf2/ARE pathway in 
the lung, but little is known as to whether selenocompounds can activate this pathway in 
other tissues. The ability of selenocystine and selenazolidines to increase phase II gene 
expression has been assessed in the liver. No common pattern of increased mRNA or 
activity by selenocystine and the selenazolidines relating to their observed 
chemoprevention activity was found when measured 24 hours after a single dose [38] or 
after a week of daily administration [39]. Differential phase II enzyme induction by the 
selenocompounds was also observed in Hepa1c1c7 mouse hepatoma cells. ChSCA 
increased Trxnd1, Nqo1, glutathione S-transferase alpha, mu- and pi classes, and Ugt1a6 
mRNA in following 18 hr treatment, and all but the increase in Ugt1a6 were 
transcriptionally dependent [40]. Selenocystine and selenomethionine moderately 
increased glutathione S-transferase alpha, and selenocystine also increased Trxnd1, but 
neither compound increased Nqo1, glutathione S-transferase m or p classes, or Ugt1a6 
expression in this system. These previous studies in liver are in slight contrast to the 
findings for the lung presented in Chapter 3 of this work. However, it is important to note 
differences in the tissue of interest and animal species. These other works analyzed the 
liver of male CF-1 mice, while this work is looking at the lung of female A/J mice. 




of selenocystine and selenazolidines to induce phase II enzymes in several tissue types. 
The induction of these enzymes by selenocystine, selenazolidines, and MSA could be 
beneficial in other tissues where both selenium and Nrf2 is implicated in cancer 
prevention, such as the colon [41-43]. It remains to be seen in what other tissues the 
Nrf2/ARE pathway can be activated in by selenocompounds. 
 
Mechanism of Cell Death with TR Knockdown 
 The results from Chapter 4 demonstrate that the ability of selenocompounds to 
deplete glutathione is a major determinant for increased cytotoxcity with TR1 
attenuation. The concept of pharmacological inhibition of either the thioredoxin or 
glutathione systems alone for cancer treatment has been previously investigated. Gold 
compounds that inhibit thioredoxin reductase, such as auranofin [44, 45], can cause 
cancer cell death through a mitochondrial pathway [46-48]. The use of BSO to deplete 
glutathione has been investigated as an adjuvant therapy in vitro and in clinical studies 
[49, 50]. However, inhibition of both antioxidant systems is a novel approach to cancer 
treatment and represents a synthetic lethality strategy. Synthetic lethality is defined as 
cell death resulting from the simultaneous inactivation of two genes that do not affect cell 
viability when independently inactivated [51]. An in vivo study investigating the role of 
TR in tumor growth and the interaction between the thioredoxin and glutathione systems 
by Mandal et al. was published at the same time as Chapter 4 [52]. In keeping with the 
data presented in Chapter 4, TR knockdown alone did not affect proliferation or the 
clonogenic and tumorigenic potential of transformed cells [52]. As a compensatory 




glutathione was required for survival and proliferation of TR deficient cells. The 
combination of genetic TR knockout and glutathione depletion by BSO decreased 
xenograft tumor mass, while no effect was seen with attenuation of either system alone. 
This in vivo study further validates the results from Chapter 4 as being an applicable 
approach to treating tumors in a whole animal system.    
 The mechanism of selenocompound-induced glutathione depletion, as well as the 
time course, is unknown. It is also unknown whether glutathione depletion is an initiating 
factor in cell death or a consequence. One explanation for the findings in Chapter 4 is that 
knockdown of TR1 places additional pressure on the glutathione system to maintain 
cellular redox status that becomes oxidative from the selenocompounds and glutathione 
levels are consequently depleted. This is supported by alterations in glutathione 
metabolism that occur to compensate for TR1 attenuation [52]. In addition to the 
evidence for cross-talk between the thioredoxin and glutathione systems in mammalian 
cells [42], there are also reports in yeast [53], Drosophila melanogaster [54] and 
Arabidopsis thaliana [55]. However, this does not explain why glutathione levels 
decrease but are not returned to baseline levels in the A549 cell line, which should have a 
high capacity for glutathione biosynthesis from its constitutive Nrf2 activity.  
 Glutathione export has been implicated in initiating apoptosis for certain 
compounds such as staurosporine [56]. When glutathione levels were decreased with 
BSO or glutathione efflux inhibited, staurosporine-induced apoptosis was prevented. The 
data for the selenocompounds do not support induction of cell death by glutathione 
efflux, as BSO slightly increased cell death observed with selenocystine, ChSCA, and 




 Based on the current data, it is unlikely that the glutathione depletion at 48 hours 
is due to glutathione-mediated export of the selenocompounds or their metabolites alone. 
It is expected that if glutathione was depleted through this mechanism, it would occur 
before 48 hours and cells would regenerate glutathione to replace what was lost in 
conjugation. Also, the current data do not indicate that reduced glutathione is depleted by 
providing reducing equivalents to reactive species generated from the selenocompounds, 
as levels of oxidized glutathione do not increase. Another theory is that selenocystine, 
BSCA, and ChSCA inhibit the rate-limiting glutathione biosynthesis enzyme glutathione 
cysteine ligase, perhaps in a manner similar to BSO, which is thought to bind to the 
enzyme as a glutamate analogue and also block the cysteine binding site [57]. 
 How this attenuation of both the thioredoxin and glutathione systems leads to 
mitochondrial dysfunction is unknown. Direct modification of protein thiol groups by 
selenium and a lack of reducing equivalents to return these thiol groups to a reduced state 
resulting from TR1 and glutathione depletion is one hypothesis. A number of 
mitochondrial enzymes have critical thiol groups that need to be in the reduced state to 
properly function [58]. Selenium was shown in cell extracts and isolated mitochondria to 
decrease mitochondrial membrane potential as a result of protein thiol modification [59, 
60]; a similar mechanism may occur in the A549 TR1 knockdown cells treated with 
selenocystine, BSCA, and ChSCA. Another explanation is that the decrease in 
antioxidant capacity results in an overwhelming oxidative stress from the mitochondrial 
generation of ATP and other biofactors that cancer cells need at high levels for their 
uncontrolled proliferation. The tendency of cancers to overexpress TR1 and have high 




metabolic demands, and the resultant need to increase antioxidant defense capacity in 
order to attenuate oxidative metabolites generated during cellular processes related to 
proliferation [61, 62]. The resultant mitochondrial stress can not be attenuated by the 
thioredoxin or glutathione systems, which have been depleted, so mitochondrial cell 
death pathways such as AIF are activated.  
 As a whole, this dissertation demonstrates that selenocompounds such as 
selenocystine and ChSCA can have applications in both cancer prevention and cancer 
therapy through their effects on cellular redox status. This scheme of the dual actions 
relating to cell survival and cell death is illustrated in Figure 5.1. MSA is also implicated 
in the Nrf2 activation cell survival pathway, but not the cell death pathway associated 
with TR1 knockdown. Selenomethionine is not implicated in either pathway. While this 
scheme is useful for generalizing the actions of two selenocompounds in both 
nonmalignant and malignant lung cells, several aspects of these pathways are missing, 
such as how the Nrf2 pathway is activated and how the combination of glutathione and 
TR1 depletion leads to cell death. Ideas for future studies in regard to these unknown 
mechanisms are discussed in the next section.  
 
Future Directions 
 The long term objective of this work is to determine the mechanism action of 
selenium in chemoprevention and cancer therapy. While the studies described in this 
work have indicated Nrf2 and mitochondrial dysfunction as mechanisms of prevention 
and treatment, respectively, these only represent single mechanisms. It is unlikely that 




organ site specific. Studies of other mechanisms, such as histone deacetylase inhibition 
[63, 64], and other tissues, such as colon, warrant investigation. In comparison to the 
other selenocompounds investigated in this work, the selenazolidines are poorly 
characterized. Studies to further characterize the selenazolidines, such as those related to 
biodistribution, metabolism and ability to redox cycle, are necessary to further understand 
their mechanism of action. The selenazolidines have only been investigated in an animal 
model of lung cancer and should be tested in models of other cancers for which selenium 
has an indicated benefit, such as prostate and colon. Additionally, the properties of the 
selenocompounds identified in this work may have applications in additional diseases. 
One example would be the use of the Nrf2-activating selenocompounds in lung diseases 
where Nrf2 has a protective role, such as asthma [65] and emphysema [66]. Future work 
related to either the chemoprevention or anti-cancer mechanisms of selenium is described 
in the remainder of this chapter. 
 
Chemoprevention Mechanisms of Selenium 
  
 Future studies need to be performed on the mechanism of Nrf2 activation by the 
selenocompounds. It is currently unknown how selenocompounds may modify key 
cysteine residues on Keap1 that would lead to Nrf2 release and which Keap1 residues the 
selenocompounds target. This could be determined using mass spectrometry to detect 
selenocompound-Keap1 adducts or Keap1 cysteine modifications. It is also unknown 
whether the selenocompounds affect the ubiquitination, and therefore degradation, of 
Nrf2 or Keap1, mechanisms that have been associated with other Nrf2 activators [67, 68]. 




with a differential mechanism could be tested for synergy with the selenocompounds to 
further enhance Nrf2 activation and downstream gene induction. 
 Selenocompounds may also have other mechanisms to activate Nrf2 in addition to 
Keap1 modification that could be investigated. Glycogen synthase kinase 3 beta 
inhibition can lead to nuclear Nrf2 accumulation [69]. MSA has been shown to inhibit 
glycogen synthase kinase 3 beta [70], but it remains to be seen whether MSA activates 
Nrf2 by inhibiting this pathway. It was shown in Chapter 2 that ROS levels are increased 
by selenocompounds prior to Nrf2 translocation to the nucleus, but it is unknown whether 
this generation of ROS is necessary for Nrf2 activation by the selenocompounds. This 
could be tested by pretreating cells with antioxidants such as NAC or a superoxide 
dismutase mimetic to attenuate selenocompound-induced ROS generation and then 
evaluating nuclear Nrf2 expression and downstream ARE gene expression.  
 Additional experiments in animal models would further elucidate what effects 
selenocompounds have on the lung. MSA still needs to be evaluated for chemoprevention 
in an animal model of lung cancer, as no such study has been published to date. MSA, 
selenocystine, and ChSCA were shown in Chapter 3 to increase glutathione levels in cell 
culture. Whether these compounds also increase lung glutathione levels at the organ site, 
similarly to what has been observed for p-XSC [71], is currently unknown. The ability of 
these compounds to increase lung glutathione levels in the mouse would demonstrate 
whether this effect observed in cell culture translates to an animal model. Another 
important aspect of the p-XSC mechanism is thought to be its ability to decrease DNA 
adducts from NNK administration [72]. It is currently unknown whether the other 




methylation and warrants investigation. The biodistribution of selenium to the lung has 
also been related to the efficacy of other selenocompounds in decreasing lung tumor 
formation [71, 72] and should be assessed in animals administered selenocompounds. 
Evidence for other cancer types that may benefit from certain selenocompounds would 
also be generated by determining if organ sites in addition to the lung have increased 
selenium levels, such as the colon or mammary glands. The inclusion of selenazolidines 
that were ineffective at decreasing the number of NNK-induced lung tumors in such 
studies assessing lung glutathione, DNA adduct, and selenium levels would also prove 
useful in determining whether these actions are important for chemopreventive benefit. 
Finally, the ability of selenocompounds to decrease lung tumor incidence in an Nrf2 
knockout mouse would determine whether Nrf2 is required for the chemopreventive 
benefit of selenocompounds, an important piece of evidence that is currently lacking. 
  
 Selenocompounds in Cancer Treatment 
 How selenocystine, ChSCA, and BSCA deplete glutathione to levels 20% of 
baseline is not understood. The current data are only for one time point, 48 hours, so it is 
unknown how early after treatment glutathione levels begin to decrease. Further 
experiments establishing a time course of glutathione depletion are needed to better 
understand how the depletion occurs. Glutathione can be used to detoxify compounds by 
forming conjugates through reactions with glutathione S-transferases or through 
reduction reactions, including those with glutathione peroxidases. It is unknown whether 
glutathione is depleted through such detoxification pathways. This could be determined 




inhibiting glutathione S-transferases and then measuring glutathione levels. A second 
possibility to be investigated is the inhibition of the rate-limiting glutathione synthesis 
enzyme glutamate cysteine ligase by these selenocompounds or their metabolites.  
 The way by which selenocompounds cause mitochondrial dysfunction in the 
A549 cells is unknown. The ability of these compounds to modify mitochondrial protein 
thiols or generate mitochondrial superoxide and mitochondrial DNA mutations should be 
assessed. Whether the selenocompounds in combination with TR1 knockdown alter 
cellular metabolism should also be determined, as the observed effects on the 
mitochondria may result in changes related to metabolism. Cellular aerobic respiration 
and glycolysis could be measured using an extracellular flux analyzer, such as the one 
from Seahorse Bioscience Inc. A second strategy would be to utilize phenotype 
microarrays from Biolog to determine if the carbon metabolism and energy pathways 
required for cell survival are altered. Further work on cellular metabolism could be 
performed using mass spectrometry and HPLC to monitor the availability of the citric 
acid cycle intermediates [73]. 
 Animal studies with selenocystine, ChSCA, and BSCA regarding their ability to 
decrease the size of existing tumors have not yet been conducted. Studies using xenograft 
models where animals are treated with these selenocompounds in combination with 
auranofin or other thioredoxin reductase inhibitors would provide evidence that these 
compounds can decrease tumor size in vivo and would also determine whether a decrease 
in tumor size with these compounds is enhanced with TR knockdown.  
 Finally, the ability of selenocompounds to synergize with current therapies such 




cytotoxicity and tolerated dose of anti-cancer drugs, including cisplatin [74, 75]. Cisplatin 
is an ideal anti-cancer drug to use in combination with selenocystine, ChSCA, or BSCA 
in the lung for several reasons. First, it is a common first-line therapy for lung cancer 
treatment and has established use in combination therapy for lung cancer. Second, 
cisplatin is known to inhibit thioredoxin reductase [76]. This would be an optimal feature 
of a drug to use in combination with selenocystine, ChSCA and BSCA, since their 
cytotoxicity is enhanced with thioredoxin reductase attenuation. Third, cisplatin 
resistance has been associated with high glutathione levels, as glutathione is involved in 
the detoxification and inactivation of platinum drugs [77, 78]. The ability of 
selenocystine, ChSCA, and BSCA to deplete glutathione in a thioredoxin reductase-
independent manner may be especially useful in lung cancers that are cisplatin resistant 
[79]. Cell death may also be further enhanced in combination therapies with cisplatin or 
other anti-cancer drugs through genetic or pharmacological methods of TR1 attenuation. 
The ability of MSA to generate ER stress in lung cancer cells may also be useful in 
combination therapy. Several compounds have been shown to increase cisplatin efficacy 
through their ability to increase ER stress [80, 81]; similar effects may occur with MSA. 
The selenocompounds should also be investigated in the lung with other anti-cancer 
drugs that inhibit thioredoxin reductase, such as alkylating agents [82], or anti-cancer 
drugs that have increased efficacy and decreased toxicity with selenium, such as 
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5-OXOPROLINASE EXPRESSION AND ACTIVITY 
 




 5-oxoprolinase (OPLAH) is the enzyme hypothesized to be responsible for the 
release of selenocystine from OSCA. This enzyme catalyzes the analogous ATP-
dependent conversion of 5-oxo-proline to glutamate. As shown in Figure 2.1 in Chapter 
2, the BEAS-2B cells were more sensitive to OSCA than the A549 cells. In fact, no 
change in viability was seen for the A549 cells at the highest concentration evaluated, 
600 µM. However, selenocystine, the compound thought to be released from OSCA by 
OPLAH, did demonstrate toxicity in both cell lines. This differential toxicity of OSCA 
and selenocystine in the A549 cells, but not the BEAS-2B cells, led to the investigation 
of OPLAH. Studies of human tissues have shown lower OPLAH expression and activity 
in tumor tissue compared to adjacent, matched nonmalignant normal tissue, including 
lung [1, 2]. These previous studies and the differential effects of OSCA we observed in 
regards to viability led to the hypothesis that malignant A549 cells have lower OPLAH 
expression and activity than nonmalignant BEAS-2B cells. OPLAH mRNA expression 
and activity were assessed to determine if the differential toxicity of OSCA observed in 
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malignant and nonmalignant cells is due to differential expression or activity of this 
enzyme. OPLAH and mRNA expression was the same in malignant A549 cells as in 
nonmalignant BEAS-2B and NHBE cells (Figure A.1). In contrast with findings of 
previous studies, OPLAH activity was found to be the same in malignant cells as 
nonmalignant cells (Figure A.2). The similar OPLAH activity levels in the two cell lines 
may relate back to the similar OPLAH mRNA expression levels. These data indicate that 
the toxicity of OSCA in BEAS-2B cells that was not observed in A549s is not due to 




































Figure A.1. mRNA expression of OPLAH in human lung cell lines. mRNA expression 
was quantified by QPCR and OPLAH copy numbers were normalized to PSMB6 copy 
numbers. Statistical analysis was performed using one-way ANOVA with Tukey post-
hoc testing. No significant difference between groups was found. Data are presented as 


























































Figure A.2. OPLAH activity in human lung cell lines. Activity was determined by 
measuring the production of glutamate by whole cell lysates in a buffer of 50 mM Tris 
HCl, 0.1 mM EDTA, 5mM 5-oxo-L-proline, and 2 mM DTT [3]. This reaction was 
performed in the presence or absence of ATP for 45 minutes. As the reaction requires 
ATP, the reaction in the absence of ATP represents background glutamate levels. 
Measurements were made using a fluorimetric HPLC assay [3,4]. Relative fluorescence 
units were converted to µg glutamate using a glutamate standard curve. Data are 
presented as mean mg glutamate/mg protein/min ± standard deviation. n = 2 or 3 for all 
groups. Statistical analysis was performed on the normalized µg glutamate/µg 
protein/min ratio (+ ATP/- ATP) using one-way ANOVA with Tukey post-hoc testing. 
The ratios for A549s and BEAS-2Bs were 3.11 ± 1.32 and 2.35 ± 0.43, respectively. No 
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MODULATION OF H1666 AND HOP92 HUMAN LUNG CANCER  
 
CELL REDOX STATUS BY SELENOCOMPOUNDS 
   
 
 
 The findings from Chapters 2, 3, and 4 indicated that the basal redox status and 
KEAP1 mutation status of human lung cell lines may be important determinates of the 
response of lung cells to selenocompounds. To further investigate the role of the KEAP1 
mutation status, the H1666 human non-small cell lung carcinoma cell line was utilized. 
H1666 was shown not to have a KEAP1 mutation or loss of heterozygosity [1]. The 
HOP92 cell line was also assessed as another non-small cell lung cancer line. It is a large 
cell lung cancer cell line that has been shown to have a high tissue similarity index to 
lung tumor, indicating similar genetic characteristics [2]. One drawback of this cell line is 
that it is poorly characterized. It is presently unknown whether this line harbors a KEAP1 
or NRF2 mutation that would lead to constitutive NRF2 activity similarly to A549 cells.  
 Free thiol and ROS levels were determined using mBBr and DCF, respectively, in 
cells treated with DMSO vehicle control to assess the basal cellular redox state. These 
measurements, along with KEAP1 status, are summarized for A549, BEAS-2B, H1666, 
and HOP92 cells in Table B.1. The A549 cells had a low free thiol level and the lowest 
ROS levels of the cell lines assessed. The BEAS-2B cells also had low free thiol levels, 
but the highest level of ROS levels assessed. As discussed in Chapter 2, these data  










Table B.1. KEAP1 mutation status and basal mBBr and DCF fluorescence 
concentrations of human lung cell lines.  
     




















No 1.40 ± 0.09 0.06 ± 0.01  
 
HOP92 
(large cell lung cancer) 
 
Unknown 1.26 ± 0.15 0.43 ± 0.04 
    
Cells were treated with 1 µL/mL DMSO as vehicle control for 24 hours. mBBr and DCF 
fluorescence concentrations were determined cytometrically as measure of cellular free 
thiols and reactive oxygen species, respectively, as described in Chapter 2. Data are 
presented as mean ± standard deviation. n = 2 or 3 for all groups. 
 
a
, Reference 1.  
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indicated that the A549 cells were in a more reduced basal state than the BEAS-2B cells. 
The H1666 and HOP92s did not exhibit a basal redox state that totally mirrored either the 
A549 or BEAS-2B cell line. Similar to the A549 cells, basal levels of ROS were low in 
these cell lines, with neither cell line approaching the DCF fluorescence concentration of 
1.40 seen with the BEAS-2B cells. In contrast to both the A549 and BEAS-2B cells, the 
H1666 and HOP92 cells had much greater levels of free thiols.  
 These data also demonstrate that KEAP1 status is not a good indicator of cellular 
redox state. This is evidenced by the H1666 line having higher free thiol levels and lower 
ROS levels than the BEAS-2B line, despite having the same KEAP1 status as the BEAS-
2B line. Other pathways related to redox status may be modulated in this adenocarcinoma 
cell line compared to the nonmalignant BEAS-2B cell line.  
 Both the H1666 and HOP92 cell lines were treated with selenocompounds to 
assess the effects on cellular viability and redox parameters. At 48 hours, the H1666 cells 
shown IC50 values of approximately 5 µM for MSA and 10 µM for selenocystine and 
ChSCA (Figure B.1). BSCA had the lowest toxicity of the compounds assessed, with 
only a 25% loss in viability at 200 µM. The viability profile with selenocystine and 
ChSCA was almost identical as that for the A549 cells as shown in Chapter 4. MSA was 
more toxic and BSCA less toxic in the H1666 line than the A549 line. (Figure B.1). At24 
hours, none of the compounds altered free thiol levels in H1666 cells (Figure B.2). This is 
in contrast to the ability of MSA, selenocystine, and ChSCA to modulate free thiol levels 
in both the A549 and BEAS-2B lines. The selenocompounds decreased ROS levels in the 
H1666s at 24 hours (Figure B.2), also in contrast to the selenocystine-mediated increase 
in A549s and lack of effect of the compounds on ROS levels in BEAS-2Bs.  









































Figure B.1. Viability of H1666 cells following 48 hr selenocompound treatments. 
Viability was assessed by measuring ATP content. Data are presented as % control mean 




































































Figure B.2. Free thiol and ROS levels in H1666 cells following 24 hr treatments. Free 
thiols and ROS levels were assessed by measuring mBBr and DCF fluorescence 
concentrations cytometrically as described in Chapter 2. Treatment concentrations were 
20 µM SEM, 2.5 µM MSA, 5 µM SECY, 5 µM ChSCA. Data are presented as mean 
viability ± standard deviation. n = 3 for all data points. One-way ANOVA with Dunnett’s 
post-hoc testing was performed to determine statistical significant. No change in mBBr 
fluorescence concentration was found with any of the treatments. ‘**’ indicates p<0.01 
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 At 24 hours, the HOP92 cell line demonstrates similar sensitivity to the 
selenocompounds as the A549 cell line (Figure B.3). However, the redox response of the 
HOP92 cells to was more similar to the BEAS-2Bs. The ability of the selenocompounds 
to modulation free thiol and ROS levels followed the same pattern in the HOP92s as the 
BEAS-2Bs, with selenocystine and ChSCA decreasing the free thiol content and none of 
the compounds altering ROS levels (Figure B.4). As with the A549s and BEAS-2Bs, 
selenocystine and ChSCA shifted the mitochondrial membrane potential of the HOP92s 
to the depolarized state (Figure B.5). The basal mitochondrial state was more depolarized 
than for the HOP92s than the other two cell lines. 
 In summary, the H1666 and HOP92 non-small cell lung cancer lines did not 
demonstrate similarities in keeping with either the A549 adenocarcinoma line or     
BEAS-2B nonmalignant line. Since a direct relation to either the line could not be made, 
even when taking into account the KEAP1 mutation status of the H1666 cells, the data 
for the HOP92s and H1666s was not included in Chapter 2. Overall, selenocystine and 
ChSCA tend to decrease free thiol levels and depolarize the mitochondria in human lung 
cells, with selenomethionine and MSA demonstrating little effects on these parameters. 
The H1666 cell line is the exception to these observations.  










































Figure B.3. Viability of HOP92 cells following 24 hr selenocompound treatments. 
Viability was assessed using tetrazolium salt reduction by NADH (CCK-8) as described 
in Chapter 2. Data are presented as % control mean viability ± standard deviation. n = 3 




















Figure B.4. Free thiol and ROS levels in HOP92 cells following 24 hr treatments. 
Free thiols and ROS levels were cytometrically measured using mBBr and DCF as 
described in Chapter 2. Treatment concentrations were 100 µM SEM, OSCA, ChSCA, 
and SECY and 2.5 µM MSA. Data are presented as mean fluorescence concentrations ± 
standard deviation. n = 3 for all data points. One-way ANOVA with Dunnett’s post-hoc 
testing was performed to determine statistical significant. No change in DCF fluorescence 
concentration was found with any of the treatments. ‘**’ indicates p<0.01 versus DMSO 
control.   
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Figure B.5. Assessment of mitochondrial membrane potential in HOP92 cells 
following 24 hr treatments. JC-1 was used to determine polarized mitochondria (575 
nm fluorescence; JC-1 red) and depolarized mitochondria (525 nm fluorescence; JC-1 
green) populations cytometrically as described in Chapter 2. Treatment concentrations 
were 100 µM SEM, OSCA, ChSCA, and SECY, 2.5 µM MSA, and 25 µM CCCP. Data 
are presented as mean ± standard deviation. n = 3 for all data points. One-way ANOVA 
with Dunnett’s post-hoc testing was performed to determine statistical significant. “**’ 
indicates p<0.01 versus DMSO control.  
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